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ABSTRACT 
This thesis is divided into two distinct sections which can be combined under the broad 
umbrella of structural bioinformatics studies related to drug discovery. The first section 
involves the establishment of an online South African natural products database. Natural 
products (NPs) are chemical entities synthesised in nature and are unrivalled in their 
structural complexity, chemical diversity, and biological specificity, which has long made 
them crucial to the drug discovery process. South Africa is rich in both plant and marine 
biodiversity and a great deal of research has gone into isolating compounds from organisms 
found in this country. However, there is no official database containing this information, 
making it difficult to access for research purposes. This information was extracted manually 
from literature to create a database of South African natural products. In order to make the 
information accessible to the general research community, a website, named “SANCDB”, 
was built to enable compounds to be quickly and easily searched for and downloaded in a 
number of different chemical formats. The content of the database was assessed and 
compared to other established natural product databases. Currently, SANCDB is the only 
database of natural products in Africa with an online interface.  
The second section of the thesis was aimed at performing structural characterisation of 
proteins with the potential to be targeted for antimalarial drug therapy. This looked 
specifically at 1) The interactions between an exported heat shock protein (Hsp) from 
Plasmodium falciparum (P. falciparum), PfHsp70-x and various host and exported parasite J 
proteins, as well as 2) The interface between PfHsp90 and the heat shock organising protein 
(PfHop). The PfHsp70-x:J protein study provided additional insight into how these two 
proteins potentially interact. Analysis of the PfHsp90:PfHop also provided a structural insight 
into the interaction interface between these two proteins and identified residues that could be 
ii 
 
targeted due to their contribution to the stability of the Hsp90:Hop binding complex and 
differences between parasite and human proteins. These studies inspired the development of a 
homology modelling tool, which can be used to assist researchers with homology modelling, 
while providing them with step-by-step control over the entire process.  
This thesis presents the establishment of a South African NP database and the development of 
a homology modelling tool, inspired by protein structural studies. When combined, these two 
applications have the potential to contribute greatly towards in silico drug discovery research.  
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THESIS STRUCTURE 
This thesis has been divided into two independent sections, which are united under the 
common theme of drug discovery. The first part of the thesis, which consists of Chapters 1, 2 
and 3, is centred around working with natural products data. More specifically, the 
establishment of a freely accessible, online database of compounds, isolated from organisms 
found in South Africa.  
Chapter 1 gives a general introduction to natural products and why such a great deal of 
research attention has been given to them. This looks into their use in traditional medicines 
and how these have contributed to our modern day understanding of drugs and drug 
development, with specific examples of drugs that have been discovered as a direct result of 
their use, or the use of their source organisms, in traditional medicine. The vast biodiversity 
of South Africa is then described, along with the pharmaceutical potential of both plant and 
marine life from this part of the world. Finally, the reasoning for the research undertaken in 
this part of the thesis is given. Simply put, in spite of a great deal of research that has gone 
into isolating and characterising natural products from South Africa, there is currently no 
official database containing this information, nor a resource which allows researchers to 
easily find and access these compounds or work with their chemical data. This problem is 
addressed in Chapters 2 and 3, firstly by constructing and establishing a database of South 
African natural products, then by creating on online resource which makes this information 
easily and freely accessible.  
Chapter 2 describes the design and layout of a South African natural products database, 
including the collection of compound data from literature, as well as other information 
considered relevant for further study of these compounds. To contextualise this, the 
introduction to this chapter reviews a number of well-established and prominent chemical 
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databases, to show both the diversity of focuses employed by these databases and the 
magnitude of data contained within. The process of building the database, collecting 
information and addressing data curation and quality control are described. The content of the 
database is discussed and compared to other natural products databases. Plans for further 
development of the database are also discussed.  
Chapter 3 describes the construction of an online interface for the database which has been 
named “SANCDB”. The background given in this chapter focuses more on the value of 
making such data publically accessible and the means by which this can be achieved. The 
development of the website is described along with the process by which users may search 
for information, download content or follow links to access additional data. Future 
developments to the site are also discussed, largely within the context of the expansion of the 
database itself. 
Section 2 is focused around protein structural bioinformatics, with Chapter 4 giving a general 
introduction to this part of the thesis. An overview of the study of protein structures is given 
with reference to gaining a mechanistic insight to better understand protein function. The 
efforts of structural genomics are reviewed, as are the challenges of obtaining experimental 
structures for proteins and how in silico approaches can be used to study proteins with 
structures that have not yet been solved by experimental means. A brief overview of the work 
performed in this part of the thesis is given. Primarily, this includes structural studies 
involving malarial heat shock proteins (Hsps) and interactions with their cochaperones 
(Chapter 5), which led to a secondary aim of assisting with future structural studies by 
providing a means to quickly and reliably perform homology modelling of target proteins 
(Chapter 6).  
xxii 
 
Chapter 5 focuses on the structural characterisation of Hsps from Plasmodium falciparum (P. 
falciparum) and their human counterparts. Specifically, these include Hsp70s, Hsp90s, J 
proteins and the Hsp70/Hsp90 organising protein, Hop. At a broad perspective, Hsp70s are 
molecular chaperones involved in protein folding and preventing aggregation, but also have 
other functions. Their activity is both assisted and mediated by J proteins and in some cases, 
the final maturation of peptide substrates involves transfer to Hsp90, which is facilitated by 
the cochaperone, Hop. P. falciparum Hsp70-x (PfHsp70-x) is a malarial protein which has 
recently been found to be exported outside the parasite during the blood stages of its lifecycle 
and localise in the host red blood cell cytosol. The first part of this chapter therefore focuses 
on the potential interactions of PfHsp70-x with other exported malarial J proteins and host J 
proteins, using both homology modelling and protein-protein docking. Another recent 
research effort described a structure of a new interaction interface between Hsp90 and Hop in 
yeast. The second part of the chapter reports structural work of this interaction interface in P. 
falciparum, human, yeast proteins. 
The structural characterisation studies involved a great deal of protein homology modelling 
and remodelling. Chapter 6 was directed at creating a set of Python scripts to automate the 
various steps involved in homology modelling. As they are scripts that break down the 
homology modelling process, they may be used to automate as much or as little of this 
process as desired by the user, as well as quickly test different modelling parameters. This 
tool has been designed to help users with varying degrees of expertise in homology 
modelling. It can be used to identify and evaluate templates, as well as perform alignments, 
modelling and model evaluation. The scripts were assessed and improved through a simple 
benchmarking test, described in this chapter. By the end of Chapter 6 the structural 
characterisation of a number of malarial target proteins has been described and potential 
target sites for drug screening studies were identified. Methods were developed to perform 
xxiii 
 
this type of analysis in other protein targets and scripts were written to aid with this. 
Additionally, a homology modelling tool was designed to assist with the modelling of 
proteins for future structural characterisation and in silico screening studies.  
To tie these two sections of the thesis together, Chapter 7 summarises the results and 
discusses future work that can be performed. It is explained that this thesis describes the 
development of an online database containing compounds isolated from South African 
organisms, and structural work, which includes both the identification of protein target sites 
to be investigated through ligand docking studies, as well as the development of a tool to 
model proteins for future studies. These two parts of the thesis both lend themselves to a 
clear, subsequent step, which is to perform in silico ligand docking studies on the protein 
targets identified in this study. Likewise, the homology modelling tool can be used to either 
characterise new protein targets or model known targets to be included in these docking 
studies with the eventual goal of identifying lead compounds, from the South African natural 
products available, for drug development.  
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Section 1: Establishment of a South 
African natural products database
2 
 
Chapter 1 Introduction to natural products research 
1.1 Natural products 
Natural products (NPs) are chemical entities that are produced by living organisms [1]. Of 
specific interest are those known as secondary metabolites, as opposed to primary metabolites 
which are common organic molecules, such as DNA/RNA, amino acids and some sugars, 
found in most cells. Unlike primary metabolites, secondary metabolites can perform 
functions outside a specific cell or organism in which they are produced. This usually 
involves interactions with other organisms, and is what makes them so useful. These are 
products of selective evolutionary processes by which they are naturally ‘designed’ to interact 
with other biological macromolecules. As such they display exceptional structural diversity 
and biological specificity when compared to purely synthetic compounds [2, 3]. A good 
example of this occurs with respect to multiple drug resistance (MDR) pumps, found in 
certain microorganisms [4]. These expel unrecognised molecular and chemical structures 
from cells as a defence mechanism. NPs resemble naturally occurring chemical compounds 
within organisms and making them less susceptible to expulsion by these MDR pumps [5]. A 
study by Nascimento et al. [6] tested the ability plant extracts to inhibit the growth of 
multiple drug resistant bacteria. Most notable were the clove and jambolan extracts, which 
displayed antimicrobial activity against 83% of strains tested. It is believed that up to 28% of 
higher plant species have associated medicinal properties and that nearly 75% of drugs that 
have been derived from plant extracts were discovered as a result of traditional knowledge 
[5]. 
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1.2 Traditional medicine 
For thousands of years, mankind has turned to nature to treat a multitude of different ailments 
[7, 8]. This has been witnessed in civilisations from across the world and is referred to as 
traditional medicine (TM) or complimentary/alternative medicine (CAM). Although there is a 
distinction between these two they are often used interchangeably. According to the World 
Health Organization (WHO), the definition of TM includes skills, knowledge and practices 
used in health care, performed based on experience or belief of different cultures [9]. 
Practices used in CAM are similar to those of TM, but are not based on long-standing 
indigenous knowledge, nor do they form part of any official health care system. Globally the 
demand for TM health care options has increased in recent years as countries have recognised 
its value [9]. In many rural areas, people have severely restricted access to established health 
care or qualified physicians and as a result, TM is their only option [10]. TMs have been 
developed to treat the patient, not necessarily just the disease [11, 12]. This makes treatment 
more personal and is often preferred for this reason. TM is also considered part of some 
cultures and although modern treatments are not necessarily outright rejected, they are 
considered to only be suitable after TM fails [11]. 
1.2.1 Traditional medicine in Africa 
It is estimated that in some African countries, up to 80% of the population are reliant on TM 
[13, 14]. The use of TM in Africa has been previously frowned upon, as practitioners were 
associated with witchcraft, which may have contributed to the breakdown in communication 
between modern medicines and TMs in Africa [10]. In Africa, efforts driven by the WHO 
were made to raise awareness of TM in countries across the continent and incorporate TM 
into their health care systems [15]. In 2010 it was noted that 22 African countries, including 
South Africa, had established studies to test TMs against malaria, HIV, sickle-cell anaemia, 
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diabetes and hypertension. Mali, where TM is part of the health care system, has established 
the Department of Traditional Medicine (DMT). This collaborates with the World Health 
Organisation (WHO), in order to study TM and aims to develop it to be used in tandem with 
modern medicines [10]. In South Africa, only Western medicines are officially acknowledged 
[16]; however, it is estimated that more than 3 million people in this country currently use 
indigenous plants for medicinal purposes [17]. Some medical aid schemes have even 
incorporated TMs into their cover plans [18]. The South African government and the 
National Research Foundation (NRF) have made efforts to increase the level of research into 
South African TMs and natural products. A similar trend has been witnessed on a global scale 
over the past 30 years [10]. 
1.2.2 Traditional Chinese medicine 
Traditional Chinese medicine (TCM) is probably the most trusted form of traditional medical 
treatment and is often incorporated into Western medicines [19]. Having been used for 
thousands of years, this is a very complex form of treatment, but focuses largely on balancing 
yin and yang within the human body [12]. In additional to treating illnesses, TCM tries to aid 
recovery of the body, often focusing on the main organs; the liver, heart, spleen, lung, kidney, 
referred to as ‘organ networks’.  
1.2.3 Undesirable effects of traditional medicine 
TM treatments for specific ailments may have side effects, although a perceived advantage of 
TM is its milder nature. When compared to Western medicines, the healing effects of TMs 
may be less-potent, but so are the side-effects [20]. The side-effects of TMs can, however, be 
dangerous if administered incorrectly, or if given in combination with certain drugs. A large 
number of these effects are untested and therefore unknown [9, 13]. Many plants used in TM 
also produce a number of metabolites that are toxic when ingested [21]. For example, 
Steenkamp & Gouws [22] reported incidences of patients with severe liver damage, believed 
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to be caused by pyrrolizidine alkaloids found in TMs they had taken. It was also revealed that 
this information was not reported back to the traditional healers [23].  
1.3 NPs in drug discovery 
The discovery and isolation of many medicinal compounds from natural sources can be 
attributed to known properties of the organisms that produce of these chemical agents. One of 
the earliest described isolation of a pure compound for medicinal use was that of morphine in 
approximately 1804, by Friedrich Serturner from opium [24]. At the time, opium was known 
as an addictive narcotic, though also used in pain management as early as the Middle Ages. 
The  antimalarial drug, quinine was isolated in 1820 by Pelletier and Caventou from the bark 
of the cinchona tree [25, 26]. This tree bark had been used to treat malaria since the 1600s 
and also formed part of South American traditional medicine for the treatment of fevers [7]. 
Another naturally derived analgesic, and one of the most widely used drugs of all time [27], 
is acetylsalicylic acid, registered under the name “Aspirin” [28]. The precursor to this was 
salicylic acid from willow (Spirea ulmania) bark. The leaves of this plant were used for both 
their analgesic properties and anti-inflammatory effects by the Ancient Egyptians [28]. The 
accidental discovery of penicillin in 1928 is relatively well-known. Alexander Fleming is 
credited with having witnessed that Staphylococcus bacterial colonies were unable to grown 
around a small area surrounding mould of the Penicillium genus [29]. Though not derived 
through known TM, the isolation of penicillin only came through this observation of the 
organism that produced it. Fleming tested this effect on different microorganisms and 
deduced that because some were unable to grow even within several centimetres of the mould 
that it must be producing an antibacterial substance [29]. An increase in drug resistance to 
quinine and its derivatives led to a need for alternative antimalarials and the isolation of 
artemisinin from Artemisia annua [30]. In TCM this plant has been used for over a thousand 
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years to treat fevers [30]. The compounds, 5’-methoxyhydnocarpin from Berberis fremontii, 
used in Native American TM, has been shown to inhibit the function of the MDR pump, 
found in multiple drug resistant bacteria [31]. This indicates a role for NPs in combination 
with other drugs. 
1.3.1 Pharmaceutical potential of marine NPs  
Marine NPs are a relatively new source of pharmacological agents [32], but display diverse 
and unique chemistry [33]. In addition to the drug potential of these compounds, as they 
occur naturally, they may also be used as template molecules for the design of even more 
advanced, novel medicinal compounds. In 2014, eight marine NP-derived drugs had been 
approved, three of which required no additional modification after extraction [34]. These 
include uses as anticancer agents, antivirals, pain medication and treatment of cardiovascular 
disease. Between 1951 and 1960, experiments conducted using arabinose-containing 
nucleosides (spongonucleosides), extracted from the sponge, Cryptotethia crypta, found that 
these had an inhibitory effect on DNA/RNA metabolism [35]. Two of these 
spongonucleosides, spongothymidine and spongouridine, were modified to produce the drugs 
cytarabine (anticancer) and vidarabine (antiviral), respectively [34]. Although cytarabine was 
approved over 40 years ago, it is still a leading modern anticancer drug. The other antiviral is 
sold over the counter as a nasal spray, Carragelose
®
, which contains Iota-carrageenan from  
Rhodophyceae seaweeds [34]. The peptide toxin, zinconotide, was isolated from venom 
produced by the marine snail, Conus magus [36]. This required no further modification for 
the treatment of chronic pain and was approved in 2004/2005 for use in patients suffering 
from cancer, AIDS and neuropathy [34]. A combination of omega-3 fatty acids from fish oils 
have been have been artificially synthesized and formulated into the drug, Lovaza
®
, by 
GlaxoSmithKline (GSK). This is used to treat severe hypertriglyceridemia, based on the 
observation that individuals native to Alaska, whose diets were high in these omega-3 fatty 
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acids, were far less prone to cardiovascular disorders [37]. The compound, trabectedin, was 
first isolated from the tunicate Ecteinascidia turbinate [38]. It displays potent anticancer 
activity and is currently marketed as the drug, Yondelis
®
 [34]. The yield of this compound 
from its source organism is too low to be viably extracted for drug production, but can be 
semi-synthesised using a much higher-yielding NP, cyanosafracin B, from the Pseudomonas 
fluorescens [39]. Another anticancer compound, halichondrin B, was isolated from the sponge 
Halichondria okadai in 1986 [40]. Again, due to low yields, the compound needed to be 
synthesised to be studied. This allowed the derivative compound, eribulin mesylate, to be 
discovered, which is currently approved as an anticancer drug [34]. The final anticancer marine 
drug is brentuximab vedotin, which is a structural analogue of dolastatin 10 from sea hare 
Dolabella auricularia [41].  
1.3.2 Recurrence of NPs in drug discovery 
The process of producing a novel, approved drug is very long and incredibly expensive [42]. 
In the 1990s, high throughput screening (HTS) methods were introduced in order to speed up 
drug discovery process. This allowed companies to screen large synthetic chemical libraries 
to test for specific biological activity [42]. NPs are not suited to HTS and many 
pharmaceutical companies consequently discontinued their NP drug discovery programs [43]. 
The decline of NPs in pharmaceutical drug discovery programs has been attributed to a 
number of factors. From the side of industry, these included 1) lack of technologies available 
in the 1990s for NP-based drug discovery; 2) pharmaceutical companies trying to investigate 
too many different sources at the same time, rather than giving sufficient attention a small 
number of NPs; and 3) a lack of expertise in industry for establishing and maintaining NP 
libraries [44]. NPs themselves are also inherently more difficult to work with than synthetic 
compounds. They are generally produced in small amounts, as part of a mixture with other 
small molecules and biomass. This makes obtaining sufficient quantities of pure compounds 
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for testing labour-intensive, time-consuming and ultimately highly costly [44]. The process of 
NP screening is also prone to re-discovery of an already identified NP with specific activity. 
This is because some NPs are isolated more frequently than others and dereplication 
methodologies don not always identify these as the same compound [44]. Finally, the 
structural complexity of NPs makes them difficult to work with, modify and synthesise [44]. 
Recent advances in technology and chemical methodologies has seen some of these 
challenges addressed and NPs are being reintroduced into the drug discovery process [2]. 
This has also been due to the failure of HTS technologies to produce the results expected. 
HTS libraries use combinatorial chemistry to produce a myriad of new chemical entities 
(NCEs). Unfortunately, these technologies identify compounds with specific biological 
activity and do not distinguish whether or not they will be a good or safe drug component 
[42]. HTS also has low selectivity, as approximately 50 - 85% of tested compounds will go 
through to subsequent stages in the drug discovery process [45]. Even so, the process of 
combinatorial chemistry with HTS has only yielded a single NCE that has been approved as a 
drug [2, 8]. 
1.4 NPs of South Africa 
South Africa ranks third in the world in terms of its terrestrial biodiversity [46], and it is 
estimated that 3000 different plant species are used for medicinal purposes in this country, 
mostly as part of traditional medicines [47]. It is estimated that more than 3 million people in 
this country currently use indigenous plants for medicinal purposes [17]. Organic extracts 
from South African plants have been shown to display both antibacterial and antifungal 
activity [48, 49]. Additionally, chemical compounds extracted from these plants have shown 
promise as agents against cancer [50], Mycobacterium tuberculosis [51] and various 
neurological disorders [52]. Clarkson et al. [53] reported at least moderate antiplasmodial 
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activity from 49% of the 134 different South African medicinal plant extracts tested. 
Likewise, Bessong et al. [54] reported a series of South African plant extracts that displayed 
anti-HIV activity. The antimicrobial activity of South African plant life is reviewed by van 
Vuuren [55], including examples of specific compounds isolated from these plants and their 
measured antimicrobial activity. Kelmanson et al. [18] reported screening of 14 different 
plants used by Zulu traditional healers and found a wide variety of antibacterial activity, 
mostly against Gram-positive bacteria. Some women in South Africa use TMs to help with 
labour and antenatal care. Kaido et al. [56], tested some of these treatments and found them 
to regulate acetylcholine and oxytocin. 
Although early research attempts were made, Southern African marine chemistry research 
only really took off in the 1990s with compounds isolated showing a great deal of potential as 
anticancer agents [57]. Further, South African marine organisms have been shown to 
synthesise many novel compounds which also display pharmaceutical potential [58, 59]. The 
marine and plant life of South Africa represents an untapped resource of chemical 
compounds. 
1.5 Research motivation 
NP scaffolds are an important component in the drug discovery process [3]. With regard to 
the chemical structure of morphine, Rishton [60] noted that it is one that would never be 
achieved through rational drug design by medicinal chemists, thus highlighting the value of 
its discovery from a natural source. Additionally, nearly 65% of all drugs approved between 
1981 and 2010 were either derived from or inspired by NP precursors [61]. More recent 
studies reveal that since 2008 25 new NP-derived drugs were approved, and in 2014 there 
were 31 additional drugs either at or past phase III clinical trials [62]. The development of in 
silico methods for drug discovery has presented faster and cheaper ways to screen for 
10 
 
compounds with pharmaceutical potential [63]. This approach is meant to supplement and 
direct in vivo screening, which is required for experimental proof that a drug is effective. 
With on-going development in this area of research, in silico drug screening methods are 
becoming more accurate and more reliable with time [64]. Online databases, such as ZINC 
make compounds freely available for in silico screening [65]. For similar reasons, a number 
of NP databases have been developed, though are mostly dominated by compounds extracted 
from traditional Chinese herbs and medicines. The flourishing NP research in Africa has also 
resulted in a number of NP databases [66–68] emerging in recent years, though nowhere near 
the scale of their Chinese counterparts. None of these African databases have an online 
interface to access this data, nor do they focus on NPs from South Africa, where there is a 
wealth of chemical biodiversity. Data concerning potential medicinal compounds from 
organisms indigenous to this country has become severely scattered across a variety of 
databases, as well as hundreds of journal articles which often require a fee to gain access to 
[69]. Additionally, information in literature is not easily searchable, especially when 
attempting to acquire specific information or finding compounds with specific properties. It 
would be greatly beneficial to South Africa if compounds from this region were freely 
available and easily locatable and accessible for research purposes. This would increase 
exposure to these small molecules and enhance the range of compounds tested as inhibitors 
against potential drug targets. 
1.6 Research aim 
The focus of this project was to make a resource available containing compounds from South 
African organisms. As such, the overall aim is to develop a web-based database containing 
biologically relevant information about compounds extracted from South African plant and 
marine life. This is divided into the following objectives: 
11 
 
1. Design and create a database to store information regarding South African natural 
products 
2. Populate the database with relevant information 
3. Establish a web interface which would enable anyone to access this information for 
their own research purposes. 
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Chapter 2 South African natural products database 
There are a myriad of well-established databases around the world, which specialise in 
information pertaining to chemical compounds, both natural and synthetic. This chapter 
reviews a number of these databases and their uses, as well as the ways to work with 
chemical data. Described herein is the design and construction of a database of South African 
natural products, which aims to contain fully-referenced information from literature regarding 
these compounds, the organisms from which they were isolated and their uses. Information 
about each compound was extracted manually from literature and linked to external 
databases, where possible. The physicochemical properties of all compounds were calculated 
and each compound was converted to different file formats to allow them to be used in 
computational experiments. The uploading of compound data was subjected to manual 
curation and various error-checking steps to ensure data quality. The current content of the 
database is described, as well as potential plans for the future developments that can be made 
to enhance its value. The work presented in this chapter and Chapter 3 was recently accepted 
for publication [70]. 
2.1 Introduction 
2.1.1 Current compound databases 
Compound databases exist to describe and quantify our knowledge of chemical entities and 
assist with the identification of new entities [71]. Unlike other databases, they may contain 
information about the structures of chemical compounds, as well as reaction data. To date, a 
number of chemical compound databases have been created, each with a specific purpose. 
The most well-established databases, described below, contain millions of records with in-
depth information about each compound.  
13 
 
2.1.1.1 PubChem 
PubChem is an open online repository consisting of three related databases, namely the 
Compound, Substance and BioAssay databases [72]. It was developed by the National Center 
for Biotechnology Information (NCBI) as part of the US National Institutes of Health (NIH) 
program to establish of molecular libraries [73]. Together these contain information about 
small molecules and their biological properties. The Substance database contains records of 
all deposited substances and the BioAssay database contains information regarding screening 
studies against gene and protein targets. The Compound database contains unique entries 
from the Substance database, after processing and standardising the data. In 2010, PubChem 
contained over 25 million compounds and 90 million bioactivity data for thousands of protein 
targets. The database was developed to help researchers with drug development [74]. 
2.1.1.2 ChEMBL 
ChEMBL was developed at the European Molecular Biology Laboratory (EMBL). This is a 
curated bioactivity database, containing information manually extracted from literature. The 
data contained within ChEMBL includes binding activity, functional bioassay data, and 
absorption, distribution, metabolism, excretion and toxicity (ADMET) properties for over a 
million compounds. The only compounds considered are those with drug-like properties [75].  
2.1.1.3 DrugBank 
DrugBank contains a wealth of information about approved and experimental drugs and drug 
targets [69], including definitions of drug molecules as well as detailed information about 
their chemical and pharmaceutical properties. The database is ever-expanding to include 
additional information about each drug, such as detailed drug pathways and interaction data 
in DrugBank 3.0 [76] and recently more detailed ADMET profiles and quantitative structure 
activity relationships (QSAR) information with version 4.0 [77].  
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2.1.1.4 ZINC 
The ZINC database was started with the goal of providing a set of quality compounds that 
could be used for in silico docking studies. The database also contains information pertaining 
to the purchasing of molecules from different chemical vendors. ZINC contains 
approximately 20 million compounds, which can be downloaded in ‘ready-to-dock’ format. 
Searches can be based on biological activity, structural properties, as well as an assortment of 
different chemical identifiers. This is a rapidly-expanding database, growing nearly more 
than 10-fold in size since it was started in 2005 [65, 78].  
2.1.1.5 Other notable databases 
A number of other well-established databases have also been developed. A few of these will 
be mentioned to give an indication of the variety of information collected about different 
compounds. BindingDB [79] contains experimentally-determined information about protein-
ligand binding affinity, obtained through literature searches from scientific publications. It 
was constructed to allow the study of protein-ligand interactions in order to determine the 
ideal chemical properties for pharmacophores, gain mechanistic insight into specific ligand 
binding and provide a means to check for side effects of potential drugs. The Cambridge 
Structural Database (CSD) is a resource at the Cambridge Crystallographic Data Centre 
(CCDS), containing records of small molecules solved by crystallography (both X-ray and 
neutron) [80]. It currently has records for over 700000 chemical structures, with nearly 40000 
added on a yearly basis. Chemical Entities of Biological Interest (ChEBI), developed at the 
European Bioinformatics Institute (EBI), is described as a dictionary for small chemical 
compounds, containing information about compound ontology [81]. This describes the 
relationship between a small molecule and other molecules directly associated with it. ChEBI 
aims to provide the “most correct” nomenclature for molecules, as specified by relevant 
authorities (e.g. IUPAC for names of chemical compounds), as well as ensure that all items in 
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the database are fully referenced, so that users can find the source of specific information. A 
number of metabolome databases, such as Biospider [82], The Human Metabolome Database 
(HMDB) [83] and the Yeast Metabolome Database (YMDB) [84] detail molecules with 
respect to the annotation of metabolomes. A similar database, the Small Molecule Pathway 
Database, describes over 350 small molecule pathways found in humans, which was designed 
to help with clinical metabolomics and related research [85]. Finally, the Toxin and Toxin-
Target Database [86] contains biologically important data about toxins, including 
mechanisms, chemical structures and clinical data. This includes over 3000 toxins and over 
33000 associations with 1300 targets. It is a highly comprehensive, curated database with up 
to more than 80 fields of different information for any given toxin or its target. 
2.1.1.6 Natural products databases 
NPs account for a great deal of known drugs so researchers have started to develop their own 
chemical libraries to screen NPs for drug potential [87]. Some NP databases have also been 
developed to further understanding the mechanisms of action of traditional medicines [88]. 
Since NPs are produced to interact with biological targets [2, 3], the design of these databases 
provide a biologically- and therefore pharmaceutically-relevant chemical space to work with 
[89]. The NAPRALERT database [90] was established in 1982 with the endeavour to extract 
compound information from literature since 1880. The database has been used to aid the 
development pharmaceuticals and cosmetics. Unfortunately this is a commercial resource, 
limiting its use in academic research. More recently, there have been a number of freely 
accessible NP databases established as discussed below. 
2.1.1.6.1 Traditional Chinese medicine databases 
Traditional Chinese medicine (TCM) is an incredibly well-established source of natural 
products data [91]. Some of the most well-established TCM  databases include the TCM 
Database@Taiwan [91], CHDD [92] and the Chinese Natural Product Database (CNPD) 
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[93], which together have nearly 80,000 unique chemical structures [94]. These databases 
contain compounds found in TCM and information is collected from Chinese medical texts, 
as well as scientific literature. The TCM Database@Taiwan was designed in response to a 
great deal of interest being directed towards TCM for potential lead compounds in drug 
design, especially by pharmaceutical companies. These compounds are prepared in such a 
way that they should be readily usable for in silico drug screening [91].   
2.1.1.6.2 Natural products database of Brazil 
The NuBBE database (NuBBEDB) was established to catalogue compounds isolated from the 
biodiversity of Brazil [95]. Since the database was established only fairly recently, it contains 
only 640 compounds from scientific publications. It has been integrated into a web-based 
interface, designed to help with natural products research. 
2.1.1.6.3 Natural products databases in Africa 
Currently, in Africa there is only one group with an official NP database. This was originally 
established to contain compounds isolated in Cameroon and was named CamMedNP [66]. 
This later expanded to include compounds isolated from the entire Congo Basin and therefore 
named ConMedNP [67]. The Congo Basin is rich in diverse flora and plant life in this region 
is a favoured medicinal source. The database currently contains just short of 3200 compounds 
and largely focuses on providing 3D structures of compounds, specifically for use in in silico 
drug design. The same group created a similar database, AfroDB, which contains a relatively 
small number of compounds from across the African continent [68]. The database was kept 
small, so as to be used in in silico screening by groups in Africa with limited computational 
resources. In order to achieve this, the database only contains compounds with established 
biological activity, such as anticancer activity [68].  
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2.1.1.6.4 Marine natural products database 
Since most marine organisms rely on purely chemical defence mechanisms they need to 
produce potent compounds with great biological specificity [2]. Lei & Zhou [96] have 
developed a database containing over 6000 marine natural compounds isolated since 1960. 
The database is predominantly for studying marine chemical entities to discover new 
pharmaceuticals; however, it does also provide benefits to research of marine toxins and 
chemical ecology. 
2.1.2 Working with chemical data 
Line-formula notation, developed in 1861, was used to describe chemical structures by 
separating consecutive atoms within the main chain of a compound by periods (‘.’) while 
other adjacent atoms were written before the next period [97]. A number of research groups 
used their own variations of line-formula notation to further develop it [97], but the 
convention was considered difficult to work with for those without extensive knowledge of it 
[98, 99]. Since the involvement of computer systems in handling chemical data, it became 
important to use standardised notations for representing chemical structures that computers 
can recognise and work with [98]. The most widely used formats still in use include 
SMILES, CAS, molecule file (Molfile) and structure-data file (SDfile) [98, 100]. 
2.1.2.1 SMILES 
Simplified Molecular Identification and Line Entry System (SMILES) notation was 
developed as an alternative to line-formula notation, which could be used by computer 
scientists with a limited background in chemistry [99]. It allows a compound to be written as 
a text string and follows five rules. 1) Each atom is represented by its atomic symbol. If an 
atom has a two-character symbol (e.g. Cl), then the first character is written in upper case and 
the second in lower case. Hydrogens do not need to be written in, as they are implicit, but can 
be included if required to avoid ambiguity; 2) Bonds between atoms are shown as dash 
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characters (‘-’) for single bonds, equal sign characters (‘=’) for double bonds and a hash 
characters (‘#’) for triple bonds. If a bond is not specified, it is considered to be a single bond. 
3) If atoms branch off the main chain of the chemical structure, these are enclosed in 
parentheses; 4) Cyclic structures (rings) are denoted with a digit input immediately after the 
atom that opens a ring and the same digit immediately after the atom that closes that ring; 5) 
If a ring is aromatic, then the atoms are written in lower case. If an elements in a ring has a 
two-letter symbol an exclamation mark (‘!’) is written immediately after the atom, to avoid 
ambiguity [99, 101]. Examples of chemical structures with their SMILES are shown in 
Figure 2.1. Additional SMILES specifications can be used for configuration around a double 
bond and tetrahedral centres [102]. Chirality is specified using the “at” character (‘@’) in 
square brackets, as shown in Figure 2.2 (A). If a single character is used, the branched atoms 
follow in an anticlockwise order (left), whereas two characters indicate that these follow in a 
clockwise order (right). Double bond configuration is specified using back and forward slash 
characters, as shown in Figure 2.2 (B). If two of the same slash characters are used for double 
bond atoms, it represents trans (E) configuration (left), whereas if both forward and back 
slashes are used, it represents cis (Z) configuration (right). Square brackets can also be used 
to specify charged atoms, such as [NH+] [102]. 
2.1.2.2 SciFinder  
SciFinder is a commercial research tool, developed by the Chemical Abstracts Service 
(CAS), which consists of a set of five databases containing information about chemical 
literature, substances, reactions and suppliers [103]. Over 93 million compounds are 
contained within the CAS registry [104], each with a unique CAS Registry Number 
(CASRN). The CASRN is a universal and authoritative identifier, used by chemical vendors 
and regulatory agencies [71].  
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Figure 2.1: Examples of compounds and their associated SMILES. Compounds were drawn and 
the SMILES produced using the JSME molecular editor applet [105]. Structure (A) represents a 
simple aliphatic compound; (B) shows a an aromatic ring, as well as the use of displaying branches in 
SMILES, and (C) shows an example of a non-aromatic ring with the stereochemistry fully defined. 
2.1.2.3 InChI and InChIKey 
IUPAC Chemical Identifier (InChI) was designed to be a non-proprietary, unique identifier 
for a chemical structure [98]. It is described as being a type of bar code that also contains 
structural information, meaning this data does not need to be retrieved from a database, as is 
the case with the CAS identifier. InChI is a layered representation with each layer, separated 
by a forward slash, describing different types of information. InChI can contain a number of 
different layers that together specify the formula, connectivity, isotopes, stereochemistry and 
tautomers of a chemical structure. Since the length of an InChI string will increase with the 
size of a compound, an InChIKey has also been developed. This is a 27-character 
representation of an InChI, which can be used more easily to find a chemical structure either 
in a database or an internet search engine [98]. 
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Figure 2.2: Examples of stereochemistry specifications made using SMILES. Structural 
representations are shown which indicate the different ways to specify stereochemistry when writing 
SMILES. The SMILES is shown below each structure. (A) displays the use of the ‘@’ symbol to 
represent the chirality of a tetrahedral centre. The black circle represents a tetrahedral carbon and each 
triangle represents a single bond to either a Carbon, Hydrogen, Nitrogen or Oxygen atom. (B) 
displays the use of forward and back slash characters to specify the configuration around a double 
bond. On the left, the slashes all face the same way, representing trans configuration, whereas on the 
right they face opposite directions, indicating cis configuration. 
2.1.2.4 Chemical table files 
Another series of formats that have been developed to allow computers to use chemical 
structural data are those based on the chemical table file format, designed by Molecular 
Design Limited [100]. Of these, Molfile and SDfile are the two used by major databases such 
as ZINC, ChEMBL and PubChem. The Molfile consists of a header block and a connection 
table. The header block contains information about the molecule, who created the file and 
other miscellaneous data. The connection table is common to all chemical table file formats. 
It is divided into six different blocks, which together describe the structural relationship 
between all atoms in a molecule, as well as their properties. The SDfile is an extension of the 
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Molfile and can hold structural information for multiple compounds. Each compound entry in 
an SDfile has a Molfile section, containing the same information as this format. Additional 
data sections are included, which provide more information, for example the melting point of 
the compound. Each data section contains a header, indicated by a greater than sign (‘>’), 
with the associated information on the following line and separated from other data sections 
by a blank line. Different compounds in an SDfile are separated by four dollar signs (‘$$$$’). 
2.1.3 Proposed work 
This chapter will focus on describing the design and layout of a South African NP database, 
including the collection of compound data from literature, as well as other information 
considered relevant for further study of these compounds. Additionally, the current content of 
the database is assessed, along with means of quality control of data. Future plans for further 
development of the database are also described.   
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2.2  Methodology 
2.2.1 Database 
SANCDB comprises a MySQL database, integrated into a Django application. The database 
schema is shown in Figure 2.3. The database is centred around the Compounds and 
References tables. The References table was linked to the Authors table, via the RefAuthors 
table, which, apart from linking these two tables, also keeps track of the first author of a 
publication. The References table is also linked to Journals and Depositors, each as a lookup 
table. The Depositors table houses information about individuals who upload information to 
the database. The Compounds table contains information to identify a compound (name, 
formula etc.), as well as identifiers that link them to external databases, such as PubChem. 
Compounds are linked to the References, Sources, OtherNames and Uses tables. Sources 
refer to the organisms from which a given compound was isolated and Uses refer to any 
specific activity tested for a compound; e.g. antimalarial activity. OtherNames entries are 
captured as the name used to refer to a compound in a specific publication, as well as names 
assigned to the compound by SciFinder [106] if applicable. 
2.2.2 Django 
2.2.2.1 Models 
The tables from the database layout, presented in Figure 2.3, were written as a set of Python 
[107] classes, referred to as ‘models’ in Django. These are used by Django [108] to create a 
MySQL [109] database containing the information specified in the schema and allow the 
database to be manipulated as python objects. These are specified in the file, models.py 
(refer to Appendix A). 
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Figure 2.3: ER Diagram for the SANCDB, describing the layout of the database and the 
relationship of the data. Each container represents a table in the database. The table name is shown 
at the top of each table with the different fields listed below. Links between the tables represent the 
relationships between the data as either a 1 (one) or n (many). Table and field names displayed are 
those used in the database. 
 
2.2.2.2 The admin site 
Django provides an admin site that creates an interface which allows easier control and 
visualisation of data, especially by annotators with little general scripting experience. Each 
model was registered with the admin site. This involves specifying which fields in the models 
are displayed, how they are ordered and which can be searched. These are specified in the file 
admin.py (refer to Appendix A). 
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2.2.3 Literature search 
Publications, theses and textbooks were searched for, focusing on work involving the 
extraction of compounds from South African plant and marine life. The Rhodes University 
thesis collection [110] was searched for theses by students that match these criteria. PubMed 
[111] and ScienceDirect [112] were also searched for publications matching these criteria. 
Additional literature was found using Google searches [113] and searching for publications 
and textbooks referenced in literature already found.  
2.2.4 Compound uploading 
2.2.4.1 Admin site 
The Django admin site was used to upload compounds. Depositors were registered as users 
and given permission to upload and edit data in the database. Information was uploaded in a 
specific order. Reference information was always uploaded first and a depositor was linked to 
the reference. When compound information was uploaded, the reference entry was linked to 
the compound. All information, apart from SMILES (refer to Section 2.2.4.2), classifications 
(refer to Section 2.2.4.3) and external links, was obtained from literature. Each compound 
was searched for in SciFinder and a CASRN was assigned to it, if available. This was also 
used to ensure the compound uploaded was not already in the database. The Sources, Uses 
and OtherNames tables were also populated using information from publications and linked 
to both the Compounds table and the References table via the CompSources, CompUses and 
CompOtherNames tables, respectively (Figure 2.3). 
2.2.4.2 Compound SMILES generation 
SMILES information is not readily available in literature, but an image of each compound is 
usually provided. To ensure that all known structural information of the compounds was 
captured, images were downloaded from SciFinder for compound entries. These were 
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uploaded to the OSRA compound image recognition server web interface [114], which reads 
a compound image and draws out the structure in the JME molecular editor [105]. This 
molecular editor can be used to correct mistakes made by OSRA and produce SMILES for 
the correct structure. The Daylight depict server [115] was used to check the structure 
produced by the SMILES and Open Babel [116] was used to produce InChI for the SMILES. 
This was used to ensure the SMILES matched the formula of the compound and make sure 
all known stereocentres were specified.  
2.2.4.3 Compound classifications 
Classifications for each compound were assigned by Dr Kevin Lobb from the Rhodes 
University Chemistry Department. 
2.2.5 Compound image generation 
Compound image generation was performed using the Indigo tool kit [117]. This is a Python 
module that requires compound SMILES as input. A Python script was written which uses 
this module to automate the generation of compound images, by querying the database for the 
SMILES of each compound (Appendix B; File: comp_imgGen_indigo.py). 
2.2.6 File format generation 
Compound 3D coordinates were calculated from SMILES using the CORINA structure 
generator [118, 119], saved in SDfile format. Open Babel [116] was used to convert the 3D 
coordinates to Molfile and PDB format. Open Babel was also used to convert each compound 
PDB file to GAMESS input file format. GAMESS [120] was then used to minimize the 
compounds, using RM1 basis level. These were then converted back to PDB, using Open 
Babel and saved separately as ‘minimised’ PDB files. A Python script was written to 
automate this process (Appendix B; File: CORINA_conversions.py).  
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2.2.7 Calculation of compound properties 
Properties were calculated for each compound, based on Lipinski’s rule of five [121], which 
requires the molecular mass of the compound, the calculated logP (cLogP), as well as the 
number of hydrogen bond donors (HBDs) and hydrogen bond acceptors (HBAs). Molecular 
mass was calculated from the compound’s formula, using known average mass of each 
element. The obprop program in the Open Babel installation was used to calculate cLogP 
values. A SMILES parser has also been developed (refer to Section 2.2.9.4) and was used to 
calculate both the HBAs and HBDs present in each compound. A Python script was written 
to automate this process and parse the output from Open Babel, as well as to save the values 
recorded (Appendix B; File: memcache_parse_babel_props.py). 
2.2.8 Validation and backup 
SMILES produced by OSRA were checked primarily by calculating the formula of the 
compound from the SMILES produced, using Open Babel. This was compared to the known 
formula of the compound from literature. If these did not match, it indicated that the 
compound was incorrectly drawn by OSRA and not correctly fixed by the depositor before 
saving the SMILES. External IDs were checked by their format, e.g. DrugBank compound 
IDs start with the letters ‘DB’ and are seven characters in length. Spot checks were performed 
by looking at random entries in the database and comparing the values captured to those 
found in literature to ensure information was accurately captured and no information was 
omitted. 
2.2.9 SMILES parser 
A SMILES parser was developed as a Python module to read and work with SMILES data. It 
is split into four different classes. The full script can be viewed in Appendix C; File: 
smilesparser.py. 
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2.2.9.1 Atom_position class 
This class is used to assign a position level to each atom in a SMILES string, which identifies 
where each atom is located in the compound, based on the way the SMILES is written. 
Atoms in the main chain are numbered using integers, (i.e. 1, 2, 3, etc.). Branching from the 
main chain is denoted with a colon (‘:’), which is also used to denote further branching. Each 
branch is numbered, as are specific positions on each branch, e.g. atom at position ‘3:2-5’ is 
the fifth atom along the second branch of the third atom in the main chain. The 
Atom_position class also contains functions, which enable navigation through a SMILES 
string, based on these position names.  
2.2.9.2 Square_brackets class 
The Square_brackets class simply deals with the different types of information that can be 
contained in square brackets in a SMILES string. It identifies if the atom has a charge (‘+’ or 
‘-‘) or a set chirality (either ‘@’ or ‘@@’) and also identifies the atom within the square 
brackets. 
2.2.9.3 Atom  class 
The Atom class represents an individual atom within a SMILES string. It contains an element 
identifier (e.g. ‘C’ for Carbon), an Atom_position object, ring information, a pre-bond 
identifier, charge information, chirality and double bond configuration. The ring information 
is taken directly from the SMILES as the integers that indicate if the atom either starts or 
ends a ring. The pre-bond identifier is either a dash (‘-’), equals sign (‘=’) or hash (‘#’), 
denoting a single, double or triple bond (refer to section 2.1.2.1). Charge information and 
chirality are assigned using the Square_brackets class and double bond configuration is saved 
as either a forward or a back slash if stated in the SMILES.  
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2.2.9.4 SMILES class 
The SMILES class parses a SMILES string and separates in into a list of Atom objects. It also 
uses this information determine the positions of all rings in the structure (i.e. which atom 
objects make up each ring). 
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2.3  Results and discussion 
2.3.1 Database content 
2.3.1.1 Number of compounds 
The database currently contains 600 pure compounds isolated from South African organisms. 
This information was manually extracted from 170 different references. The closest 
comparison to this is the NuBBE database in Brazil, which contains 640 compounds from 
170 different references [95], although nearly 100 of these compounds (14%) are either 
synthetic, semi-synthetic or products of biotransformation. Often in publications, researchers 
perform simple modifications to compounds. For example, Elgorashi et al. [122] used 
acetylation to convert one of the compounds isolated in the study, Lycorine, to 1, 2, Di-O-
acetyllycorine. This was achieved by simply stirring the compound with equal volumes of 
acetic anhydride overnight. These modified compounds have been omitted from the database, 
as these are not pure natural products; however, in future it may be worth including the 
information. A well known South African chemist, Frank Warren [47] has published two 
reviews of pyrrolizidine natural products [123, 124], which mostly contain these kinds of 
modifications. Efforts are constantly being made to expand the database. Searches for new 
literature have become more challenging now that so many papers have already been 
included, especially with keeping the database restricted to South African NPs. Expanding 
the database to include NPs from Southern Africa would be the next logical step, since this 
entire region does not have a NP database, with the exception of AfroDB [68], which 
contains just over 200 compounds from Southern Africa, but does not have a web interface 
for users to search or download compounds. This is further discussed in Chapter 3. 
30 
 
2.3.1.2 Compound classifications 
Compound classifications were initially taken from literature. However; these can be 
subjective and were not always consistent for the same compound found in different 
publications. As a result, classifications were assigned by inspection of each compound. This 
was done by Dr Kevin Lobb of the Rhodes University Chemistry Department.  
Classifying chemical compounds is a means of sorting large sets of data into smaller, logical 
groupings, which are more manageable and easier to work with [125]. The compound 
classifications used in the database are structural classifications, where a certain class of 
compound will have a single common structure. More specific classifications can also be 
assigned within a class of compounds. This structural hierarchy is useful because compounds 
from a specific classification may have common properties that are of interest to specific 
research [125]. Some chemical classifications are not strictly defined, making it difficult to 
assign objectively. ChEBI [81] is a dictionary for small molecules involved in biological 
processes; either naturally or by artificial intervention. It gives structural classifications of 
compounds through the use of ontologies, providing a definition of each chemical class at 
different levels. Hastings et al. [125] have described some examples of problems with the 
way certain compound structural classifications are defined. Firstly, the words “usually” and 
“not normally” are used in the definitions of alkaloids and steroids, which indicate that 
assigning some classifications requires a certain level of discretion. Secondly, the level of 
chemical expertise required to decisively classify a compound into its most specific structural 
class makes this process challenging. For this reason the classifications assigned in the 
present South African NP database are suggested classifications. A total of 116 different 
compound classifications have been assigned and where possible, more than one 
classification was assigned per compound, to be as specific as possible. The division of 
compound classifications within the database is presented in Figure 2.4.  
31 
 
 
Figure 2.4: Pie chart indicating the distribution of compound classifications within the database. 
Classifications shown are those which do not fall into a broader classification, as specified within the 
database.  The numbers of compounds that fall into each classification are shown next to each slice in 
the pie chart. Slices labelled using square brackets each contain that many compounds. Adapted from 
Hatherley et al. (in press) [70]. 
 
The main classes of compounds represented in the database include alkaloids, flavonoids, 
glycosides, steroids and terpenoids, together making up 83% of the assigned compound 
classifications. This figure is slightly lower, however, as some of these compound 
classifications overlap (Figure 2.5). Of the 144 alkaloids, 14 are also triterpenes, a sub-
classification of terpenoids. There are 19 compounds in the database known as cephalostatins, 
which are steroidal alkaloids. There are also 10 pregnanes, which are classified as both 
steroids and glycosides. Figure 2.5 shows how within the five most common compound 
classifications in the database, there are a number of sub-classifications. Many of these are 
also further classified to create more specific groupings. This gives a small glimpse into the 
diversity of compounds in the database.  
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Figure 2.5: Sub-classifications of major compound classifications present in the database. A pie 
chart is displayed for each of the five most prevalent compound classes in the database, showing more 
specific groupings of compounds within. 
 
Alkaloids from plants have been used globally in both medicines and poisons; as well as 
established drugs such as quinine, morphine and caffeine [126]. These are a structurally 
diverse set of compounds, many of which are considered to have a great deal of potential in 
modern drug discovery efforts, especially as antibacterial and antiviral agents [126–128]. 
Flavonoids, as discussed by Cao et al. [129] are an incredibly important class of compounds 
present in foods with health benefits ranging from antibacterial to anticancer properties. 
Flavonoid compounds have been tested and shown to display antibacterial, antifungal and 
antiviral activity [130]. Currently there are strategies to use bacteria to modify (biotransform) 
known flavonoids to create novel molecules with pharmaceutical potential. Mouradov & 
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Spangenberg [131] explain that the evolution of this class of compounds helped establish 
terrestrial plants and often form part of chemical defence mechanisms and protection from 
ultraviolet light. Cardiac glycosides have been used to treat heart problems and, more 
recently, cancer [132]. Steroid glycosides are common in marine organisms and mostly differ 
to terrestrial glycosides. These are structurally diverse, but very little has been done to assess 
their pharmaceutical potential [133]. Most steroids that have important pharmaceutical 
applications are made by modification of NPs, rather than synthesising them directly [134]. 
Terpenoids are the largest class of NPs [135] and make up the largest portion of the current 
database. This class of compounds is associated with a number of natural chemical defence 
processes and biological interactions, and have a number of well-characterised 
pharmaceutical properties [135, 136]. 
When comparing the collection of South African compounds collected in the present work to 
those from other NP databases, only CamMedNP and NUBBEDB [66, 95] give an indication 
of the different compound classifications present in their databases. As with our collection, 
terpenoids were the most common classification in both databases. This makes sense as 
terpenoids are the largest class of natural products [135]. Flavonoids and alkaloids were also 
prevalent in both databases, though to a relatively lesser extent for alkaloids in CamMedNP. 
The alkaloid-richness of our database may prove significant as this group of compounds are 
relatively underrepresented in pharmaceutical trials, even amongst NPs, despite their past 
successes, and it is believed that alkaloids should be used in drug discovery efforts [126–
128]. Our dataset also contains a large portion of glycosides and steroids, which make up a 
small percentage of CamMedNP and are not mentioned in NUBBEDB. There is no mention of 
some of the lesser-represented chemical classes from our database, such as organosulfurs, 
indans and taxanes in either database. These do, however, make up a small portion of the 
South African compounds, so it is possible that these classes fall into the “other” 
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classifications section mentioned in both CamMedNP and NUBBEDB. For CamMedNP, this 
would be challenging to confirm. The lack of a web interface prevents compounds to be 
searched by their classifications. The NUBBEDB website does allow compounds to be 
searched by classification (listed as ‘Chemical Class’), but provides no indication of what 
classifications are present in the database. No compounds were returned when searching the 
terms ‘acyclic’, ‘acylphloroglucinol’, ‘alkenyne’, ‘aromatic acid’, ‘furanone’, ‘indan’, 
‘norlignan’, ‘organosulfur’, ‘oxanthrone’, ‘perylenequinone’, ‘phorbol’, ‘polypropionate’, 
‘riboside’, ‘stilbenoid’, ‘taxane’, ‘tetraprenyltoluquinol’ and ‘xanthophyll’. Due to the 
partially subjective nature of classifying compounds, it is possible that some of these classes 
of compounds are present in NUBBEDB, but were simply assigned different classifications.  
In future, each compound in the database needs to be classified down to its most specific 
structural class, in order to make filtering compounds by classification as useful as possible. 
Unfortunately, this is not a trivial task. Apart from the problems already mentioned, 
compound classifications are not always logical from a structural point of view. A good 
example of this is highlighted by Bobach et al. [137] when they compare two of the 
compounds shown in Figure 2.6, androstane (A-1) and pregnane (B-1). Both are considered 
to be steroids, but fall under different classifications, which holds true for their derivatives. 
Even though the androstane skeleton is a common substructure in all compounds in Figure 
2.6, only abiraterone (A-2) is considered to be an androstane derivative. The compound 
pregnan-21-al (B-2) is a pregnane derivative and not classified as an androstane. This 
distinction between the two classifications is linked to the change in biological activity 
caused by the small structural difference [137]. As such, assigning classifications involves 
not only finding a suitable substructure, but also ensuring that a better substructure does not 
exist, which accounts for modifications, as with androstane vs pregnane derivatives. To do 
this manually would be both challenging and time consuming. Strategies are being developed 
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to automate this process to some extent by using information from chemical ontologies, such 
as ChEBI, with some success [125, 137]. This may need to be the next step taken with 
compounds in this database, as this would provide consistency and information would have 
set definitions from an authoritative source.  
 
Figure 2.6: Chemical structures of androstane and pregnane compound classifications and a 
derivative of each. The structures of androstane (A-1) and one of its derivatives, abiraterone (A-2), 
and pregane (B-1) and one of its derivatives, pregnan-21-al (B-2) are shown. Structures were drawn 
using the JSME molecular editor. 
2.3.1.3 Sources 
The database currently contains compounds isolated from 145 different source organisms. 
Although it is estimated that 3000 species of plants are used for medicinal purposes in South 
Africa [47] and there are accounts of plant extracts being tested for various forms of activity 
[53–55], it is difficult to tell how many South African species (both plant and marine) have 
had compounds isolated from them. As such, it is difficult to assess the completeness of the 
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database from this perspective. Something that can be done to further develop this section of 
the database would be to link the source organism data to external data sources. A good 
example of this is PlantZAfrica [138], which was developed by the South African National 
Biodiversity Institute (SANBI). The website provides information about plants from across 
Southern Africa and so would be useful if the database is expanded to include compounds 
from this entire region. This would be helpful to further study these organisms and gain more 
information regarding where they occur. 
2.3.1.4 Uses 
Quite a large portion of compounds in the database have confirmed biological activity 
(Figure 2.7). Of those assigned, 40% displayed some form of anticancer activity. These were 
often broken down into a specific form of activity, such as cytostatic activity against HL-60 
leukemia cells [139]. Compounds which displayed general cytotoxicity (i.e. against vero 
cells) were excluded from this grouping. Much like with the classifications, the uses can be 
divided into a hierarchy, and Figure 2.7 shows the compound uses at the highest level of this 
hierarchy. It is worth noting that when going through publications, only compounds that the 
authors considered to display significant activity were assigned use entries. Those that 
displayed low or no activity were not recorded. It may be worth recording that these 
compounds displayed no activity, so as to distinguish them from compounds that have yet to 
be tested for specific activity. Also, details about the way these activities were tested and 
actual values for each would also be helpful, though arguably ChEMBL should already have 
this information. The database would need to be modified in order to handle all this 
information, but it would enrich the data already present. An additional section that is 
currently being added is the known uses of the source organisms. Although some of the 
traditional uses may be anecdotal, a number of South African plant extracts have been shown 
to contain certain biological activities (refer to Section 1.4). Currently, the database houses 
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160 records of these uses, extracted from publications that isolate compounds from these 
sources. These have yet to be traced but to their original references, which is the next step 
that needs to be addressed for these entries.  
 
Figure 2.7: Distribution of compound uses within the database. The pie chart indicates the 
different uses recorded in the database, as well as the number of compounds with confirmed activity 
matching that use entry. 
2.3.1.5 Other names 
While searching for a compound in literature and other online databases, such as PubChem 
[72], it quickly becomes clear that an individual compound can be known by a number of 
different names. This can be challenging when finding the same compound in different 
publications. One of the goals when creating the database was keeping the information fully 
referenced. So if there was information from literature that was specific to that publication, 
the link between the compound and that information was also linked to the literature (Figure 
2.3). This helps when addressing the different names of compounds in different publications, 
which can cause confusion. A simple example of this would be the compound isolated by 
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Sidwell & Tamm [140] and given the name autumnalin. This was soon changed to 
eucomnalin [140] because the name autumnalin had already been assigned to a different 
compound. In a review by Koorbanally et al. [141], the same compound is still referred to as 
autumnalin, as well as (E)-5,7-dihydroxy-6-methoxy-3-(4'-hydroxybenzylidene)-4-
chromanone. The database keeps track of these changes and makes it easier to find a 
compound with a specific name or used to have a specific name. 
2.3.1.6 Physicochemical properties 
A common way to assess the drug-likeness of many natural products databases [67, 94, 95] is 
by using Lipinski's rule of five [121]. This involves assessing compounds, using four 
different properties: 1) the number of HBDs, 2) HBAs, 2) the cLogP value and molecular 
mass. The rule states compounds should ideally have no more than five HBDs, no more than 
10 HBAs, a cLogP value of less than 5.0 and a molecular mass not exceeding 500 Da. These 
properties were calculated for compounds in the database. The number of Lipinski violations 
within the database is summarised in Table 2.1, each displayed in more detail in Figure 2.8.  
Table 2.1: Lipinski violations of compounds within the database. Compounds are grouped based 
on the number of violations they make to Lipinski’s rule of five. The number of compounds in each 
grouping is indicated, as well as what percentage of the total number of compounds in the database 
these account for. 
Number of Violations Count % 
0 373 62 
1 112 19 
2 84 14 
3 30 5 
4 0 0 
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Approximately 62% of compounds in the database were shown to violate none of Lipinski’s 
rules and over 80% of compounds violate at most one of the rules. These are promising 
results, even when comparing to other databases. The properties used to define these 
violations are associated with the solubility and permeability of known drugs [121], which is 
why they give an indication of the “drug-likeness” of small molecules. The number of 
molecules with one or fewer violations greatly supports the potential of these compounds to 
be used for in silico drug screening studies. In addition to Lipinski’s rule of five, other 
properties have been used to assess compounds in other databases, including molecular 
volume, TPSA and number of rotatable bonds (NRB) [67, 94, 95]. Enriching the current 
compound database with this information will also be of value. 
 
Figure 2.8: Physicochemical properties of compounds in the database, based on Lipinski’s “rule 
of five”. Bar graphs are show, indicating the number of compounds with specific values for each of 
the properties calculated when determining their “drug-likeness”. These include A) Number of 
hydrogen bond acceptors; B) Number of hydrogen bond donors; C) LogP values and D) Molecular 
mass. Bars coloured in light grey indicate compounds with values above the cut-off, considered as 
Lipinski violations. Adapted from Hatherley et al. (in press) [70]. 
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2.3.2 Error fixing 
Apart from myself, three depositors assisted with uploading information to the database. 
These were David Penklar, Ngonidzashe Faya and Thommas Musyoka, each depositing a 
minimum of 100 compounds. As this was done manually, the process required steps to check 
for errors made while uploading. Firstly, within the construction of the database, a number of 
provisions were made to avoid redundancy. Fields such as DOI and CAS numbers required 
validators to be manually created in the models.py file to ensure these were unique if present. 
Scripts were written to find common errors that occurred when depositors uploaded 
compound information. These errors were identified by manually inspecting the entries of 
each depositor and are continually updated. Currently, the scripts checks for information that 
may have been omitted. For example, it checks to make sure that information linked to at 
least one reference, makes sure that references have at least one first author entry. The script 
also looks for formatting errors, such as unusual characters that should not be present in a 
SMILES string, as well as the format of external compound IDs and DOI numbers. These 
need to be entered in a specific format to ensure they can be used to link to the entry on 
external sites. Additionally, a link tester page was also created for entries with external 
compound IDs. After these IDs are entered by a depositor, the page automatically created 
links to the entry on the respective sites. These could be used by the depositor to quickly 
check that the ID was entered correctly and referred to the correct compound entry on the 
external site.  
The SMILES input process has been revised to minimise potential errors. When a compound 
image is uploaded to OSRA, the structure is automatically drawn within a JME applet 
provided by the server. This is the precursor to the JSME applet, written in Java, rather than 
JavaScript [105] and could also be used to correct the structure, if inaccurate, as well as 
produce SMILES for the resulting compound drawn. The SMILES was originally checked by 
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using the Daylight Depict site (URL), which renders a 2D image of a compound if the 
SMILES is provided. The image produced by the SMILES was compared to the original 
compound image uploaded to OSRA by visual inspection to check the accuracy and make 
sure the SMILES string was valid. It also provided a quick means to make sure all rings were 
closed when the structures were drawn and that no hidden atoms were present in the 
structure, as could sometimes happen. There are, however potential problems with just using 
Depict to check for accuracy, especially with larger and more complex compound structures. 
Depict would not always return an image of the compound in the same orientation as the 
original compound image, making it difficult to compare the two structures by visual 
inspection. Also, it was easy to miss small changes between two structures this way, such as 
an additional heavy atom in long, aliphatic chains, or a substitution of a Carbon atom with 
Hydrogen, for example. Also, there was no quick way to tell if all known stereocentres were 
defined, without explicitly checking and comparing each. To remedy this, an additional step 
was added to the upload process. The Open Babel suite provides a program called obprop, 
which calculates certain properties of compounds, including the chemical formula and InChI. 
A quick way to tell if the compound was correctly drawn was to use obprop to calculate the 
formula produced by the SMILES string of the drawn compound. If the structure looked 
similar to the original 2D image and the formulas matched, it was considered safe to assume 
that the skeleton of the structure was at least correct. The InChI was then consulted to 
determine if the stereochemistry of the compound was fully specified. If not, question marks 
appear within the certain portions of the InChI string. This allows a depositor to quickly see if 
any chiral centres may have been missed when drawing the compound. Finally, if the 
PubChem ID of the compound was known, the InChI of the compound could be compared to 
the corresponding entry in PubChem. In addition to improvements in the methods used to 
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upload compounds, the data is timeously inspected by spot checks to see if errors may have 
been made or if information was missed when depositors were going through their references.  
The generation of 3D coordinates for compounds also needed to be revised. This was 
originally done using Open Babel. However, there are parts of the Open Babel’s 3D 
generation capabilities that are still under development [116]. When this was initially used, 
structures were checked by Dr Lobb for potential inaccuracy and corrections were made 
manually by him using Discovery Studio. This was also part of the original means of 
checking the SMILES input by depositors when capturing compound information. Once 
obprop was incorporated into the error-checking process, the InChI of the 3D structures 
produced could be compared to that from the original SMILES string used as input to 
generate these structures. Using this, it was found that just under 200 of the 3D conversions 
performed by Open Babel contained at least one stereocentre that was incorrect.  Further 
investigation revealed that this was due to a specific type of substructure that the software 
struggled to handle. Although there is no official documentation that describes this problem, 
it is discussed online [142]. The way Open Babel generates 3D coordinates for compounds is 
a rule-based approach, which is used assign the backbone structure of the compound before 
the stereochemistry is fixed. The problematic substructure encountered was one where two 
rings join and the chiral atoms are bonded to three different ring atoms (Figure 2.9). These 
can not be fixed without breaking and reforming the bonds, which Open Babel is unable to do 
and leaves the substructure as is. To remedy this, the commercial software CORINA [118, 
119] was used. Conversions made using this software appeared to retain the correct 
stereochemistry specified in the SMILES string. CORINA is used by the ZINC database, 
which indicates it should produce structures of sufficient quality for public use. The well-
established online databases do used commercial software to ensure the quality of compounds 
within their databases.  
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Figure 2.9: Fused ring stereocentres. The 2D and 3D of fused rings are indicated for both trans 
(grey) and cis (blue) structures, based on the bridgehead carbons. The bonds facing out of the ring are 
coloured in red. 
2.3.3 The SMILES parser 
The SMILES parser consists of a number of scripts that are largely still under development. 
Its current incorporation into the work presented is very limited, but with a great deal of 
potential to grow. At present it has simply been used to identify and count hydrogen bond 
donors of compounds in the database as part of the chemical properties calculations (Section 
2.3.1.6). This involves looking at the number of Nitrogen or Oxygen atoms in a compound 
with free hydrogens. Since SMILES leaves hydrogens to be specified implicitly, these need 
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to be determined by looking at the number other heavy chain atoms attached to these 
Oxygens and Nitrogens, including those within rings, whilst considering bond types and the 
charges of these Oxygen/Nitrogen atoms, if present. These are fairly light-weight calculations 
that can be performed for all 600 compounds within the database virtually instantaneously, 
which make them useful to be incorporated into a simple Python script. In future, the 
SMILES parser will be improved and further developed to increase its functionality. The 
most immediate goals involve use in compound image generation and enhancing substructure 
searching. 
2.4 Conclusion 
Presented in this chapter are the design, construction and population of a compound database 
that focuses solely on natural products isolated from South African organisms. The retrieval 
of data was, as far as possible, linked to external references, which can be looked at in future 
to both verify the information extracted, as well as go back to the original work to review 
details not captured for the purposes of the database presented. Apart from the chemical 
information, data concerning other names, source organisms, uses and most recently 
anecdotal uses of source organisms were captured, each linked to at least one external 
reference where possible. The current content of the database consists of 600 compounds, 
from 170 different references pertaining to 143 different source organisms. There are also 
284 different records of compounds showing promising activity and 160 records of anecdotal 
uses for the source organisms, as used in traditional medicine. There are currently several 
plans to enhance the current data contained within the database concerning source data, use 
data, physicochemical properties data. In addition to this, the number of compounds in the 
database will continue to grow, further expanded by including simple derivatives reported in 
literature, as well as potentially increasing the borders of the information content to include 
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all countries within Southern Africa. Data quality in the database is incredibly important and 
this will continue to be monitored and means to improve error checking capabilities 
developed to ensure high quality data. Calculations performed on the compounds extracted 
indicate that over 80% have promising physicochemical properties, based on Lipinski’s rule 
of five, for future inspection in drug development. To assist with this, 3D structures of all 
compounds have been calculated and minimised for future in silico screening studies. To take 
full advantage of this, the next step, presented in Chapter 3, involves developing a means of 
sharing this data with the research community. This ensures that its use is maximised and the 
compound information isolated can be used for screening against a variety of potential drug 
targets, not just those of interest to our own research group. 
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Chapter 3 The SANCDB website 
In the previous chapter, a database of compounds isolated from organisms found in South 
Africa was established. In order to make this information easily accessible to the general 
research community, a website was created as an online interface to the database. The 
website was named the South African Natural Compounds DataBase, or SANCDB. It allows 
compounds to be searched for based on all information gathered on each and contains links to 
data from external sites. Apart from a graphical interface, a web API was also established, so 
that information can be retrieved without having to visit the SANCDB web page. Also 
included is a compound submission pipeline which will enable other researchers to openly 
contribute to the database. This will help develop SANCDB into a community driven front 
end to information gathered concerning natural products research in South Africa. The work 
presented in this chapter and Chapter 2 was recently accepted for publication [70]. This 
website will be made available at https://sancdb.rubi.ru.ac.za/ as soon as it is published.  
3.1 Introduction 
While it is not uncommon for researchers to have their own libraries of chemical compounds 
[67, 143–145], this information can often be kept within a research group or otherwise be 
difficult to access. In bioinformatics, open source databases such as the PDB and GenBank 
were found to be incredibly beneficial in progressing both molecular and structural biology 
[146]. Presently, there are a number of online chemical compound databases and the majority 
of data lies with commercial databases. For example, the commercial SciFinder houses 93 
million compounds, compared to PubChem, the largest public chemical resource, which 
contains 53 million [147]. Recent trends have indicated, however, that this may not be the 
case indefinitely [147].  
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3.1.1 Commercial compound databases 
Commercial databases pride themselves on having high-quality data, as well as a great deal 
of information not found in freely accessible databases [146]. SciFinder [103] is probably the 
most well-established and revered commercial compound database and often either SciFinder 
or CAS are referred to when discussing commercial databases [146–148]. Reaxys [149] and 
NAPRALERT [90] are other good examples which are used in present-day research [94, 
150–152]. Although Reaxys has no official publications, in literature it has been used to 
retrieve over 118 000 unique NP chemical entities, not found in other databases [94]; for 
retrieving physicochemical properties for a set of compounds [150] and searching for 
literature and patents regarding the chemical constituents and bioactivity data of a specific 
species of plant [151]; just to name a few of its uses. In 2008, SciFinder was making over 
$250 million annually, charging for their services and are able to use this to hire skilled 
chemists to ensure the high quality of their data [146].  
3.1.2 Free-access compound databases 
ChemSpider [153] is a good example of an open source collaboration. Developed by the 
Royal Society of Chemistry (RSC), the database contains over 30 million unique chemical 
structures from over 500 different online resources and even grants access to information 
from commercial databases [154]. Freely accessible databases often require a great deal of 
external funding, such as PubChem (NCBI), which is funded by the NIH [74], and the RSC is 
a group with over 50 000 members [154]. Both groups are funded for the development of 
scientific knowledge rather than commercial gain. An additional set of chemical data includes 
those from open source initiatives. These receive no funding but are managed by the 
chemistry community, as with Blue Obelisk organisation [155].  
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3.1.3 Web frameworks 
The internet forms a crucial and increasingly common means of gaining access to scientific 
information, and this is no exception to information that is pertinent to chemists [146]. The 
means of developing websites has gone through a number of stages to make handling 
increasing large quantities of data more practical and secure [156]. Web pages can be 
considered as files written in Hyper Text Markup Language (HTML), styled with Cascade 
Style Sheets (CSS), which together describe the content of a web page [157]. HTML is the 
language web pages are written in and is interpreted by a web browser [157], while CSS is 
used to specify how different parts of a web page look and is often contained in a separate 
document to an HTML file [158]. Additionally JavaScript, which allows the HTML and CSS 
within a page to be manipulated, as well as Ajax, which handles data requests without the 
page needing to reload every time, have become important to web development [159]. The 
most common way to create dynamic data-driven websites is to combine MySQL with PHP, 
a scripting language that can be embedded within web pages [156, 159]. PHP is easy to learn 
and use, which contributes to its popularity, but can just as easily introduce security risks into 
websites [156]. The latest generation web frameworks, such as Django and Ruby on Rails, 
were designed such that HTML content could be generated dynamically, but also provide 
features which automatically guard against mistakes that compromise the security of a 
website [156].  
3.1.4 Model-View-Controller design paradigm  
Model-View-Controller (MVC) is an architectural design implemented when developing an 
application [160]. It allows the application to be separated into three independent parts, which 
can each be altered without affecting the others [156]. These are named the model, view and 
controller. The model contains the so-called “business logic” of an application. Here the 
structure of the data is designed, as is the means by which it may be accessed or altered. The 
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view is simply the part of the application that the user sees and interacts with, otherwise 
known as the user interface (UI). Finally, the controller connects the model to the view, 
allowing communication between the two [160]. The relationship between these three is such 
that the user makes a request via the view. The controller sends this request and any 
accompanying information to the model, which handles the request. The response is sent 
back by the controller and used to update the view.  
3.1.5 Model-Template-View 
The Django web framework has a slightly different interpretation of the MVC paradigm. The 
framework itself acts as the controller, since communication between the model and the view 
is handled automatically. The model layer only defines the data and how it may be 
manipulated. There is a template layer describes how the data should be displayed and a 
view, which houses the logic of the application and handles communication between the 
models and the templates. This is considered to be a Model-Template-View (MTV) design, 
but otherwise operates on the same principles as the MVC design paradigm [156]. 
3.1.6 Web servers  
A web framework provides a means of designing a web application , but does not enable 
information to be sent and received over the internet [156]. This is done by a web server 
[161]. When a user accesses a web page, it will have a specific Uniform Resource Locator 
(URL), e.g. https://www.google.co.za. A web server is run on a host machine and uses the 
URL to decide what information is sent to the web browser and presented to a user. Apache is 
by far the most widely used webserver. It is designed to be secure, to handle multiple 
requests, and to support a number of different file formats when information is sent over the 
web [161].  
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3.1.7 Proposed work 
The previous chapter describes the establishment of a database of South African NP database. 
Presented in this chapter is the use of this database to create an online interface which has 
been named, “SANCDB”, through which this information may be accessed, filtered and 
downloaded. The layout of the website is described along with the process that by which 
users may search for information, download content or follow links to access additional data. 
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3.2 Methodology 
3.2.1 Website name and logo 
In order to allow users to easily identify the site, a name and logo were created. The name 
“SANCDB” was chosen, which stands for the South African Natural Compounds Database. 
The name was chosen with the criteria that it was descriptive of the contents of the database 
and also that it had not been used elsewhere. This second criterion was checked by means of 
a Google search [113]. Secondly, a logo was designed and created using simple shapes 
provided by Microsoft PowerPoint. 
3.2.2 Layout of the website 
The SANCDB website was created using a CSS bootstrap template [162], which had 
previously been modified by David Brown from the Research Unit in Bioinformatics (RUBi), 
Rhodes University; and further modified for use in this project (Appendix D). Django was 
used to specify the content of each page and handle calls to the database. JavaScript and Ajax 
were used to provide functionality on each page, after these had been rendered by Django.  
3.2.1 Web API 
A RESTful API was also included using the Django REST framework. A set of Serializer 
classes were created, based on the Django models describing the database. These serializers 
simply describe the layout of the data to be transferred, much like the classes in models.py 
do. API View functions were written for a variety of URLs to account for different possible 
usage scenarios. The API Views, URLs and Serializer classes are shown in Appendix A; 
Files: serializers.py, urls.py and views.py. 
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3.2.2 Website pages 
3.2.2.1 Search pages 
The search pages generally comprised four main components: 1) Initial logic from the view 
function, which renders each page; 2) Template scripts and forms, which present search 
options, capture search queries and make Ajax calls; 3) A second view function which 
queries the database for the information requested and returns the data retrieved to the 
template and 4) Scripts which updates the template and page with the search results. The 
Python library, pylibmc, was used to cache common database calls. The logic incorporated 
into these pages works as follows. 
3.2.2.1.1 Rendering view function logic 
For pages with browse sections, a database call is made which retrieves all search entries for 
that page and sorts them alphanumerically. These are stored in a list of tuples, with the name 
of the entry as the first item in the tuple and the ID of that entry as the second item in the 
tuple. The template for the page is then rendered with this information. 
3.2.2.1.2 Template forms and search logic 
Template scripting was done using JavaScript, using the jQuery and jQuery UI JavaScript 
libraries. The code used to perform these searches was specific to different search types 
(Appendix E; Files: sanc.js, sanc_advanced.js, sanc_physico.js, sanc_refs.js and 
sanc_search.js). Firstly, for pages with browse sections, the data from section 3.2.3.1.1 was 
used to create a list of names, relevant to the page and divided into sections, based on the 
letter they started with. A set of buttons was created, each of which with a single letter of the 
alphabet displays the list of names that start with that letter. The ID associated with each 
name was used to create a link to a page containing data specific to that entry.  
53 
 
The jQuery UI autocomplete function was used to create search bars which update as the user 
types, showing all possible search terms that contain the letters typed so far. The data used to 
populate these was retrieved using an Ajax call to cached data. When the search button is 
clicked, the search terms are converted to JSON and an Ajax call is made. 
3.2.2.1.3 View search logic 
The view function was written to convert the JSON from the Ajax call using the json Python 
library and queried against the database. Django’s Q objects were used for queries involving 
multiple search criteria. The results are included in a list, converted to JSON and sent as a 
response to the Ajax call.  
3.2.2.1.4 Template display of results 
The results of the Ajax call are tabulated, with links to the compound summary pages and 
functionality to download specific compounds.  
3.2.2.2 Compound summary page 
Included in the URL for a given compound summary page is the ID of the compound, as it 
appears in the Compounds table of the database (refer to Section 2.2.1). This ID is used as a 
parameter in the view function to retrieve information for that specific compound. The SANC 
ID for the compound is prepared, as are the list of other names for the compound, the 
compound formula, the reference citations, as well as the links to PubChem and DrugBank 
(refer to Section 3.2.3). This information is used when rendering the template (Appendix F; 
File: comp_page_2.html).  
3.2.2.3 API documentation page 
The API documentation page was generated using the Django REST Swagger documentation 
tool. The information specified in the documentation was included in each API view 
function. 
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3.2.3 Data preparation functions 
A number of functions were incorporated into the Views file for the SANCDB application. 
These simply prepared the data in a specific format so it could be used within certain pages. 
The following were all incorporated into the compound summary page. 
3.2.3.1 SANC ID 
The SANC ID of each compound is an identifier, used to name the compound within the 
database. Each SANC ID is the same length, consisting of the prefix “SANC”, followed by a 
five-digit ID number, which reflects the compound’s primary key ID in the Compounds table 
of the database. This was used when naming compounds, as well as files associated with the 
compound. For example, compound SANC00101 can be searched locally in the database 
using its ID ‘101’ and coordinate files of the compound will be named SANC00101.pdb, 
SANC00101.sdf, etc. 
3.2.3.2 Compound names 
When the names of compounds were captured, unusual characters, such as ‘α’ and ‘β’ were 
converted to ‘[alpha]’ and ‘[beta]’, respectively when stored in the database. These were 
converted back to the original characters for display on the summary page. The script also 
includes steps to standardize the way a compound is written, with respect to capital letters, 
italics, etc., since these were provided in different ways by different references and also 
handled differently by depositors. The script identifies ‘whole words’ within the name, based 
on the presence of spaces, dashes, commas etc. These are compared to a pre-rendered list of 
terms, for example, “trans” and “cis”. If the word is not in this list and it is the first word in 
the name, it is capitalised. If it is in the list, depending on the term, it will generally be 
italicised and not capitalised. This is done for all captured names of the compounds and the 
script is updated based on new names and exceptions encountered as compounds are 
uploaded to the database. 
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3.2.3.3 Citations 
These are just the way a referenced work is displayed on the summary page. The format is 
fairly simple and follows the pattern of 1) First author, 2) Author suffix, 3) Year, 4) 
Reference title. The Author suffix, changes based on the number of authors listed in the 
reference. For a single author, there is no suffix. For two authors, the suffix “and [Author 2]” 
is used, and for more than two authors, “et al.” is used.  
3.2.3.4 External links 
The links to external databases include the URLs of compound entries in other databases, 
including ZINC, PubChem, ChEMBL and DrugBank. The URL was constructed based on the 
ID of the entry in the external database, as these have a standard format in each external 
database. The links were automatically created, based on the values stored in the database. 
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3.3  Results and discussion 
3.3.1 Website layout 
The general layout of the site is displayed in Figure 3.1. The template divides the website into 
three portions: 1) The navigation section; 2) The sidebar and 3) The content section. 
 
Figure 3.1: Layout of the SANCDB web interface. The general layout of pages within the 
SANCDB website is shown, with the different sections of the template used, labelled. The content 
section is the only part of the page that changes, displaying content that is relevant to the specific page 
accessed. The navigation section and sidebar can be sub-divided as follows. A) Navigation links; B) 
Login/logout button and widescreen button; C) Compound search links; and D) Additional links. 
3.3.1.1 The navigation section 
This contains additional links and drop down menus (Figure 3.1 A), as well as the 
login/logout button and a button which shows/hides the sidebar (Figure 3.1 B). The name of 
the site, SANCDB, is displayed in the left corner of the screen and links to the homepage. 
57 
 
The rest of the navigation links summarise the sidebar section into a series of dropdown 
menus. This section also contains links not found in the sidebar section of the screen. 
3.3.1.2 User login 
User login and signing up is handled by an application created by David Brown. A user needs 
to provide their username and password to log in and use the website. If the user does not 
have an account, they can sign up for free. The signup screen has been modified for use is the 
SANCDB website to capture the name and university/organisation of the user. As the website 
aims to be freely accessible, users will not be obligated to sign up or log in to browse the 
website content and download data. Login will be encouraged, however, as a means to simply 
help us keep track of who is using the website. This will also allow sessions to be geared 
towards specific users. For example, the site could keep track of usage history, so users could 
quickly retrieve compounds they downloaded previously or be notified if similar compounds 
are uploaded. User login will be required for compound submission (Section 3.3.5), as these 
entries may will need to be linked to the user’s account.  
3.3.1.3 The sidebar and page content 
The sidebar contains quick links, commonly used in the in the website, including links to the 
different compound search options (Figure 3.1 C) provided, as well as tools associated with 
the site (Figure 3.1 D), each described in more detail below. The tools section is reserved for 
additional content and functionality that might be included in the site in future. 
3.3.2 Searches 
The SANCDB website currently provides ten different search options to allow users to find 
compounds of interest. These include searches based on 1) The name of a compound; 2) 
SMILES; 3) Structure; 4) Properties; 5) Source organisms from which a compound has been 
isolated; 6) Classification; 7) Uses; 8) Authors who have isolated or worked with a 
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compound; 9) Referenced works that pertains to a compound and 10) Combining multiple 
search criteria (Advanced search).  
3.3.2.1 Text-based searching 
Most pages involve searching simple terms to find compounds, based on a specific attributes. 
To describe these types of search pages, the Source Organisms search page will be used as an 
example (Figure 3.2).  
 
Figure 3.2: Source Organisms search - First view. The content section of the source organisms 
compound search page, as indicated in Figure 3.1, is shown. This page provides ways to search for 
compounds from specific organisms (top) and browse through the set of source organisms currently 
housed within the database (bottom). 
These search pages are split into a Search section at the top and a Browse section just below 
this. The browse section of the page (Figure 3.3) contains buttons indicating the letters A-Z, 
as well as an asterisk (‘*’) and an ‘ALL’ option. As soon as one of these buttons is selected, 
the Search section falls away. A ‘Show Search’ button is presented in the top right corner of 
the page, which will show the Search section again. While browsing, the user may select any 
of the lettered buttons mentioned and all entries starting with that letter will be listed. The 
asterisk option is for entries that do not start with letters or begin with special characters, such 
as α or β. Clicking on any of the entries listed will direct a user to a page of all compounds 
associated with that entry. 
 
59 
 
 
Figure 3.3: Source Organisms search - Browse section. This interface is shown when the browse 
section of the page is engaged. The search section is hidden, but can be returned by clicking in the 
‘Show Search’ button. The source organisms are those that start with the letter ‘A’, displayed when 
the button for this letter is clicked on. 
 
The Search section simply contains an input box in which users type in their search query. An 
autocomplete function has been employed, which indicates entries containing the letters input 
so far. Users may select search terms from the autocomplete list or use a semicolon (‘;’) to 
separate different search terms. Multiple search terms can be input this way. Once again, 
when the ‘search’ option is clicked on, the Browse section falls away and is replaced by the 
‘Show Browse’ button in the top right corner of the page. The actual search is handled by an 
Ajax request, which queries the database and displays the results without having to reload the 
page. The search results are tabulated as shown in Figure 3.4. The way the results are 
tabulated varies across the different pages, depending on what information is available. The 
SANC ID of each compound will be displayed, which links to the summary page for that 
compound (Section 3.2.2.2), along with its image and a check box to select it for download. 
If possible, the phrases matched when querying the database will also be displayed. For 
example, in Figure 3.4 the results are shown for a Source Organism search matching the 
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phrase “eucomis”. Compound SANC00221 ((R)-Scillascillin) has been isolated from both 
Eucomis schiffi and Eucomis humilis, so these are listed under ‘Organisms Matched’. The 
tabulated results have check boxes to select specific compounds for download, as well as a 
‘select all’ option, which selects all check boxes for this purpose. The download process 
(Figure 3.5) allows compounds to be downloaded in Molfile (MOL2), PDB, SDfile (SDF) or 
SMILES format, as well as minimised compounds in PDB format. Once one of these options 
is chosen, all compounds selected are set for download as part of a .ZIP file. 
 
Figure 3.4: Source Organisms search – tabulated results. Search results are shown for searching 
using the query ‘eucomis’. Compounds are tabulated with their 2D images shown, as well as links to 
their summary pages. All sources that match the search criteria are also shown, and the check boxes 
on the right can be used to select compounds from this list for download. 
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Figure 3.5: Downloading process. The download process is summarised. After compounds of 
interest are selected, the ‘Download selected’ button can be clicked to display a dropdown list of file 
formats in which the compound set can be downloaded. Once one of these is selected, the download 
process is initiated and compounds are downloaded as a .ZIP file. 
3.3.2.2 SMILES- and structure-based searching 
The SMILES search page and structure search page are similar in that they both use SMILES 
to query the database for matching compounds. The structure-based search is, however, more 
user-friendly as it employs the JSME applet (Figure 3.6). This allows users to simply draw in 
a chemical structure, substructure or functional group of a compound they might be interested 
in. The advantage of this is that the user requires no working knowledge of SMILES and can 
visualise the desired chemical entity before they search for it. This kind of search has become 
standard in chemical web databases. For example, ZINC [78] and NuBBE [95] both use the 
WebME drawing tool from Molinspiration  [163], whereas ChEMBL offers a number of 
different drawing tools for this purpose [75]. These pages perform substructure searches by 
default, using Open Babel. In future, options will be provided to search based on similarity, 
again using Open Babel.  
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Figure 3.6: JSME applet. The structure drawing applet is indicated with a substructure drawn in. By 
clicking on the ‘Show SMILES’ button, the SMILES for the compound gets displayed, as shown. By 
clicking the ‘search’ button, the database will be queried for all compounds that contain the 
substructure drawn. 
3.3.2.3 Properties search 
The Properties search page allows users to search for compounds based on the 
physicochemical properties that have been calculated for these compounds. Currently, these 
are based on Lipinski’s rule of five [121] include molecular mass, LogP, number of hydrogen 
bond acceptors and donors (Section 2.2.7). Slider bars are provided on this page in order to 
allow users so search for compounds with properties that fall within a specific range (Figure 
3.7). This section will be expanded as the means to calculate additional properties become 
available.  
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Figure 3.7: Properties slider bars. The search slider bars are shown for the Properties search page. 
The sliders can be used to set a specific range of values for mass of the compounds, cLogP, HBAs and 
HBDs. When the ‘Search’ button is clicked, the database will be queried to find all compounds with 
properties that fall within the ranges specified. 
3.3.2.4 Reference search 
The Reference search section is a more advanced version of the simple text-based search 
pages. As with these, the user can browse different references by their title. However, as with 
compounds, references have a number of different attributes by which they can be searched 
against. As such, the Reference page allows users to search for references based on Title, 
Year, Authors, Journal, Source Organisms and Uses. These can be distinguished using radio 
buttons, to allow users to decide which attribute they would like to search by. As with other 
text-based search pages, an autocomplete function is incorporated to allow users to filter their 
search options as they type. The list of options provided by this function changes based on 
which search option is selected. This is demonstrated in Figure 3.8. The result of a search is 
still a tabulated list of compounds. The title of the reference matched for each compound is 
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displayed, as well as the search phrase that was matched when querying the database (i.e. the 
name of the author or journal etc. searched).  
 
Figure 3.8: References search bar. The References search page is shown. References can be 
searched for based on Title, Year, Author, Journal, Source Organism or Use. These are selected using 
the radio buttons shown. When a radio button is selected, the content of the autocomplete function id 
updated to be relevant to the search option. For example, in (A) a set of source organisms make up the 
search list and in (B), the names of journals are used. 
3.3.2.5 Advanced search 
The Advanced Search page combines text searches across different compound attributes that 
could be searched individually through the various other text-based search pages. Currently, 
compounds can be searched by combining search queries for source organisms, compound 
classifications, uses, year of publication and author name of publication. These are presented 
as five separate search bars (Figure 3.9), each with their own list for the autocomplete 
function. Entries from different search bars are treated as ‘AND’ queries and those from the 
same search box are treated as ‘OR’ queries.  
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Figure 3.9: Advanced Search bar. The Advanced search page is shown, which allows compounds to 
be searched for using a number of different criteria. Each search bar has its own autocomplete 
function. 
3.3.3 Compound summary page 
The compound summary page contains all information in the database about a given 
compound. The header of the page is the SANCID of the compound, followed by basic 
information, such as the compound’s name and formula. If available, external IDs are given 
for entries of the same compound in other online databases, along with links to the compound 
entry pages in those databases. Two different graphic representations are provided for each 
compound (Figure 3.10). By default a 2D image of the compound is shown, as produced by 
the Indigo toolkit. A ‘3D View’ button is provided which shifts this to a 3D representation of 
the compound without hydrogens. The compound shown is a PDB file rendered in GLMol. 
This uses WebGL and allows the compound to be freely rotated on screen to get a better look 
at it. A ‘2D Image’ button is also provided to switch back to the 2D compound image 
representation. Just below the compound image is a download section. This works in the 
same way as the tabulated download system, except a single file will be downloaded for the 
compound in the specified file format, rather than a compressed .ZIP file. Below this is the 
rest of the information available for the compound, including its SMILES, references and 
recorded classifications, other names, source organisms and uses. The references section also 
contains links to the online resource containing the reference. This is done based on the 
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references DOI number and usually goes to the journal’s website entry for that specific 
article. 
3.3.3.1 External links 
As each compound was added to SANCDB, the external databases ChEMBL, DrugBank, 
PubChem and ZINC were searched to see if they contained the compound. PubChem 
searches yielded 141 compounds, which was the greatest number found in these databases, 
followed by 96 compounds from ChEMBL. This is understandable, since PubChem is the 
largest publically-accessible compound database [147]. Only 19 compounds were found in 
ZINC and nine from DrugBank.  
 
Figure 3.10: Compound 2D image and 3D representation. The 2D image and 3D representation of 
compound SANC00229 (Autumnariniol) is shown. The 2D image was created using the Indigo toolkit 
and the 3D coordinate file for the compound was rendered using GLMol. Both of these depictions can 
be viewed on the compound summary page. 
3.3.4 Web API 
The web API allows content of the website to be accessed and retrieved without needing to 
use the web interface. This is also easier to incorporate into external applications that do not 
have access to the database used by the SANCDB website. The web interface of SANCDB 
provides a link to the documentation for the web API, generated using the Django REST 
Swagger tool. There are two different ways to retrieve information from the web API. Firstly, 
there are search URLs (Figure 3.11), with the “/api/search/” prefix which provide similar 
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search options to the web interface. This accepts search terms to query the database and find, 
for example, all records of compounds from the source organism Acacia karroo (URL: 
/api/search/compounds/source/acacia%20karroo/). These search URLs were designed to 
return information about each compound, as well as references associated with them. The 
information is returned in JSON format, structured as it appears in the database.  
 
Figure 3.11: Django REST Swagger documentation page, showing search options for web API. 
The second way to retrieve information is to use the specific retrieval URLs (Figure 3.12). 
These are useful if the IDs are known for specific entries, which are included in the data 
returned when using the search URLs. These URLs currently apply to authors, classifications, 
compounds, other names, references, sources and uses. To demonstrate how this may be 
used, the source organism, Cephalodiscus gilchristi, can be considered. This organism has the 
ID “100” in the Sources table of the database. To retrieve information about the structural 
classifications of compounds found in this organism, the URL, 
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/api/sources/100/classifications/, could be used. To find all references in the database 
associated with this organism, the URL, /api/sources/100/references/, would be used. As 
such, by combining the search URLs with the retrieval URLs, a great deal of specific 
information can be retrieved for different entries in the database, without having to use the 
SANCDB web interface.  
 
Figure 3.12: Django REST Swagger documentation page, showing retrieval options for web 
API. 
3.3.5 Compound submission pipeline 
The compound submission pipeline is a workflow, created by David Brown, which allows 
users to submit their own compounds to the database. It has been designed to mimic the 
upload process used by depositors and integrates scripts used to generate compound 3D 
coordinates, covert coordinate files into different formats, as well as perform minimisations. 
After compounds are submitted, they will be checked by curators from RUBi. If the 
compounds are from published literature, this process will also involve ensuring that all 
relevant information was extracted from these publications. Users with compounds that have 
69 
 
not been published may still submit their own compounds, but these will be linked to their 
users account. One of the goals of this project was to ensure that compound information was 
fully referenced, so as to be linked to an authoritative source. Until suitable literature is 
found, the user will be the authority on the compounds they submit.  
3.3.6 Site documentation 
The SANCDB website provides documentation for users that are new to the site. This page 
currently explains how to search for and download compounds. As the database expands to 
incorporate new information or new tools are integrated into the website, this page will be 
updated to describe and explain how to use these new features. 
3.3.7 Integration of tools in future 
Future developments to the site include enhancing the content of the database, as well as the 
integration of simple and useful tools. Currently the SANCDB website links to a web API 
and submission pipeline. There are several tools that are being developed, such as SMILES 
parser (Section 2.3.3) and the automated modelling tool (Chapter 6). The integration of these 
tools and their potential value to the site is discussed in Chapter 7. 
3.4 Conclusion 
SANCDB is an online interface to the South African natural products database established in 
Chapter 2. It is a user-friendly site that provides a number of different search options to find 
information collected about compounds in the database. Compounds can also be downloaded 
in a number of different formats, which will allow them to be further characterised or studied 
computationally. An API has also been added to provide an additional means to access the 
data housed within SANCDB and a compound upload screen has been incorporated to aid in 
the expansion of the database.   
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Section 2: Development of a homology 
modelling tool, based on protein 
structural studies 
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Chapter 4 Structural bioinformatics and its 
applications 
4.1 Proteins, their structure and function 
Proteins form an integral part of nearly all biological processes [164]. The structure of 
proteins have been shown to be responsible for their function [165]. The native state of a 
protein can be considered the overall spatial arrangement of its structure in which it is 
biologically active [164]. As such, a key goal of structural biology is to be able to determine 
the native structure of proteins in order to better study the mechanisms by which they 
function. 
4.2 Structural genomics 
Structural genomics projects aim to determine the structures of a large number of proteins 
[166]. This was brought about mostly by the success of genome projects producing a large 
quantity of sequence data, which has led to the establishment of a number of structural 
genomics projects in America, Asia and Europe [166]. This was aided by advances in both X-
ray crystallography and NMR techniques, as well as the methodologies to express 
recombinant proteins [166]. The goal of structural genomics is to produce a protein structure 
for each sequence known for an organism. Proteins are, however, inherently more difficult to 
work with than DNA. They are far more diverse in their make up and vary greatly in physical 
properties and solubility. This has limited the number of proteins that have been produced as 
a pure, soluble sample with sufficient quality for X-ray crystallography and solution NMR 
[166]. 
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4.3 Experimental methods of structure determination 
4.3.1 X-ray crystallography 
The bulk of the protein structures deposited in the PDB each year are solved using X-ray 
crystallography (Table 4.1 and Table 4.2). Since 1990, a number of improvements have been 
made to X-ray crystallography. Firstly, the processes involved in both the production and 
crystallisation of proteins have been automated. Other developments include the availability 
of more powerful X-ray sources and the advancement of the algorithms involved in collecting 
and processing X-ray diffraction data [167]. The use of robotics has also severely decreased 
the amount of pure protein required to produce crystals for structural determination X-ray 
crystallography. The first crystal structure, published in 1958, was that of myoglobin, solved 
at a 6 Å resolution [167, 168]. X-ray crystallography has come a long was since then, but can 
still be an incredibly difficult process, which requires high yields of pure protein crystals. 
This can prove challenging, as the process of crystallization is complex and not entirely 
understood. Often, protein samples fail to produce crystals of suitable quality, and sometimes 
crystals must be obtained through trial and error using a number of different approaches [167, 
169]. The formation of protein crystals involves adding a precipitant to a protein solution. 
This can be achieved through a number of different methods; although the process of 
equilibrating the protein solution with the precipitant is becoming standardised, especially for 
automation [167]. Proteins are rarely produced directly from their source organisms for 
crystallography and are usually engineered to be expressed in Escherichia coli (E. coli) or 
certain eukaryotic cell lines [167]. The actual X-ray crystallography process involves 
exposing a crystalized protein sample to X-rays of a single wavelength that have been 
focused into a beam. This is repeated a number of times, while rotating the proteins crystal 
sample around a set axis. The X-rays are scattered by electrons within the protein structure 
and during this process the diffraction patterns of these X-rays are recorded [170]. This also 
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helps to determine the dimensions and orientation of the unit cell, which is defined as the 
smallest repeating unit that makes up a crystal [169]. The way the X-rays are diffracted, as 
well as the intensities of each individual diffracted X-ray, is based on the size and shape of 
the unit cell, as well as the position of each atom in the crystal [167]. As a result, modelling 
any given part of the unit cell requires the rest of the structure to be modelled as well, which 
is one way X-ray crystallography differs to other methods. The X-ray diffraction data yields 
an electron density map, which is processed to predict the positions of individual atoms and 
molecules within the crystal structure [167]. The electron density map is often refined to 
account for possible experimental errors [169]. The protein model produced from the electron 
density map is also refined based on energy minimisation and stereochemistry. An electron 
density map is calculated, based on the refined model and an R-factor is determined by 
comparing this to the experimental electron density data [169]. 
Table 4.1: Number of structures present in the PDB. The numbers of structures present in the PDB 
are listed by method used to solve the structure. Structures are divided into protein structures and 
“Other”, which include nucleic acids, protein-nucleic acid complexes and heteroatoms. The 
information was obtained from the PDB on 01/06/2015. 
 
4.3.2 NMR 
One of the main advantages of NMR over other techniques is that the structure of proteins 
can be solved in solution [171]. Unlike X-ray crystallography, solution NMR works with 
protein in non-static poses and can be used to characterise protein dynamics, kinetics and 
thermodynamics [171]. This technique also solves structure at atomic resolution, but is 
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generally limited to proteins less than 25 kDa in size. For the purposes of protein structure 
determination, NMR uses the nuclear Overhauser effect (NOE) caused by nearby hydrogen atoms 
in the protein [172]. This allows different hydrogen atoms to be observed as long as they are 
within 5 Å of each other, even if they belong to different residues. Proteins are relatively large 
molecules and a single NMR run will produce thousands of peaks, even with small proteins 
[172]. Solving structures larger than 25 kDa compromises data quality unless higher-power 
magnets are used to improve resolution and prevent signal overlap [171]. Apart from signal 
overlap, there is a need to distinguish between peaks that are specific to the protein and those 
which are artefacts of the technique itself [173]. This is a very complex problem so the data is 
generally interpreted computationally. Protein NMR has seen some developments in recent years. 
Cell-penetrating peptides enables N15-labelled proteins to be introduced into active cells for what 
is termed “in-cell NMR”, which is carried out in vivo [174, 175]. Additionally, a number of 
different protocols have been developed to solve larger structures and the number of NMR 
studies with such proteins is increasing [171].  
Table 4.2: Number of structures deposited in the PDB each year. This table includes all structures 
(protein, nucleic acid, etc.) deposited each since 2010, listed by method. The 2015 entries are up until 
01/06/2015. 
 
4.3.3 Electron microscopy 
Electron microscopy (EM) is related to light microscopy, but uses electrons rather than 
photons, thus allowing specimens to be observed at a molecular level [176]. Electron 
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scattering from contact with the biological sample results in the image that is formed and 
therefore the electron beam is kept in a vacuum to prevent scattering by gas molecules [177]. 
Image resolution quality could theoretically be comparable to X-ray crystallography (based 
on wavelength of electrons), but is primarily hindered by damage caused to samples by 
electrons [176]. Negative staining using heavy metal coating of samples prevents such 
damage, but does not provide structural information beneath this coat. Without negative 
staining, a less intense beam of electrons would need to be used, such that it does not damage 
the biological sample. Unfortunately, these samples consist mostly of low molecular weight 
elements which poorly diffract electrons, meaning this approach leads to a poor signal-to-
noise ratio [176, 178]. By performing EM at very low temperatures (cryo-EM), radiation 
damage to samples can be reduced considerably, even when using an intense electron beam 
[176, 179]. Additionally, a large number of identical units are visualised and averaged as a 
supplementary means to improve resolution [176, 178]. EM is a technique that has been 
integrated into structural biology to study macromolecular assemblies that are not suited to 
study by NMR or X-ray crystallography [176]. 
4.4 In silico approaches 
The prediction of the 3D structure of proteins can be achieved using either template-
based modelling or so-called “free modelling” methods [180, 181]. In template-based 
modelling, the protein structure to be predicted is referred to as the “target”. This is modelled 
based on one or more protein structures that have been determined experimentally, referred to 
as “templates”. The template is usually evolutionarily related to the target protein, as in 
the case of homology modelling. However, in the absence of available homologous 
proteins with known structure, threading is used, which predicts secondary structure and 
protein folds to assign templates [180]. When homology searches and threading 
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methods are unable to identify suitable templates, free modelling methods are used 
which build models without the use of templates [181]. There is also a developing trend 
of overlap between homology modelling, threading and free modelling methods [180].  
4.4.1 Homology modelling 
Homology modelling works on the principle that structural features of a protein are far more 
conserved than its primary amino acid sequence. It has been determined that the structure of a 
protein may be conserved up to ten times more than its sequence [182]. For this reason, early 
attempts at homology modelling considered a template to be suitable for modelling only if it 
shared a high enough sequence identity with the target to be modelled [183–185]. Homology 
modelling is considered to be the most accurate form of in silico modelling. If an adequate 
homologous template is available, most homology models will have a root mean square 
deviation (RMSD) of 1 – 2 Å from the native structure of the target [180, 186]. This method 
is discussed in more detail in Chapter 6. 
4.4.2 Threading 
By its definition, threading is simply the process of aligning the sequence of a protein to the 
structure of a template [187]. Threading techniques rely on fold recognition, which uses 
force-fields and statistical potentials to select the most appropriate template for modelling, 
where there is no clear homologous structure available [188, 189]. The predicted folds can 
also be matched against a library of all known protein folds, to help identify the most likely 
fold for any given part of a sequence [190]. This is based on the concept that there are a 
limited number of structural folds proteins can adopt [187, 191]. The results obtained from 
threading are generally less accurate than those obtained through homology modelling 
methods. Models produced by threading will usually have an RMSD between 2 - 6 Å from the 
native structure [180, 192]. 
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4.4.3 Ab initio methods 
Free modelling methods were originally called “ab initio” methods, which aimed to 
predict the 3D structure of a protein, using nothing but the amino acid sequence. The ability 
to do this accurately is considered by many as the “holy grail” of structural biology [193]. 
Currently this is highly impractical as the purely ab initio methods available would take an 
inordinate amount of time to model even a small protein structure [194]. The computational 
time of these methods also increase exponentially with the length of the protein to be 
modelled. As a result, free modelling methods are now used, which combine these ab initio 
methods with knowledge-based approaches [181]. One of the most successful methods 
developed for free modelling is one which involves assembling fragments of known 
structures from the PDB. This was later incorporated into the program ROSETTA [195, 
196], which is discussed in Chapter 6. 
4.5 CASP 
The Critical Assessment of Structure Prediction (CASP) initiative is a community-driven 
project which assesses different protein modelling methods [197]. One of the aims of CASP 
is to identify the pitfalls of modelling techniques and determine which challenges need to be 
addressed in order to improve the accuracy of theoretical models. CASP runs every two years 
and participants are given targets that have not yet been solved and are also given a wide 
range of proteins to model to account for methods with specific biases. The evaluation of 
structures is also done using a number of different techniques for the same reason. CASP is 
seen as a competition, as different groups will model the same target proteins. The results and 
models are all freely available afterwards so that the data may be used by anyone [197]. 
CASP targets are ranked by difficulty and groups may enter based on the method of structure 
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prediction, such as comparative modelling, free modelling, automated servers or just 
prediction of model quality. 
4.6 Uses of protein structural data 
One of the purposes of structural biology is to understand how organisms function at a 
molecular level [198]. Protein structural data can be used for drug discovery purposes; both 
for the identification of lead compounds and further development into more potent drugs 
[199]. As such, many efforts have gone into solving the structures of potential drug targets 
[199]. Structural biology has also helped characterise protein-protein interactions, the 
assembly of multiple-protein complexes and helped to elucidate mechanisms involved in 
biochemical pathways [200]. Functional predictions have been made about proteins under the 
assumption that proteins with similar structures should have similar functions. This is not 
always the case, however, as some proteins with similar folds will have different functions, 
even if they have similar active sites [198]. Structural data can be studied to understand 
known functional differences in these cases [201]. Problems faced with protein expression 
and crystallisation may also be overcome through analysis of available structural data [198].  
4.7 Successful use of computational protein modelling 
Although many homology modelling efforts are aimed at ligand docking for drug discovery, 
this method is also used to characterise proteins whose structures have not yet been solved 
experimentally. A good example of this is the modelling of purine riboswitches by Sharma et 
al. [202]. The group modelled the active site of both adenine and guanine riboswitches 
allowing them to use various forms of binding interaction analysis and energy analysis. This 
granted a mechanistic insight into the function of these proteins and how they interact with 
their metabolites, as well as the mechanisms involved in substrate specificity. Advances in 
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predictive techniques has provided more structures to be used to guide drug discovery efforts 
[203]. Homology modelling and virtual screening was used to successfully identify and 
develop compounds that were highly effective agonists of muscarinic acetylcholine receptor 
[204]. The final compound produced this way showed indications of cognitive enhancement 
when tested in animal models. Homology modelling and ligand docking has been used to 
target the P-protein involved in melanin production, for cosmetic purposes [205]. Using these 
methods to screen a molecular library of potential inhibitors resulted in the identification of 
five compounds that, when tested in vitro, resulted in reduced melanin production and 
minimal toxicity. Recently, structural studies were performed using computational models of 
cytochrome B of Plasmodium falciparum (P. falciparum) [206]. This was done to investigate 
the rapid resistance of P. falciparum to the drug, atovaquone, which targets this protein. By 
combining structural modelling with both ligand docking and molecular dynamics, Akhoon 
and co-workers demonstrated than even a single residue change to the active site of 
cytochrome B, led to atovaquone binding elsewhere on the protein, rendering the drug 
ineffective. 
4.8 Research aim 
Structural bioinformatics provides a means to study proteins in such a way as to gain a 
mechanistic insight into how they function. This section of the thesis initially focused on 
performing structural characterisation of P. falciparum heat shock proteins, with the goal of 
characterising their interactions with prospective cochaperones. This involved performing 
homology modelling a number of times, often remodelling using different parameters until 
suitable models were obtained. This gave rise to the development of a homology modelling 
tool, which can perform the various steps involved in homology modelling from 
identification of a suitable template, to assessment of the models produced.    
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Chapter 5 P. falciparum structural studies 
This chapter is centred around two of my published works and therefore describes two 
different studies. The content of these publications is described here in more detail. The first 
[207], focuses on one of the P. falciparum 70 kDa heat shock protein  (PfHsp70s), namely 
PHsp70-x. This is one of the six PfHsp70s, and the only one that does not have an 
orthologues in other plasmodial species. Potential interaction sites between PfHsp70-x and 
exported P. falciparum and host erythrocyte J proteins were interrogated by modelling and 
protein-protein docking. Docking results indicated that interactions between PfHsp70-x and 
each of the Hsp40s tested seem equally likely, suggesting that the J domain may not provide 
the specificity in the formation of unique Hsp70-Hsp40 complexes, but that the specificity 
might be provided by other domains of Hsp40s. By studying different structural 
conformations of PfHsp70-x, it was shown that Hsp40s can only bind when PfHsp70-x is in a 
certain conformation. The second study [208] concerns the heat shock organizing protein 
(Hop), which is important in modulating the activity and co-interaction of Hsp70 and Hsp90. 
Recent research has suggested that Plasmodium falciparum Hop (PfHop), PfHsp70 and 
PfHsp90 form a complex in the trophozoite infective stage. There has been almost no 
computational research on malarial Hop in complex with other malarial Hsps. Homology 
modelling was used to study the interactions of PfHop and human Hop (HsHop) with their 
own cytosolic Hsp90 and Hsp70 C-terminal peptide partners. The results indicated that these 
interactions at the concave TPR sites of Hop are highly conserved between both P. 
falciparum and host proteins. Analysis of additional binding sites between the convex sites of 
Hop TPR2 motif and the Hsp90 middle domain showed that these interactions are distinctly 
less conserved between human and the malaria parasite. The low conservation of these 
convex sites indicates that their potential for malarial inhibitor design may be more viable 
than the concave sites, which have been the focus of previous efforts.  
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5.1 Introduction 
5.1.1 Malaria 
Malaria is the most devastating parasitic disease of the current age. The World Health 
Organisation (WHO) reported that an estimated 3.2 billion people are at risk of malaria 
infection, with approximately 198 million cases occurring annually [209]. Of the 584 000 
estimated malaria deaths in 2013, 90% occurred in Africa and 78% of the total deaths were 
children under the age of five [209]. There is also a great economic burden associated with 
malaria. Currently funding more malaria efforts is at 2.7 billion US dollars, which is just over 
half the amount required to control the disease [209]. The disease is caused by parasites of 
the genus Plasmodium and spread by an insect vector; the female Anopheles mosquito [210]. 
There are five species within the Plasmodium genus that cause malaria in humans – P. 
falciparum, P. vivax, P. malariae, P. ovale and most recently P. knowlesi. Most focus on P. 
falciparum and P. vivax, the latter of which produces far milder symptoms, but is the most 
wide-spread form of malaria and can exist at a larger range of environmental conditions and 
geographic locations. The most lethal species is P. falciparum, which accounts for the 
majority of deaths that occur, especially in Africa [209].  
5.1.1.1 Life cycle of P. falciparum 
The life cycle of P. falciparum involves stages in both vertebrate human host and invertebrate 
mosquito hosts, both with vastly different internal environments [211]. There are a number of 
stages in the development and reproduction of P. falciparum, illustrated in Figure 5.1. These 
include the sporozoite, merozoite, trophozoites and gametocyte stages; although a ring stage 
is also said to occur between merozoite and trophozoite stages [210]. The parasite enters the 
human host when the mosquito feeds and releases  
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Figure 5.1: Life cycle of P. falciparum. Illustrated are the stages which take place inside the human 
host, discussed in text. The stages are labelled as follows: 1) Mosquito feeding, releasing sporozoites 
into the host’s bloodstream; 2) Sporozoites invading the hepatocytes; 3) Release of merozoites from 
the liver; 4) Erythrocytic stages of the malaria lifecycle; 5) Gametocytes taken up by the mosquito 
during feeding. Adapted from Fujioka and Aikawa (2002) [210]. 
thousands of sporozoites into the bloodstream, which invade liver cells (hepatocytes). P. 
falciparum lacks dormant phase in the liver, seen in other Plasmodium species, such as P. 
vivax, which can stay in the liver up to a number of years, causing relapse of the disease 
[210]. Thousands of merozoites are released from the liver and invade red blood cells 
(RBCs). The trophozoite stage includes remodelling of the RBC and modification of its 
surface. The contents of RBC cytoplasm are also digested in food vacuole. This includes 
haemoglobin, which is degraded to provide nutrients for the growth of the parasite [212]. 
Following this is asexual reproduction, involving the production of merozoites, which are 
then released into the blood after RBC rupture [211]. The gametocytes are involved in sexual 
reproduction, which only occurs in the mosquito host [211]. They exist in two structurally 
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distinct forms, simply named male and female and are taken up by the mosquito when it 
feeds. A thorough understanding of the processes that occur during the life cycle of the 
malarial parasites are considered to be important for developing drugs which target each 
stage [211].  
5.1.1.2 Treatment strategies and drug resistance 
Currently, the most effective treatment strategies include preventative measures, 
chemoprevention and diagnostic work [209]. The use of insect-treated nets (ITNs) is 
predicted to reduce the number of malaria infections by half [213]. ITNs are a favoured 
means of prevention, since they may also hinder other diseases that are transmitted by insect 
vectors [214]. Chemopreventive measures are part of an intermittent preventive treatment 
(IPT) approach, which involves issuing antimalarial treatment at predetermined times to 
prevent malaria, rather than treat it [215]. Chemopreventive therapies, such as sulfadoxine-
pyrimethamine [216] and mefloquine [217] have been shown to be effective [218, 219]. The 
early stages of malaria are referred to as uncomplicated malaria, which develops into severe 
malaria over time. Severe malaria is life-threatening if untreated [219]. The current treatment 
for uncomplicated malaria, recommended by the WHO is artemisinin-based combination 
therapies (ACTs) [209, 220]. These combine artemisinin derivatives with longer-lasting drugs 
and have been used to successfully treat malaria [219]. P. falciparum has developed 
resistance to most antimalarial drugs available, including amodiaquine, chloroquine, 
mefloquine, quinine, and sulfadoxine-pyrimethamine [221]. More recently, multiple cases of 
artemisinin resistance have also been reported [209]. These reports of P. falciparum 
developing drug resistance to an increasingly large number of antimalarial drugs highlights a 
need to identify new drug targets to combat the parasite.  
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5.1.2 Heat shock proteins 
A number of studies have identified the heat shock proteins (Hsps) of P. falciparum as 
prospective drug targets [222–228]. Hsps are a group of molecular chaperones, which are 
proteins that assist with the correct folding of other proteins and prevent protein aggregation 
[229]; although Hsps may also perform other functions [230]. Hsps are up-regulated during 
times of physiological stress, including temperature increase, hypoxia, the presence of heavy 
metals and radiation, as well as glucose deprivation [231]. In P. falciparum, Hsps perform 
essential functions as part of the heat shock response of the parasite, helping it survive the 
temperature increase of more than 10°C when moving from the mosquito vector to its human 
host, as well as during recurrent fevers experienced by patients with malaria [228]. Hsps have 
also been implicated in host RBC remodelling [228] and regulation of actin polymerization 
[232], which is linked to the actin-myosin motor system, thought to facilitate RBC invasion by 
merozoites [233]. Subjeck et al. [234] reported that the proteins most greatly up-regulated during 
times of stress are the 70 kDa, 90 kDa and 110 kDa Hsps (Hsp70, Hsp90 and Hsp110, 
respectively). 
5.1.2.1 Hsp70s 
In addition to performing the roles associated with molecular chaperones, Hsp70s assist with 
the folding of newly translated proteins, the translocation proteins across membranes, the 
disassembling of protein complexes, as well as the degradation of unstable proteins [235]. 
These proteins bind and release peptide substrates in an ATP-dependant cycle, assisted by 
Hsp40 cochaperones [236]. The domain structures of Hsp70, along with Hsp90, J proteins 
and the Hsp70/Hsp90 organising protein (Hop), is illustrated in Figure 5.2. 
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Figure 5.2: Domain structures of Hsp70, Hsp90, J proteins and Hop. The domains that make up 
each protein are shown, with their relative positions in each protein. Each is discussed in more detail 
in text. 
5.1.2.1.1 Structural features of Hsp70 
Hsp70s consist of two major structural domains [237]. Firstly, the 45kDa N-terminal domain, 
also called the nucleotide binding domain (NBD) or ATPase domain; and the 25 kDa C-
terminal domain, otherwise known as the peptide-binding domain or substrate-binding 
domain (SBD). These two domains are connected by a flexible linker region, which 
facilitates communication between the ATPase domain and SBD [238, 239]. The ATPase 
domain and SBDs both regulate each others’ functions [240]. The SBD is further subdivided 
into a β-sandwich subdomain, which contains the substrate-binding pocket, and the α-helical 
lid subdomain [241, 242]. This lid region is not directly involved in substrate binding, but 
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does close over the bound substrate and has been found to stabilize substrate binding [243, 
244].  
5.1.2.1.2 ATPase cycle of Hsp70 
During the ATPase cycle of Hsp70 Figure 5.3, the protein undergoes transitions between an 
ATP-bound state, in which it has a relatively low affinity for peptide substrates, and an ADP-
bound state, in which it has a high affinity for peptide substrates [235]. In ATP-bound state it 
can rapidly cycle between substrates and it is in this state that Hsp70 initially binds its peptide 
substrates. ATP hydrolysis is then stimulated by a J protein cochaperone, causing Hsp70 to 
strongly bind the peptide substrate [245, 246]. There is also evidence to suggest that through 
its own peptide binding activity, the J protein recruits misfolded peptide substrates to be 
bound by Hsp70 [247]. Another cochaperone, the Hsp70-interacting protein (Hip), stabilizes 
the ADP-bound form of Hsp70 by preventing release of ADP [248]. Regeneration of the 
ATP-bound state of Hsp70 is facilitated by a nucleotide exchange factor (NEF), which binds 
to the ATPase domain of Hsp70 and lowers its affinity for ADP [249, 250]. The ADP from 
Hsp70 is exchanged for the ATP from the NEF and, in an ATP-bound state, Hsp70 releases 
the bound peptide from its SBD and is able to bind another misfolded protein. 
5.1.2.1.3 P. falciparum Hsp70s 
A total of six Hsp70 genes have been identified in P. falciparum [251], given the names 
PfHsp70-1, PfHsp70-2, PfHsp70-3, PfHsp70-x, PfHsp70-y and PfHsp70-z [230]. Of these, 
PfHsp70-1 has by far been studied in the greatest detail.  
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Figure 5.3: ATPase cycle of Hsp70. The ATP-dependent binding of a misfolded peptide (MP) 
substrate and release of a correctly-folded protein (FP) by Hsp70 is indicated, as described in text.  
PfHsp70-1 is located in the cytosol of P. falciparum and expressed in all blood stages of the 
parasite’s life cycle [252]. It has been shown to be capable of reversing the thermosensitivity 
of an E. coli strain with a partially defective DnaK [253]. A chimeric Hsp70 protein, 
composing of the ATPase domain of E. coli DnaK and the SBD of PfHsp70-1 was shown to 
be functional when expressed in a thermosensitive E. coli strain [253]. PfHsp70-1 was also 
able to reproduce some of the functionality of yeast Hsp70s, Ssa1 and Ssa2, when expressed 
in strains lacking these proteins [254]. The importance of the linker region of PfHsp70-1 has 
also been established, as mutations in this region rendered the protein non-functional [253]. 
PfHsp70-1 can also suppress thermally-induced malate dehydrogenase aggregation, as well 
as reactivate denatured glucose-6-phosphate dehydrogenase [255] PfHsp70-1 may also 
facilitate the transport of proteins to the apicoplast of the malarial parasite [256, 257]. PfHsp70-1 
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is also able to interact with the heat shock binding protein of P. falciparum (PfHSBP), indicating 
that it may play a role in the heat shock response mechanism of the parasite [258].  
The other cytosolic Hsp70 candidate of P. falciparum, PfHsp70-x [251] has only recently 
received any research attention. The expression of the protein was first confirmed in 2009 by 
mass spectrometry of the proteome of clinical isolates of the parasite [259]. PfHsp70-x had 
never been detected in laboratory strains, which suggested that it was only expressed 
pathogenic stages of the parasite’s life cycle. PfHsp70-x has been shown to be partly 
exported to the host erythrocyte, and partly present in the PV [260, 261]. Another interesting 
aspect of PfHsp70-x is the carboxy-terminal EEVN motif, since an EEVD motif is 
characteristic of cytosolic eukaryotic Hsp70s [230]. 
Like PfHsp70-1, PfHsp70-2 is expressed in all blood stages of the parasite’s life cycle [252, 
262, 263]. This protein localises in the endoplasmic reticulum (ER) of P. falciparum. There has 
been little work done to characterise PfHsp70-3, which is thought to reside in the mitochondria of 
the parasite, due to similarity to other eukaryotic mitochondrial Hsp70s [264]. There is evidence 
to suggest that this protein may localise in the PV of the P. falciparum [265] and also may be 
targeted to the apicoplast [257]. PfHsp70-y and PfHsp70-z, appear to be Hsp110 homologues 
[230]. Although these are structurally related to Hsp70s, they are part of a different and 
distinct sub-family of proteins [266]. PfHsp70-y and PfHsp70-z are predicted to localise in 
the ER and cytoplasm, respectively [251]. 
5.1.2.2 Hsp90s 
Hsp90s are not required for folding of most proteins, but rather for the final maturation of 
specific target proteins, referred to as “clients” [267–269]. Hsp90 acts on proteins whose 
native states are more difficult to be achieved and, as such, during heat stress, its range of 
client proteins increase [267]. This protein also does not prevent denaturation of other 
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proteins, but will facilitate refolding [267]. In addition to protein folding, the functions of 
Hsp90 include a role in signal transduction, intracellular transport, and protein degradation 
[268]. The protein has been implicated in the assembly of numerous multi-protein complexes 
and is involved in many cellular pathways [270]. 
Like Hsp70, the function of Hsp90 is linked to an ATP-dependant cycle (Figure 5.4), 
involving conformational changes [271]. However, Hsp90 acts as a homodimer with a 
parallel arrangement [268, 269]. Its activity occurs through a nucleotide-bound molecular 
clamp mechanism, wherein the homodimer goes through open and closed conformation 
during its ATPase cycle [269, 272, 273]. The monomeric structure of Hsp90 consists of an N-
terminal (N) domain, a middle (M) domain and a C-terminal (C) domain [269, 274], as 
indicated in Figure 5.2. The N domain is the site of the ATP-binding pocket and therefore 
responsible for the ATPase activity of Hsp90 [275]. It also contains a number of residues that 
form a lid, which closes over the ATP-binding site when ATP is bound [269]. The N and M 
domains are connected by a flexible linker region that is required for Hsp90 functioning and 
believed to facilitate inter-domain communication [274, 276]. The M domain contains a 
catalytic loop believed to recognise the gamma-phosphate of ATP and initiate ATP 
hydrolysis [274]. The M domain is also believed to interact with client proteins [274]. Hsp90s 
dimerize at the C domain, as well as a portion of the M domain [269, 277]. There are also 
interactions between N domains in ATP-bound state [269, 273].  
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Figure 5.4: ATPase cycle of Hsp90. Hsp90 is shown as a dimer, with each domain coloured 
differently, as labelled in the top left structure. The process of the ATPase cycle is described in text. 
5.1.2.2.1 Cochaperones of Hsp90 
In prokaryotes, evidences suggests that Hsp90s (HtpG) act without the need of cochaperones. 
In eukaryotes, however, over 20 different cochaperones have been implicated in regulating 
the function of Hsp90 [278]. These are reviewed in detail by Li et al. [278]. Examples 
include cochaperone p23 (Sba1 in yeast) which stabilizes the closed conformation of the 
Hsp90 homodimer by inhibiting the hydrolysis of ATP [269, 279]. This allows client protein 
maturation by preventing its release. In contrast to this, another cochaperone, known as the 
activation of Hsp90 ATPase protein 1 (Aha1) stimulates ATPase activity of Hsp90 [280, 
281]. An interesting cochaperone is the Hop, which facilitates transfer of protein substrates 
from Hsp70 to Hsp90 [282]. Hop is one of the proteins focused on in this chapter and is 
discussed in more detail in Section 5.1.2.4. 
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5.1.2.2.2 P. falciparum Hsp90s 
In P. falciparum, there is only one cytosolic Hsp90 (PfHsp90), as opposed to the two 
cytosolic Hsp90s found in humans [227, 283]. Like its human counterparts, PfHsp90 interacts 
with client proteins involved in cellular pathways, as well as kinases and transcription factors 
[227]. The mechanisms of PfHsp90 function have also been implicated with enhancing the 
parasite’s pathogenesis during febrile episodes experienced during malarial infections [284]. 
PfHsp90 may play a role in development of resistance to antimalarial drugs [283]. PfHsp90 
has also been shown to be essential to the parasite’s survival and is a promising antimalarial 
drug target [223, 225, 227].  
5.1.2.3 J proteins 
J proteins are traditionally called Hsp40s in eukaryote organisms, but the molecular weight of 
these proteins can often vary quite significantly from 40 kDa. For this reason, they are more 
recently being referred to collectively as J proteins [285, 286]. As mentioned above, these 
cochaperones stimulate the ATPase activity of Hsp70s [287]. J proteins are incredibly diverse 
and have different domain structures [288]. As such their only definitive structural feature is 
the presence of a conserved J domain through which it interacts with Hsp70 [286, 288–291]. 
The J domain is approximately 70 residues in length and contains a Histidine-Proline-
Aspartic acid (HPD) motif [288]. The HPD motif is required to stimulate ATPase activity of 
Hsp70 [292]. There are four proposed types of J proteins, based on the presence and 
architecture of specific structural features, which are simply referred to as types I-IV [288, 
293]. Type I J proteins, based on DnaJ from E. coli, contain a J domain, followed by a 
flexible glycine- and phenylalanine- (G/F) rich region and a Cysteine-rich Zinc finger. Type 
II only contains the J domain and the G/F-rich loop and type III only contains the J domain, 
located anywhere within the protein [288]. Type IV J proteins also only have a J domain, but 
have a variation on the conserved HPD-motif [293].  
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5.1.2.3.1 P. falciparum J proteins 
The P. falciparum genome is currently believed to encode at least 49 different J proteins, 19 
of which are exported [286]. There are two Type I J proteins found in the parasite [293]. One 
of these, PfJ1 (NP_702750.1), has been found to be up regulated, at an mRNA level, during 
heat shock [294], but has been shown to localise in the apicoplast [295]. The other, now 
termed PfHsp40 (NP_702248.1), is also up regulated during heat shock and has been 
confirmed to localise in the cytosol, as well as moderately stimulate the ATPase activity of 
PfHsp70-1 [296]. This protein was also found to suppress protein aggregation when used 
alone, as well as enhance the ability of PfHsp70-1to suppress protein aggregation [296]. 
Additionally, PfJ4, a known P. falciparum Hsp40, which localises in the cytoplasm and 
nucleus of the parasite, has been shown to associate with PfHsp70-1 [297]. Recently, two 
type II J proteins, PFE0055c and PFA0660w (PfA and PfE, respectively), have been found to 
be exported and localise along with PfHsp70-x in structures called “J dots” [260]. Another P. 
falciparum J (PfJ) protein, PFB0090c (PfB), has also been predicted to be exported to the 
erythrocyte cytosol [293].  
5.1.2.4 Hop 
The Hop cochaperone (otherwise known as p60; or Sti1 in yeast) has not been as well-studied 
as Hsp70 or Hsp90, but plays an important role in facilitating the transfer of client proteins 
from Hsp70 to Hsp90 [282, 298, 299]. When client protein is bound, Hop inhibits ATPase 
activity of Hsp90 [300]. PfHsp70-1 and PfHsp90 have been shown to form part of the same 
multi-chaperone complex, as seen in other systems [223]. Interestingly, evidence suggests 
that host chaperones Hsp70, Hsp90 and Hop are recruited by the parasite in detergent-
resistant membrane-bound complexes [301]. It has recently been suggested that the Hsp70-
Hop-Hsp90 complex forms within the host erythrocyte during the trophozoite stage of the P. 
falciparum life cycle [302]. 
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5.1.2.4.1 Structure and function of Hop 
Hop consists of three tetratricopeptide repeat (TPR) domains and two DP domains (Figure 
5.2). Currently there is no experimentally-determined full-length structure for Hop [298]. 
Each TPR domain has a concave and convex surface [303]. There have been various studies 
which focus on the mechanisms of both the Hop:Hsp70 and Hop:Hsp90 interaction [298, 
299, 304, 305]. What has been determined is that the concave surfaces of the TPR1 and 
TPR2B domains bind the C-terminal EEVD peptide of Hsp70 [298, 299, 304, 305] and the 
concave surface of the TPR2A domain C-terminal MEEVD peptide of Hsp90 [305–308]. 
Richter et al. [309] determined that the binding energy of the concave interactions between 
Hop and Hsp90 did not account for total affinity between these two proteins. Schmid et al. 
[298] suggest a conformation for this transfer, shown in Figure 5.5.  
 
Figure 5.5: Hop-mediated substrate transfer from Hsp70 to Hsp90, as proposed by Schmid et al. 
[298]. The substrate (S) transferred is coloured red, while Hop is coloured in orange, with its 
individual domains labelled. This conformation allows the concave surfaces of TPR2A and TPR2B to 
bind the C-terminal peptides of Hsp90 and Hsp70, respectively, while the convex surfaces of these 
domains interact with the Hsp90 M domain. 
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5.1.2.5 Drugs targeting Hsps 
Geldanamycin is a drug that has been shown to inhibit the function of Hsp90 [223, 225, 310, 
311]. It has also been shown to be an effective antimalarial against chloroquine-resistant 
strains and can therefore be used in combination with this drug [225]. Geldanamycin and its 
many derivatives [312] act by competitively binding to the Hsp90 nucleotide binding cavity, 
inhibiting its ATPase activity [275]. There have been a number of other Hsp90 inhibitors, but 
these have been designed to combat cancer [312–314]. Shahinas et al. [315] screened over 
4000 FDA-approved drugs for Hsp90 ATPase inhibitors and found compounds 2-Amino-3-
phosphono propionic acid, harmine and acrisorcin, which showed potent antimalarial activity, 
as well as synergistic effects with chloroquine, as seen with Geldanamycin [225]. The 
majority of Hsp90 drugs target the ATPase activity of the molecular chaperone [312, 316]. 
Other inhibitors, such as novobiocin, which targets the C-terminal of Hsp90 [316, 317], and 
celastrol, gedunin and H2-gamendazole, which target interactions with cochaperones [317]. 
Cortajarena et al. [318] designed peptides that mimic the interaction between the Hop TPR2A 
domain and Hsp90, inhibiting Hsp90 activity. Unlike other Hsp90 inhibitors, this did not 
result in increased expression of Hsp70, which is a perceived advantage of targeting the 
Hsp90:Hop interaction. 
There are fewer Hsp70 drugs that have been developed, though this may be an emerging drug 
target [319]. The first inhibitor of Hsp70 was 15-deoxyspergualin (DSG), which enhances the 
ATPase activity of Hsp70 [320, 321]. Compounds related to DSG and their derivatives have 
displayed Hsp70 inhibition and are being developed in an effort to identify potential 
anticancer drugs [321]. Anticancer research efforts have found a number of different Hsp70 
inhibitors that target ATPase and substrate-binding activity, as well as interactions with 
cochaperones, such as Hip and Hop [314, 321]. Studies have also been performed to identify 
Hsp70 inhibitors that have potential as antimalarial agents. Chiang et al. [224] identified nine 
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pyrimidinone Hsp70 inhibitors that displayed activity against P. falciparum, including the 
compound DMT2264, which had stronger inhibitory effects towards PfHsp70-1 than on both 
yeast and human homologs, Ssa1 and HsHsp70. Cockburn [322] identified malonganenone 
A, which specifically inhibited both PfHsp70-1 and PfHsp70-x and not the human Hsp70, 
Hsp70A1A. This compound was also found to display antimalarial activity, while displaying 
relatively low toxicity towards mammalian cells. Pesce et al. [319] suggest that targeting 
Hsp90, along with cochaperones, such as Hop could be a good strategy and chances of 
developing resistance would be lower. Also raise concerns about targeting PfHsp90 and not 
hostHsp90. Also suggest targeting Hsp40:Hsp70 system could be very effective. 
5.1.3 Proposed work 
This chapter initially covers work that following on from the structural characterisation of 
PfHsp70 proteins, performed during my masters [323]. Specifically, this involves exploring 
the potential interactions between PfHsp70-x and other exported malarial J proteins and host 
J proteins, using both homology modelling and protein-protein docking. Also reported is the 
structural work surrounding the comparative characterisation of the Hsp90:Hop convex 
interaction interface of human, yeast and P. falciparum proteins and comparing these 
interaction sites to the concave interaction interface, which is the targeted region of the 
Hsp90:Hop interaction in current drug therapies.   
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5.2 Methodology 
Unless otherwise stated , all programs were run using default parameters. 
5.2.1 Sequence acquisition 
The sequences of PfHop (PF3D7_1434300), PfHsp70-1 (PF3D7_0818900), PfHsp70-x 
(PF3D7_0831700), PfHsp90 (PF3D7_0708400), PfA (PF3D7_0113700), PfB 
(PF3D7_0201800) and PfE (PF3D7_0501100.1) were downloaded form PlasmoDB v9.3 
[324]. Additionally, HsHsp90 alpha (accession number: NP_005339.3) and HsHsp90 beta 
(accession number: NP_031381.2) and HsHsp70-1A (accession number: NP_005337.2) were 
obtained from the NCBI’s Protein database [325]. As well as sequences for two type I human 
Hsp40s, HsDnaJA1 (NP_001530.1) and HsDnaJA2 (NP_005871.1), two Type II human 
Hsp40s, HsDnaJB1 (NP_006136.1) and HsDnaJB4 (NP_008965.2), and two Type III human 
Hsp40s HsDnaJC5 (NP_079495.1) and HsDnaJC13 (NP_056083.3). 
5.2.2 Homology modelling 
5.2.2.1 Acquisition of templates 
Templates for modelling were identified using HHPred [326], with the exception of the 
coordinate file for the Saccharomyces cerevisiae (S. cerevisiae) Hop:Hsp90 
(ScHop:ScHsp90) convex complex, which was kindly supplied by Schmid et al. [298]. This 
structure contained the ScHopTPR2AB domain complexed with ScHsp90 M and C domains 
(ScHopTPR2AB-ScHsp90MC). The authors calculated this by docking an ScHopTPR2 
fragment (PDB ID: 3UQ3) to a low-resolution spin-labelled model ScHsp90 M and C domain 
fragment. During the preparation of this coordinate file, Hsp90 residues S-411, S-422 and S-
184 with CXM residues, which is a Cysteine residue with an additional proxyl group [298]. 
Two different templates were prepared: Firstly, the CYS-template, where these three residues 
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were converted to Cysteine residues, by simply removing the proxyl group in the coordinate 
file; and secondly, a SER-template, where each of these residues in the CYS-template was 
converted to Serine, using MODELLER’s mutate-function.  
5.2.2.2 Modelling 
Alignments of template sequences to target sequences were done using PROMALS3D [327] 
and corrected manually by inspection, if necessary. Modelling was performed using 
MODELLER [328], with slow refinement. For each protein or complex, 100 models were 
built. The best three models were selected based on their calculated DOPE Z scores. These 
models were further evaluated using MetaMQAPII [329]. Final evaluations were performed 
using MetaMQAPII, Verify3D [330] and ProSA [331, 332]. 
5.2.2.2.1 Conformations of full-length PfHsp70-x 
The full length structure of PfHsp70-x was modelled in two different conformations. Firstly, 
in its ATP-bound conformation (i.e. before hydrolysis of ATP), using bovine Hsc70 (PDB ID 
1YUW, chain A) [333] as a template. Secondly in its substrate- and ADP-bound state (i.e. 
after hydrolysis of ATP), using E. coli DnaK (PDB ID 2KHO, chain A) [334] as a template. 
5.2.2.2.2 PfHsp70-x complexed with J proteins 
The template used for modelling the Hsp70:J domain interaction was 2QWO [291]. This 
contained ATPase domain of bovine Hsc70 disulphide-cross-linked to a bovine Type III J 
protein, auxillin. Due to the low sequence identity between auxillin and the different Hsp40s 
being studied, a hybrid modelling approach was used [335] to model these complexes. First, 
each Hsp40 J domain was modelled separately as monomers. Templates with the following 
PDB IDs were used for modelling each J protein: PfA - 1HDJ, PfB - 2CTR, PfE - 2CTP, 
HsDnaJA1 - 2O37, HsDnaJA2 - 1HDJ, HsDnaJB1 – 1HDJ, HsDnaJB4 – 1HDJ, HsDnaJC5 – 
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2CTW and HsDnaJC13 – 2CTW. Each J domain model was superimposed with auxillin of 
template structure to replace auxillin, using PyMOL [336]. These hybrid structures were used 
as templates for modelling PfHsp70-x and each J protein complexes. The resulting models 
underwent residue repacking and were then put through 100 cycles of energy minimisation, 
both done using PyRosetta [337]. 
5.2.2.2.3 Hsp90 with the convex surface of Hop 
The ScHopTPR2AB-ScHsp90MC template was used to model the convex interaction 
interface of Hop with Hsp90 for the following combinations of proteins: 1) PfHsp70-1 with 
PfHop; 2) HsHsp90 alpha with HsHop; and 3) HsHsp90 beta with HsHop.  
5.2.2.2.4 Hsp90 with the concave surface of Hop 
Interactions between the concave surfaces of Hop and the C-terminal peptides of Hsp70 and 
Hsp90 were modelled using templates 1ELW, 3UQ3 and 3UPV. These templates contained 
the following: 1) PDB ID 1ELW: Human HopTPR1 with a synthetic heptapeptide, residues 
GPTIEEVD (HopTPR1-Hsp70GPTIEEVD) [306]; 2) PDB ID 3UQ3: ScHopTPR2AB with both 
MEEVD from the Hsp90 C-terminus, as well as EVD from the Hsp70 C-terminus 
(HopTPR2AB-Hsp70EVD-Hsp90MEEVD). In this complex, HopTPR2A interacts with 
Hsp90MEEVD and HopTPR2B interacts with Hsp70EVD [298]; 3) PDB ID 3UPV: 
ScHopTPR2B with C-terminal residues PTVEEVD from S. cerevisiae Hsp70, SSA4Hsp70 
(HopTPR2B-Hsp70PTVEEVD) [298]. 
5.2.2.3 Molecular docking 
Protein-protein docking was performed using the High Ambiguity Driven biomolecular 
DOCKing (HADDOCK) webserver [338]. The best docked structures chosen, based on their 
HADDOCK score, which is the weighted sum of van der Waals energy, electrostatic energy, 
desolvation energy, the energy from restraint violations and the buried surface area. 
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5.2.2.3.1 Hsp70:J proteins 
Each J domain model was submitted to HADDOCK along with PfHsp70-x. For each J 
protein, residues set to be actively involved in binding those forming the HPD motif, and for 
PfHsp70-x, residues R201, N204, T207, I246 and V419 were set. No passive residues were 
set for each docking run, but assigned automatically by the server.  
5.2.2.3.2 Hop:Hsp90 
For these, two sets of docking parameters were used: 1) with active residues set as those that 
formed interactions in the ScHopTPR2AB-ScHsp90MC template, with passive residues 
being automatically assigned by the server; and 2) with active residues set as in the most 
conserved interactions across the modelled complexes and the rest set as passive. The 
ScHopTPR2AB-ScHsp90MC template was also resubmitted for docking in order to confirm 
the docking orientation for this complex returned by HADDOCK and also determine the 
HADDOCK scores returned for this complex orientation.  
5.2.3 Identification of important residues in complexes 
5.2.3.1.1 Hsp70:J protein 
The Protein Interactions Calculator (PIC) webserver [339] was used to identify residue 
interactions in each protein complex. Default settings were used when submitting models to 
the PIC server.   
5.2.3.1.2 Hsp90:Hop 
Complexes for the HopTPR2AB-Hsp90MC interaction (convex analysis) were submitted to 
the PIC web-server. Python scripts were written to calculate the conserved interacting 
residues. An interacting residue was considered to be conserved if it interacted in more than 
half of the complexes observed. Then for each conserved residue, the script would go back to 
the PIC results and record which residues it interacted with. Using the same conservation 
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level cut-off, these interactions were used to create conserved interaction networks for the 
different groupings. Each HopTPR2AB-Hsp90MC complex was also submitted to the 
Robetta Alanine Scanning web-server [339]. Again, Python scripts were written to record the 
conserved “hot spot” residues for each grouping. The binding hot spot cut off value used was 
a ∆∆Gbind ≥ 1.0 kcal.mol
-1
 [340]. 
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5.3 Results and discussion 
5.3.1 PfHsp70-x:J domain interactions 
Experimental evidence has indicated that PfHsp70-x is exported from malarial parasite, into 
the host erythrocyte cytoplasm, localising in structures called J dots, along with Type II 
parasite J proteins, PfA and PfE [260]. The work presented aims to characterise this 
interaction at a structural level. In addition to PfA and PfE, another Type II J protein 
predicted to be exported from the parasite, PfB [293], was also included in this analysis. 
Since PfHsp70-x is exported to the host erythrocyte cytosol, its interaction with potential 
human J proteins was also considered. These included two type II J proteins, HsDnaJB1 and 
HsDnaJB4, and two Type III J proteins, HsDnaJC5 and HsDnaJC13; all four of which are 
expressed within the erythrocyte [341, 342]. Two Type I host J proteins, HsDnaJA1 and 
HsDnaJA2, were also included in the analysis. These are not expressed within the host 
erythrocyte, so should not come into contact with PfHsp70-x. As such, they formed a type of 
negative control, though there is insufficient experimental evidence to suggest these are 
incapable of interacting with PfHsp70-x. 
5.3.1.1 Modelled interactions 
The structure of bovine Hsc70 interacting with the J domain of a Type III, J protein, auxillin 
is available in the PDB, deposited by Jiang et al. [291]. To the best of my knowledge, this is 
the only structure of a J protein interacting with the ATPase domain of an Hsp70 protein (i.e. 
in a manner that induces ATP hydrolysis). To study this interaction in the context of 
PfHsp70-x, a hybrid complex modelling approach [335] was used and interactions assessed 
using the PIC webserver [339]. The results of the nine different J domains interacting with 
PfHsp70-x, as determined by this hybrid modelling approach are summarised in Figure 5.6. 
Since this was done for nine different J proteins, the residues are numbered according to the 
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alignment shown in Figure 5.6B. The interactions displayed were found to be mostly 
consistent with those reported previously by Jiang et al. [291]. From PfHsp70-x, residues 
I246, F247, I410 and L411 formed hydrophobic interactions with one or more of the J 
domains modelled. The only consistent hydrophobic interaction here though, was between 
L411 of PfHsp70-x and P12 from the HPD motif of the J domains, which was found to occur 
in all nine J domains studied. This residue also formed hydrogen bonds with H11 of the HPD 
motif, which only occurred in four of the nine modelled complexes, but was the most 
conserved interaction involving H11. Hydrogen bonds were formed between K29 of the J 
proteins and residues A418 and V419 of PfHsp70-x, as well as between D13 of the HPD 
motif and L200 and R201 of PfHsp70-x. There were some interactions found that have not 
previously been reported, including ionic interactions between D13 of the HPD motif and 
residues K189 and R201 of PfHsp70-x. Additionally, J protein residue E25 (E26 in Type I 
human J proteins) was found to interact with K420 of PfHsp70-x, by both ionic interactions 
and hydrogen bonding. Jiang et al. [291] reported an interaction between L200 of PfHsp70-x 
and H11 of the J domain, which was only seen in the two type III human J proteins. The J 
protein used by these authors for their structural studies, auxillin, was also a Type III J 
protein, which may explain this discrepancy. In spite of this, there were few interactions 
observed that were specific to either type of J protein or in either the PfJ proteins vs their 
human counterparts. The P. falciparum proteins did contain a 3 - 6 residue insertion (residues 
16 - 21), when compared to the various human J domains. There were some interactions 
formed here, obviously absent in the human proteins. The residues here vary greatly and did 
not form consistent interactions, making unlikely that they play an important role in this 
interaction with PfHsp70-x, specifically.  
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Figure 5.6: Modelled interaction of PfHsp70-x with different J proteins. The aligned sequences of 
PfHsp70-x (A) and the various J proteins (B) are shown, with residues involved in interactions 
highlighted as measured in the following complexes. Red: modelled complexes; Blue: minimised 
complexes; Green: Both modelled and minimised complexes. The human J proteins are labelled as 
follows. JA1: HsDnaJA1, JA2: HsDnaJA2; JB1: HsDnaJB1; JB4: HsDnaJB4; JC5: HsDnaJC5; JC13: 
HsDnaJC13. C) Interaction network diagram, representing the conserved interactions which took 
place between PfHsp70-x and the different J proteins. The portion of the J domain involved in the 
interaction interface is displayed as a cartoon and residues that form interactions are labelled and 
coloured black. Interacting PfHsp70-x residues are labelled and coloured blue. Used in Hatherley et 
al. (2014) [207]. 
5.3.1.2 Docked interactions 
The Hsp70-J protein interaction structure crystallised by Jiang et al. [291] currently presents 
the only experimentally-determined structure of Hsp70 interacting with the J domain of a J 
protein. Due to the transient nature of this interaction, the complex could only be determined 
by cross-linking the residues equivalent to R201 of PfHsp70-x and the aspartic acid of the 
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HPD motif. This was done because previous work performed by Suh et al. [290] indicated 
that these two residues interact during Hsp70-J domain binding. Jiang et al. [291] noted that 
the J domain could freely rotate around this covalent bond when the structure was solved and 
it was possible that the orientation of this bound structure may not have been biologically 
relevant. Additionally, the interactions identified in their structure failed to account of a 
number of interactions reported previously in literature. Namely residues to R201, N204 and 
T207 [290], as well as I246 [333] of PfHsp70-x. To further investigate this possibility, each J 
domain from the modelled complexes was docked to the ATPase domain of PfHsp70-x using 
HADDOCK [338]. The docking runs were set up to specifically include these residues and 
the results of this are displayed in Figure 5.7: Docked interaction of PfHsp70-x with different 
J proteins. All top-scoring complexes displayed favourable interaction energies when scored 
by HADDOCK. Interestingly, each J domain docked in a different orientation around the 
PfHsp70-x ATPase domain. Additionally, each of these orientations satisfied the criteria set 
for docking. A closer look at the various interfaces revealed that each revolved around an 
interaction between D12 of the J domain HPD motif and that this residue interacted with 
R201, N204 and T207 of PfHsp70-x. In spite of the various orientations adopted by the 
different J domains, a number of consistent interacting residues were found in both PfHsp70-
x and the different J proteins. Hydrophobic interactions formed with I246 of PfHsp70-x in all 
docked orientations and most commonly involved residues A7, M8 and F28 of the J domain. 
Jiang et al. [333] performed a number of site directed mutagenesis experiments and found 
that all tested mutations involving this residue specifically (I216 of BvHsc70) resulted in 
decreased auxillin binding. 
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Figure 5.7: Docked interaction of PfHsp70-x with different J proteins. A) Alignment of different J 
proteins, labelled as in Figure 5.6. Residues involved in interactions with PfHsp70-x are highlighted 
in green, with the most conserved interacting residues further marked by a red dot. B) A 
superimposition of the ATPase domain of PfHsp70-x in the different complexes. A zoomed in view of 
the region indicated by a dotted border is shown in (C). Residues of PfHsp70-x are shown as sticks, 
coloured grey and residue D1 of each J protein is also shown as a stick and coloured yellow. Adapted 
from Hatherley et al. (2014) [207]. 
The results of computational alanine scanning (Table 5.1) identified I246 as a hot spot 
residue (∆∆Gbind ≥ 1.0 kcal.mol
-1
), with the exception of the interaction with PfE, which 
returned a ∆∆Gbind of 0.94 kcal.mol
-1
 for this residue. The most consistent hydrogen bonds 
involved R201, N204 and T207 of PfHsp70-x. As mentioned before, each of these interacts 
with D13 of the HPD motif by forming hydrogen bonds and R201 forms ionic interactions 
D13. Again the exception to this was the PfE complex, in which R201 did not interact in any 
way with D13. Only R201 of these three PfHsp70-x residues was identified as a hot spot 
residue across all complexes. The complexes with HsDnaJA2 and HsDnaJB1 identified 
R201, N204 and T207 as hotspot residues. Two adjacent acidic residues of PfHsp70-x, E243 
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and D244, formed both hydrogen bonds and ionic interactions with either R4 or K14 of the J 
proteins. 
Table 5.1: Alanine Scanning of PfHsp70-x docked with different J proteins. Results are shown for 
PfHsp70-x (A) and J protein residues (B), as measured in complex. J proteins are named as in Figure 
5.6 and values indicating hot spot residues are coloured red. Adapted from Hatherley et al. (2014) 
[207]. 
 
Much like the HPD motif, R4 of the J domain is conserved as a positively charged residue (as 
R or K) and its importance has been reported in various J proteins [292, 343–345]. Residue 
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K14 took part in a number of interactions with additional residues, including D216, D248, 
K420 and D421. This is understandable, since it is adjacent to D13, around which the 
difference orientation formed and in most complexes this residue was identified as a hot spot 
residue. Of the different residues K14 interacted with, either E248 or K420 were identified as 
hotspot residues in most complexes. Residue H11 of the J domain took part in a number of 
varied hydrogen bonds across the different docked complexes and was identified as a hot spot 
residue in all complexes in which it formed an interaction. 
5.3.1.3 Comparison of modelled complexes to docked complexes 
The initial approach undertaken in this work involved using hybrid modelling to study the 
interaction interface of PfHsp70-x with potential J proteins, based on the BvHSc70:auxillin 
template structure solved by Jiang et al. [291]. This was supplemented with molecular 
docking using HADDDOCK, guided by residues highlighted in literature as being important 
to the Hsp70-J protein interaction. The docking results yielded a substantially different set of 
interactions to those found by complex modelling. On inspection, the HPD motif formed 
interactions in a similar area in both interaction sets, but residue D13 was buried deeper 
within the ATPase domain interface. This enabled interactions to be formed with N204 and 
T207. In their study, Jiang et al. [291] reported a reduced binding affinity between BvHsc70 
and the auxillin J domain, as prepared by disulfide-linking (refer to Section 5.2.2.2.2). It is 
possible that this cross-linked interaction prevented the J domain from completely entering 
the binding groove in the ATPase domain. There are a number of features that support the 
interactions described by docking over those obtained through hybrid modelling. Firstly, 
since these were specified in the docking parameters, the active involvement of I246, N204 
and T207 in this set of interactions, means that these agreed more closely with work 
performed by Suh et al. [290] and Jiang et al. [333]. Since the HPD motif comprised the only 
active residues specified when docking, it was interesting to find a number of other residues 
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in the interaction interface that, through review of literature, have experimental evidence 
which suggests their importance in the Hsp70-J protein interaction. These include R4 [292, 
343–345], K14 and F28 [292]. Another interesting find was an NMR-based structural study, 
performed by Ahmad et al. [346]. This focused on J domain interactions with Hsp70 in its 
ADP-bound state (i.e. after stimulation of ATP hydrolysis). Their results indicated that in the 
ADP-bound form, the interaction interface shifts from the HPD motif to the positively-
charged residues of Helix II of the J domain, which interact with acidic residues of the loop 
of Hsp70. These acidic residues of this loop surround the residue corresponding to I246 of 
PfHsp70-x. Helix II of the J domain used in the present study comprises residues R1 – M8. 
Results presented here indicate that A7 and M8 form hydrophobic interactions with I246 of 
PfHsp70-x and that R4 forms both hydrogen bonds and ionic interactions with E243 and 
D244. Therefore, this more buried complex interface includes interactions involving more 
residues previously found to be important in Hsp70-J protein binding and also describes a 
pose in which The J domain interface can switch to interact with the acidic loop of Hsp70.  
5.3.1.4 Hsp70 conformation during J protein docking 
The two templates used to model the full-length structure of PfHsp70-x were 1YUW and 
2KHO, which represent this protein in its ATP- and ADP- bound state, respectively. The nine 
different docked orientations were superimposed to these two models to provide further 
evidence to suggest which the correct binding orientation is. All docked orientations clashed 
with the SBD of PfHsp70-x in its ATP-bound state (Figure 5.8A). In this structural 
conformation lid of the SBD interacts with the residues surrounding I246 of PfHsp70-x [333]. 
Taken together with the finding that J domain stimulation regulates the inter-domain 
communication between the SBD and the ATPase domain [291], this would suggest that the J 
domain competes with the SDB of Pfhsp70-x to interact with the ATPase domain by binding 
to these residues and displacing the lid of the SBD. The findings of Ahmad et al. [346], that 
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the J domain interaction shifts to focus mainly this site in the ADP-bound state of Hsp70 
further support this. 
 
 
Figure 5.8: Docking orientations superimposed to PfHsp70 in both ATP and ADP-bound states. 
The docked complexes for the three PfJ proteins, as well as two host J proteins, in complex with 
PfHsp70-x are shown, superimposed with the full-length structure of PfHsp70-x, modelled in its ATP-
bound state (A) and ADP-bound state (B). J domains are coloured as follows: PfA - purple; PfB - 
yellow; PfE – orange; JA1 - brown and JA2 - teal. Used in Hatherley et al. (2014) [207]. 
110 
 
In the ADP-bound state of PfHsp70-x, only complexes with PfB, PfE and HsDnaJA2 did not 
clash with the SBD (Figure 5.8B). It is tempting to argue that one of these represent the 
correct docked orientation. The interactions of the J domain with the ATPase domain of 
Hsp70 are, however, highly dynamic [346] and the shift away from interactions with the HPD 
motif and toward helix II of the J domain may change this. 
5.3.1.5 Correct orientation for docking 
The presence of different docking orientations makes it difficult to characterise this 
interaction. Unfortunately each docked orientation had its merits. Only complexes with 
HsDnaJA2 and HsDnaJB1 had all four residues specified in the docking, R201, N204, T207 
and I246, as hot spot residues. Complexes with HsDnaJA1, HsDnaJA2, HsDnaJB4 and 
HsDnaJC4 identified residue R4 of the J domain as a hot spot residue and complexes with 
PfA and PfB had Y3 as a hot spot residue, which is also supported by Genevaux et al. [292]. 
Superimposition to the ADP-bound state of PfHsp70-x, suggest PfB, PfE and HsDnaJA2 as 
promising orientations. Again, the dynamic nature of this interaction may suggest a number 
of these interactions may be correct. HsDnaJA2 does seem to be the most promising though, 
as these interactions include the most residues supported by literature and it did not clash 
with the SBD of PfHsp70-x when superimposed to this protein in its the ADP-bound state. 
5.3.2 Hsp90:Hop interactions 
The second set of interactions studied were those between Hsp90 and Hop. Based on 
structural work performed by [298], a comparative study was undertaken to characterise the 
Hsp90:Hop convex interaction interface between both human and P. falciparum proteins. 
Further, the better characterised concave interaction interface was also investigated and 
compared between human and P. falciparum. 
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5.3.2.1 Convex interaction interface 
The convex interaction interface template consists of both the M and C domains of Hsp90 
and Hop TPR2A and TPR2B domains. This complex will be referred to as Hsp90MC-
HopTPR2AB. As with the PfHsp70-x-J protein interaction analysis, Hsp90MC-HopTPR2AB 
complexes were generated using both a modelling and docking approach and done for 
PfHsp90 (PfHsp90MC-PfHopTPR2AB), HsHsp90-alpha (HsHsp90αMC-HsHopTPR2AB) 
and HsHsp90-beta (HsHsp90βMC-HsHopTPR2AB), with their respective potential Hop 
counterparts. Unlike the Hsp70:J-protein complexes, both the docked and modelled 
complexes of the Hsp90:Hop interaction interface formed in the same orientation. Since there 
were four different complex models representing each Hsp90:Hop interaction interface (two 
from modelling and two from docking), the results of the PIC web-server protein-protein 
interactions were analysed using python scripts. The results were summarised to create an 
interaction network diagram for each interaction interface (Figure 5.9). 
 
Figure 5.9: Hop:Hsp90 convex interaction interface. An interaction network is shown for the 
Hop:Hsp90 convex interaction interface. The Hsp90 M domain is shown in cartoon, with interacting 
residues shown as blue ovals. Hop residues are indicated as red rectangles. Interactions are shown as 
follows. Solid line: ionic interaction; Dotted line: hydrogen bonding; Triangle: hydrophobic 
interactions. Used in Hatherley et al. (2015) [208]. 
112 
 
Although both the M and C domains of Hsp90 were present in these models, the interaction 
interface was limited to Hsp90 M domain only. The common interactions between 
HopTPR2AB and the Hsp90 M domains across the different sets of complexes were 
quantified and presented in Table 5.2. A more detailed list of these interactions is available in 
Appendix G; Table G1 and Table G2. 
Table 5.2: Total interactions common and unique to convex Hsp90:Hop interaction interfaces. 
The number of common interactions observed was totalled and summarised. A) Comparison of 
human complexes to the yeast template used in this study. B) Comparison of the human complexes 
with P. falciparum complex. The conserved column indicates that the interactions were common to all 
three complexes. Complexes are named, based on the Hsp90, as follows. Alpha: HsHsp90α; Beta: 
HsHsp90β; Pf: PfHsp90; Template: ScHsp90. Adapted from Hatherley et al. (2015) [208]. 
 
When comparing the two human complexes to the yeast template, the majority of interactions 
were common to all three complexes and seven interactions were found only in the yeast 
template complex (Table 5.2A). Thereafter, few differences were found when comparing 
these three complexes. When considering the PfHsp90 complex and the two human 
complexes, the number of interactions common to all three interfaces drops to 12 (Table 
5.2B). Nine interactions found in both human Hsp90 complexes were not present in the 
PfHsp90 complexes and 11 interactions were specific to the PfHsp90:Hop interaction 
interface.  
5.3.2.1.1 Common interactions in the convex interface 
Again, to make the different complexes comparable, the residues were numbered according 
to their positions in an alignment between the different sequences. The concave interaction 
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interface of Hsp90 and Hop is not very well characterised and a structure describing this 
interaction was only published in 2012 [298]. The complexes modelled and docked in the 
present work provide an interaction interface for both P. falciparum and human proteins. 
Combining the interaction data of these with the yeast template a general interaction interface 
has been predicted. A number of interactions were common to all four sets of complexes 
(yeast, human α-, β- and Pfhsp90s with their respective Hop counterparts). Primarily, for all 
complexes, ionic interactions occurred between Hsp90-E15 and Hop-K157, Hsp90-D30 and 
Hop-K157, Hsp90-D180 and Hop-R120 (K120 in HsHop and ScHop), Hsp90-E181 and Hop-
R120, as well as Hsp90-E194 and Hop-K77 (for actual residue numbers, refer Appendix G; 
Table G3 and Table G4). Many of these also formed hydrogen bonds. Cation-π interactions 
also occurred between Hsp90-W28 and Hop-R176. Residue W28 (W300 in ScHsp90) has 
been previously highlighted in literature as being important to the interaction with Hop in 
yeast [347]. Hsp90-W28 also formed a hydrophobic interactions with L180 of Hop (Y180 in 
HsHop). The alanine scanning results identified this residue as a hot spot residue in the 
human and yeast complexes, but not in the P. falciparum complexes (this difference is 
discussed in 5.3.2.1.2). Interestingly, there were also conserved hydrogen-bond interactions, 
despite a lack on conservation at a residue level across the different species. Residue D190 of 
PfHsp90 (present as S108 or T108 in the other HsHsp90s and ScHsp90), formed hydrogen 
bonds with N108 of PfHop (present as T108 in both HsHop and ScHop). This was the only 
exception where such a lack of conservation between the human, yeast and P. falciparum 
proteins did not cause a difference in the way they interacted. There was just one interaction 
common to the human and P. falciparum complexes, but not seen in the yeast template. This 
was an ionic interaction between K143 of Hsp90 and E119 of Hop.  
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5.3.2.1.2 Differences between P. falciparum and human complexes 
As mentioned above, the human Hsp90:Hop complexes displayed interactions not seen in 
their P. falciparum counterparts and vice versa. Some of these had no obvious cause, as with 
the hydrogen bonding between Hsp90-N26 with both L183 and E185 of Hop. All of these 
residues are conserved in both the human and P. falciparum systems. There were two 
hydrophobic interactions with Hsp90-W28 only seen in the human complexes, involving 
residues M156 and L188 of HsHop. In PfHop these are polar residues K156 and S188 and so 
did not form these hydrophobic interactions with PfHsp90-W28. The absence of these four 
interactions involving N26 and W28 of PfHsp90 may explain why W28 was not identified as 
a hot spot residue through alanine scanning. It is possible that the W28 interactions are not as 
crucial to the stability of the PfHsp90:PfHop complex as with the human and yeast 
complexes. The importance of this residue has so far only been indicated in yeast [274, 347] 
and it would be interesting to test its importance in both PfHsp90 and the two HsHsp90s. 
Another noted difference was the hydrogen bonding and ionic interactions between 
HsHsp90-E140 and HsHop-K123. The latter of these residues is present as PfHop-E123, 
which instead forms an ionic interaction with PfHsp90-K143. The final interaction conserved 
in the human complexes was an ionic interaction between HsHsp9-E194 and HsHop-H106. 
Again the residue is different in PfHop, present as D106 and formed no interactions with 
PfHsp90. The interactions seen in the P. falciparum complexes and not their human 
counterparts were more blatant and could be attributed to residue differences in either 
PfHsp90, PfHop or both. These included a hydrogen bond between PfHsp90-K177 and 
PfHop-E199. This was due to an unconserved Hsp90 residue, present as A177 in HsHsp90α 
and Q177 in HsHsp90β. PfHsp90-D180 formed both hydrogen bonds and ionic interactions 
with PfHop-K116 (Q116 in HsHop). Ionic and hydrogen bonds also occurred between 
PfHop-R112 (L112 in HsHop) and both PfHsp90-E187 and PfHsp90-D190 (T190 and S190 
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in HsHsp90α and HsHsp90β, respectively). Finally, PfHsp90-E194 formed hydrogen bonds 
with PfHop-N108 (T108 in HsHop). These final two sets of interactions may be the most 
significant in this study. Residues PfHop-N108, PfHop-R112 and PfHsp90-E194 were 
identified as hot spots, which was not found to be the case in their human counterparts (Table 
5.3). These may be worth testing experimentally as they could present good target sites for 
drug development. 
Table 5.3: Hot spot residues from the Hsp90:Hop convex interaction interface. Hot spot residues 
are indicated for the different complexes. Residues are numbered as in the models used to characterise 
these interactions, with the actual residue numbers shown in brackets. Complexes are named as in 
Table 5.2. Used in Hatherley et al. (2015) [208]. 
 
5.3.2.2 Concave interaction interface 
The concave sites of Hop are interact with the C-terminal peptide regions of both Hsp70 and 
Hsp90 [298, 299, 304–308] and is the target site for drugs that target Hop:Hsp70 or 
Hop:Hsp90 interaction [314, 318, 321]. These drugs have been developed as part of cancer 
treatments and therefore target human proteins. The work presented here involves identifying 
differences between human and P. falciparum chaperone systems as potential targets for drug 
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development. As such, the concave interface has also been investigated in order to determine 
how well suited it is to this purpose. The results of this analysis indicate a number of 
interactions in each complex that in each common to both human and P. falciparum (Table 
5.4). On the other hand, relatively few were specific to only human or P. falciparum.  
Table 5.4: Total interactions common and unique to concave Hsp90:Hop interaction interfaces. 
The number of common interactions observed was totalled and summarised for the different concave 
interaction interfaces studied. Adapted from Hatherley et al. (2015) [208]. 
 
An even more interesting result was obtained when comparing results across the different 
TPR domains (Figure 5.10). There were several interactions conserved even across these 
different TPR domains (TPR1, TPR2A and TPR2B). This indicates that the manner in which 
Hop interacts with the C-terminal peptides of Hsp70 and Hsp90 is highly conserved across 
different species and different TPR domains. This explains why it is a promising target for 
anticancer drug development. The potential of this interaction interface as a target site for 
selective inhibitors of the PfHsp90:PfHop or PfHsp70:PfHop complex interaction may be 
more limited.  
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Figure 5.10: Alignment of different TPR domains, highlighting common Hsp70/Hsp90 C-
terminal peptide contact points. Residues from each TPR domain which formed interactions in the 
complexes studied are highlighted in green. Used in Hatherley et al. (2015) [208]. 
5.4 Conclusion 
Through the analysis of interaction between PfHsp70-x and various J domains, the docking 
results appeared to account for a more complete interaction interface than the modelled 
complexes. This interface contained interactions involving residues that were supported by 
experimental data and fits the data suggesting a shift toward helix II of the J domain after J 
protein-stimulated ATP hydrolysis. The main problem faced was identifying the correct 
docking orientation from the different HADDOCK results and there was insufficient data to 
make this decision. In spite of this, a number of residues were found to consistently be 
involved in this interaction and, once again, many were supported by literature. Part of this 
study was aimed at finding ways to target the PfHsp70-J protein interaction. Unfortunately all 
residues identified to be important in this interaction occur in highly conserved regions of the 
protein [207]. Therefore targeting the ATPase domain of PfHsp70-x does not appear to be the 
correct interface for targeting this interaction. Both Botha et al. [296] and Hennessy et al. 
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[344] highlight that J domain interactions display promiscuous selectivity, even with Hsp70s 
from different organisms. It may be interesting to expand on this study by including both 
human Hsp70s and the other cytosolic P. falciparum Hsp70, PfHsp70-1. This may help to 
better characterise the Hsp70-J domain interaction interface for comparative purposes. The 
high level of conservation at the different J domain contact points suggests that these would 
not provide any new information. However, including additional analysis techniques, such as 
molecular dynamics or Perturbation-Response Scanning [348], may reveal features of this 
interaction that was missed by molecular docking. 
The results from the Hsp90:Hop analyses were more promising. When compared to the 
concave interaction sites, the interaction interface at the convex sites were far less conserved 
between human and P. falciparum proteins. In addition to this, a number of hot spot residues 
were identified specifically in the malarial complexes and not in their human counterparts. 
These residues may be potential site for drug development, aimed at specifically inhibiting 
the Hop:Hsp90 interaction of P. falciparum. 
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Chapter 6 Automated homology modelling tool 
Homology modelling is a fairly well-established technique that has become a fundamental 
tool in bioinformatics for studying proteins which have no solved structures available in the 
PDB. A number of automated protein modelling servers are available, but each has their own 
limitations. Presented in this chapter is a simple set of scripts that automate various aspects of 
the homology modelling process, while still allowing user input where desired. A simple 
benchmarking test was run to assess the reliability of the tool and accuracy of models 
produced using the tool. A web interface is also currently under development to provide 
academic users with access to this tool for their own research purposes. This is presented to 
show how the modelling tool can be integrated into a web-based application that allows users 
to intuitively and reliably model target proteins of interest. 
6.1 Introduction 
Homology modelling provides a means to obtain structural information about a protein, 
where this has not been determined experimentally, by means of X-ray crystallography, NMR 
or EM) [185]. As with other theoretical approaches to protein structure determination, homology 
modelling works primarily on the concept established by Epstein and co-workers in 1963 [349], 
that the structure of a protein is determined by its amino acid sequence [185]. This technique also 
relies on the observation that the structure of a protein is far more conserved than its amino acid 
sequence. While this holds true the longer a protein sequence is [183], it has been shown that the 
structure of a protein can be up to ten times more conserved than its sequence [182].   
6.1.1 Steps involved in homology modelling 
The process of homology modelling can be divided into seven different steps: 1) Template 
identification; 2) Sequence alignment; 3) backbone modelling; 4) loop modelling; 5) side-chain 
modelling; 6) structural refinement and 7) model evaluation [184, 185].  
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6.1.1.1 Template identification 
The selection of a template is greatly important step in the homology modelling process [184, 
350]. The Protein Data Bank (PDB) is an online resource containing the structures of proteins and 
nucleic acids that have been solved experimentally [351]. The database currently (June 2015) 
contains 101,356 protein structures and is updated on a weekly basis [352]. These, however, 
account for only 35,747 unique protein sequences. The challenge of template identification is to 
find a protein with known structure that is similar to the target protein of interest [350]. Initially, 
only the sequence identity between target and template was used when making this decision 
[183–185]. Some empirical guidelines were established to help with this, the most well-known 
being that proteins that share more than 40% sequence identity will have similar structures, which 
is true with few exceptions [184]. Below this “safe zone” [185], is the so-called “twilight zone”, 
which describes another threshold at which it is unclear whether or not two proteins are 
homologous [183]. This is usually set between 20 – 35% sequence identity, depending on the 
length of the alignment between the two sequences. The Basic Local Alignment Search Tool 
(BLAST) [353] is commonly used to identify templates [185, 350], especially if only sequence 
information is considered. This uses substitution matrices to score alignments which positively 
scores conserved substitutions and penalises gaps and poorly substituted residues when 
comparing sequences. BLAST assesses local similarity using a word-based approach, which 
aligns short segments (default length 3 residues for protein BLAST) from the query sequence 
against sequences in a database, and scoring these short alignments. If a segment pair scores 
above a certain threshold, it is extended and rescored, until it falls below the threshold. This 
approach aims to identify a maximal scoring pair (MSP), which is the highest scoring aligned 
region between to sequences of the same length. This way it is able to quickly search the large 
number of protein sequences and return those which are most similar to the sequence queried. In 
1997, a Position-Specific Iterated BLAST (PSI-BLAST) was released which uses the output from 
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BLAST to construct a position-specific score matrix (PSSM), which it uses in subsequent 
searches to find more distantly related homologues [354].  
At best, this approach will provide a set of potential templates, along with their sequence 
identity to the target. The use of a substitution matrix does provide more information about 
the evolutionary relationship between two sequences, rather than just looking at sequence 
identity; however, improved template identification can be achieved by incorporating 
structural information into a template search, such as secondary structure prediction [184]. 
Secondary structure prediction simply distinguishes whether regions of a protein sequence 
form an α-helix, β-sheet or disorder regions [355]. Another successful method incorporates 
the use of Hidden Markov Models (HMMs) [356, 357], as with the HHPred server [326]. 
This program builds profile HMMs using the results from a PSI-BLAST search, as well as 
secondary structure information either predicted using PSIPRED [358] or assigned from PDB 
structures using DSSP [359]. This contains position specific information on each residue in a 
sequence, with an assigned probability for each possible amino acid substitution, as well as 
insertions, deletions and gap extensions. The HMM is then compared to a precompiled set of 
HMMs for each structure searched against when identifying potential templates for modelling 
[326].    
Template evaluation is another consideration when identifying a suitable template for 
modelling [184, 350]. It is important to look at the quality of the structure solved. The PDB 
currently produces validation reports for its X-ray crystallographic entries [360], which are 
summarised when an entry is viewed. For X-ray crystal structures, the resolution can be a 
good, quick measure of the structure’s quality when assessing a potential template [350]. 
Factors relating to biological relevance may also come into consideration, such as the 
presence or absence of bound ligands or substrates. It can be helpful comparing the predicted 
secondary structure of the target to the assigned and predicted secondary structure of the 
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template, as provided by HHPred [326]. Finally, query coverage (how much of the target 
sequence is accounted for by the 3D structure of the template) is important to look at since 
some structures have only been partially solved. This information is returned when searching 
for templates using programs such as BLAST and HHPred. 
6.1.1.2 Sequence alignment 
Once a template is obtained, amino acids from the target sequence need to be mapped to the 
3D structure of the template (described in Section 6.1.1.3), which is done based on the 
alignment between the target and template sequences [184, 328, 361–363]. Westhead & 
Thornton [364] reviewed the original CASP results (CASP1 and CASP2) and found that a 
correct sequence alignment most greatly affected the accuracy of models for comparative 
modelling. Reports for both CASP4 and CASP7 highlighted alignment accuracy as an 
important hurdle that needed to be overcome in order to improve the quality of predictive 
models [365, 366], though there has been steady progress in successive CASP experiments 
[367]. 
Many different sequence alignment programs have been developed, each with different 
algorithms to improve alignment accuracy (Section 6.1.2). There are, however, a number of 
different techniques that can be applied to ensure a better alignment. In CASP3 the use of 
multiple sequence alignments (MSAs), as well as the use of structural data was attributed to 
greatly improve alignment accuracy, when compared to CASP1 and CASP2 [368, 369]. In 
the case of low sequence identity, MSAs help to identify positions in the sequence where 
certain types of residues are conserved through evolutionary processes, which may not be 
apparent when simply aligning two sequences [185, 370]. Likewise, consulting the 3D 
structure of the template and other homologous proteins can help to positions gaps in the 
alignment such that they are easier to model [185]. Some alignment algorithms, such as 
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Promals3D [327] and 3D Coffee [371, 372], are designed to take structural information into 
account when performing sequence alignments. 
6.1.1.3 Modelling backbone structure 
This involves fitting the amino acid sequence of the target to the 3D structure of the template 
[184, 328, 361–363]. The process starts with assigning the backbone of the protein structure, 
followed by improving the loop regions and positioning side chains of each residue. There 
are a number of different methods to predict the backbone of the homology model. The 
original method of comparative modelling was the assembly of rigid bodies [373]. This 
involves superimposition of a number of homologous structures and taking main chain 
positions as an average value for that position in the different structures. It still forms part of 
a number of homology modelling algorithms [374–376]. Another method, segment matching, 
involves assembling small fragments of protein structure together to build a protein piece by 
piece [373, 377]. Satisfaction of spatial restraints is the method used by MODELLER [328]. 
The spatial restraints are presented in the form of a probability density function (PDF). The 
PDF is used to predict the most probable 3D structure of a protein, based on Phi/Psi angles, 
Cα-Cα distances, etc., taking residue type into consideration. The protein is modelled in such 
that the molecular PDF is optimised [328]. 
6.1.1.4 Loop refinement 
Loops are considered to be parts of a protein that do not have a rigid secondary structure, 
such as alpha helices or beta strands [164]. They still have been found to play important 
biological roles. The antigen-binding sites of antibodies contain antigen binding loops that 
may confer specificity [378]. Serine proteases cleave specific loops in target substrates, 
which are mimicked as a part of certain inhibitor design strategies [379]. Many proteins also 
contain loop regions responsible for binding metal ions [380]. Additionally, if sections of a 
model cannot be determined from the template structure, due to insertions or deletions, these 
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are modelled as loops with structures determined using ab initio methods [381]. These are 
determined using database approaches or search-based methods to predict the structure [164]. 
These use loops from known structures in the PDB to predict the loop in question, since the 
PDB structure's loop represents that amino acid sequence in its 'natural' conformation. This 
method is considered to be more limited than others when predicting loops, though the limit 
of length of loops predicted using this method is 15 amino acids [164, 382]. Search-based 
methods use conformational sampling and energy calculations to predict the structure of a 
loop, based on the knowledge of the physicochemical properties of amino acids. These 
approaches are often supplemented with database search methods [164]. MODELLER 
provides a loopmodel class for loop refinement [383]. This involves optimising a statistical 
energy function developed specifically for the prediction of accurate loop conformations 
[384].   
6.1.1.5 Side chain positioning 
Determining the correct positions of amino acid side chains within a modelled 3D protein 
structure is an incredibly difficult and computationally expensive task [385]. This process 
usually involves the use of rotamer libraries [386], which contained preferred side-chain 
conformations for each amino acid [387]. The use of this library meant that fewer 
conformations had to be searched, making the process far less computationally expensive 
[387]. Still, this requires the best rotamer to be calculated for each residue in the protein 
[184]. Due to this, heuristic methods are used, since they are relatively fast, though they will 
return an answer that is the local minimum and not necessarily the most correct [388]. With 
MODELLER, side chain positioning is calculated as part of the spatial restraints, including 
all bond angles, as well as preferred distances from the main chain atoms and other side chain 
atoms [383].  
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6.1.1.6 Structural refinement 
This is an area of modelling that still requires a great deal of progress to be made [184]. 
Refinement of protein structures use an approach proposed by Levitt & Lifson [389], which 
involves refining the structure of a protein model, using a generalised force field, until it is in its 
most energetically favourable conformation. By default, MODELLER performs structural 
refinement as part of the modelling process [383]. After optimising the objective function, models 
are refined using molecular dynamics with simulated annealing [328]. 
6.1.1.7 Model quality assessment 
In the absence of an experimental structure it is impossible to tell how closely a modelled 
protein resembles its native state [366]. This is why in the CASP experiments there is a great 
deal of focus on model quality assessment programs. Being able to distinguish between a 
good and a bad quality model is an aspect that is key to developing a strong protein 
modelling method. Model quality assessment programs are usually developed by either 
computing physicochemical properties or by observing the differences between theoretical 
models and experimental structures [390]. As with all aspects of modelling, there are many 
different model quality assessment programs (MQAPs) available (Section 6.1.3). Each 
approach has its own strengths and limitations, so when evaluating models a number of 
different programs should be used [329].  
6.1.1.8 Repeat where necessary 
After evaluating the model, it may not display sufficient quality and will need to be modelled 
again, by changing certain parts of the modelling process [350]. Every step in the homology 
modelling process will influence the overall quality of the protein model, although the earliest 
steps will have the greatest effect [391]. Most often, improving model quality can be 
achieved by adjusting the alignment [350]. However, choosing to use different modelling 
software, as well as performing structural modifications can also have positive results [374]. 
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The example of structural modification provided by Wallner et al [374] is use of the software 
SCWRL [392], which can be used to improve side chain positioning after modelling has been 
completed. 
6.1.2 Sequence alignment algorithms 
Protein and nucleic acid sequence alignments are a central to the field of bioinformatics 
[370]. Sequences can be aligned across their entire length (global alignment) or only in 
certain regions (local alignment).  
6.1.2.1 Clustal 
There are a number of different MSA programs released in the Clustal series and are widely 
used for global MSA [370]. These have undergone a number of changes to improve the 
quality of alignment produced. Clustal uses a progressive alignment strategy. This involves 
comparing two sequences at a time to progressively build the MSA. The order in which these 
alignments are performed is based on a guide tree, created using phylogenetic-based 
algorithms. In order to improve the algorithms used by Clustal, up-weighting of more 
divergent sequences was implemented to reduce the biases caused by near-identical 
sequences [393]. Position-specific gap penalties attempt to introduce gaps in loop regions 
rather than portions of the sequence that form secondary structure [393]. Dynamic 
programming was introduced in order to improve accuracy of the alignment [370, 394] as 
well as neighbour-joining methods to produce a more accurate guide tree [395]. An iterative 
refinement option was later introduced, which wherein individual sequences are removed 
from the alignment and realigned. A weights sum of pairs score is used to assess the 
alignment and recalculated after each iterative alignment [396]. 
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6.1.2.2 MAFFT 
MAFFT was developed with the goal of minimising computational time involved in large-
scale MSAs, while still retaining the accuracy of the alignment [397]. The alignment 
algorithm is optimised to align residues based on volume and polarity, under the assumption 
that protein evolution favours substitutions which retain similar physicochemical properties 
of this nature, as described by Miyata et al. [398]. A fast Fourier transform (FFT) conversion 
is used to represent each amino acid in the sequence as a vector, describing its volume and 
polarity. Homologous regions between two proteins in an alignment are identified based on 
these values. The algorithms used by MAFFT perform up to 100 times faster than other 
widely used MSA programs. MAFFT has developed a series of different alignment strategies 
for specific types of data sets [399].  
6.1.2.3 MUSCLE 
MUSCLE uses a progressive alignment algorithm to produce MSAs with comparable 
accuracy to MAFFT [400, 401]. Two sets of progressive alignments are used. The first is 
based on a guide tree constructed using the sequences before they are aligned. After the initial 
alignment stage, a more accurate guide tree is constructed using this alignment and used for 
the next alignment stage. The alignment is then further refined using a profile function [400, 
401]. 
6.1.2.4 PROMALS3D 
PROMALS3D is a program that takes both sequence and structure into account when 
aligning two sequences [327]. The program uses both sequence- and structure-based 
constraints to produce an alignment. The sequence-based constraints use alignment 
information from PSI-BLAST and secondary structure predictions from PSIPRED to create a 
profile hidden Markov model (HMM) [356]. Homologous structures are identified using PSI-
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BLAST or specified by the user and form part of the structure-based constraints. Using both 
sets of data has shown to greatly improve the accuracy of a sequence alignment [327]. 
6.1.2.5 T-Coffee, 3D-Coffee and Expresso 
The Tree-based Consistency Objective Function for alignment Evaluation (T-Coffee) 
combines local and global alignment strategies with a progressive alignment to balance 
accuracy with speed [402]. It uses two pairwise-alignment libraries, one constructed using the 
Needleman & Wunsch [403] algorithm (global alignment library) and one using the SIM 
[404] algorithm (local alignment library) [371]. The alignments in each two libraries are 
scored based on sequence identity and combined into a single library, which balances the 
weighting from both local and global sequence alignment. This precompiled library is then 
used to guide the MSA, using a progressive alignment technique [402]. This program was 
improved by including structural information and released as 3DCoffee [371, 372]. To make 
the identifications of structures easier for users, Expresso was released, which runs a BLAST 
search against the PDB to automatically identify structural homologues to be used by 
3DCoffee [405]. 
6.1.3 Model quality assessment programs 
6.1.3.1 PROCHECK 
PROCHECK is a suite of programs that consider only the stereochemistry when assessing  a 
protein structure [406]. The suite runs five different programs and was designed to assess 
structures submitted to the PDB. As such it produces a number of different plots which allow 
a user to compare their structure to other structures with similar resolution and also provides 
an account for each amino acid in a structure, indicating which may be problematic. Though 
no longer maintained [407], the PROCKECK suite still forms part of the assessment of 
process of modern day homology modelling projects (e.g. [408, 409]). 
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6.1.3.2 VERIFY3D 
Verify3D evaluates protein models using a set of three different environments considered to 
be favoured each amino acid [330]. These consider 1) How buried the side chain on a residue 
is; 2) The fraction of the residue exposed to polar contact and 3) The local secondary 
structure where the residue resides. By combining these factors, 18 different environments 
were assigned and located in proteins of known structure. Scores were assigned to each 
amino acid based on the degree to which the environmental class was either favoured or 
disfavoured by that amino acid. The Verify3D program sorts each residue in the model into 
one of these environmental classes and scores it accordingly. The sum of these scores is used 
to assess global model quality. The local quality of the model can be assessed by individual 
scores given to each residue. For graphical purposes, this score is often averaged over a 
window of 21 residues [330, 410]. 
6.1.3.3 ProSA 
The Boltmann’s principle is a knowledge-based description of the forces that stabilise a 
protein in solution [411]. Force fields derived from the Boltmann’s principle were used to 
develop the Protein Structure Analysis (ProSA) model evaluation program [331, 332]. These 
consider protein-solvent interactions, as well as the energy inter-atomic interactions within 
the protein, expressed as a function of spatial separation [411]. The ProSA application 
constructs a polyprotein, approximately 50 000 residues in length, using fragments from 
known protein structures. This is constructed using only backbone atoms and includes atomic 
distances and steric information to ensure that all parts of the polyprotein are in a reasonable 
conformation. The model to be assessed is hidden within this structure, which is then 
assessed using a hide and seek method [331]. Here the structure is assessed in fragments of 
the same length of the model, which is used to establish a Z-score, indicating the extent to 
which the mean force potential of the model deviates from the random conformations of the 
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polyprotein [331]. The current online version of ProSA graphically represents the Z-score for 
the model in the context of all known structures in the PDB as a function of sequence length 
[332]. If the model Z-score falls outside the range established by native structures it is 
considered to be inaccurate. Additionally, the mean force potential of the model is plotted as 
a function of its amino acid sequence, averaged across both 10 and 40 residue windows 
[332]. 
6.1.3.4 MetaMQAPII 
MetaMQAPII was developed to provide a means of accurately assessing the local structural 
quality of a model, as this is where other programs perform relatively poorly [329]. 
MetaMQAPII incorporates eight other model quality assessment programs, including 
Verify3D, ProSA, ANOLEA [412], BALA-SNAPP [413], TUNE [414], REFINER [415] and 
PROQRES [416]. Each residue in a structure is assessed by placing it into one of 315 groups, 
determined by assessing the structures submitted to the CASP 5 and CASP6 experiments, in 
the category of template-based modelling. First, the models were assessed using ProQ [416] 
and given a global accuracy score. Based on these scores, each model was divided equally 
into one of seven bins – Bin 1 containing residues from the worst-scored models, while bin 7 
contained residues of models with the best ProQ scores. Secondly, in each bin, residues were 
further divided equally into another one of five bins, based on the extent to which they were 
buried within their respective structures, as determined by ResDepth. After this, each residue 
was further subdivided into one of three bins, based on residue type – hydrophobic, 
hydrophilic and other. Finally, each residue was then further subdivided into another one of 
three bins, based on local secondary structure. A combination of all these bins yielded 315 
groups into which a residue of a structure could be divided. Linear regression model were 
developed to predict the RMSD of a residue in each group from its location in the native 
structure, using the scores of the combination of eight different MQAPs as input. Due to the 
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nature of linear regression models a scores from 0 – 100 is predicted, which is then converted 
to an RMSD value. MetaMQAPII returns a predicted GDT_TS score, which gives a 
prediction of the global quality of the model, as well as a predicted global RMSD value, 
describing the predicted deviation in angstroms from the true protein structure. Additionally, 
the residue scores of each MQAP used in the assessment is returned. Finally, a PDB 
coordinate file of the model is returned, wherein the B-factor for each residue is replaced with 
the ranking score from the meta-predictor calculation. This can be used to give a graphical 
representation of the model and easily identify problematic regions [329]. 
6.1.3.5 DOPE score 
The Discrete Optimized Protein Energy (DOPE) score is a statistical potential derived using 
calculated PDFs of non-redundant structures from the PDB [417]. The score is dependent on 
inter-atomic distances of all atom pairs within a structure. Benchmark studies performed by Shen 
& Sali [417] indicated that the DOPE score function was better at finding the top model in a 
model set compared to other scoring functions. As the DOPE score is dependant of the length of 
the protein model, a normalised DOPE score (DOPE Z-score) was developed, which takes the 
length of the model into account [383]. 
6.1.4 Automated modelling tools 
6.1.4.1 SWISS-Model 
SWISS-Model is the longest-standing automated modelling server and focuses on being a 
user friendly interface for non-expert users to produce models for their research [418]. The 
server uses its own annotated template library, with structures from the PDB. Modelling is 
performed using ProMod-II and assessed using Qmean [419]. In 2005, SWISS-Model was 
criticised for lack of reliability, crashing more than 10% of the time it was run in bench-mark 
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tests [374]. This problem has been addressed by using MODELLER to perform modelling 
when ProMod-II crashes [418]. 
6.1.4.2 I-TASSER 
The iterative threading assembly refinement (I-TASSER) server was the top performing 
automated modelling server in the CASP7 experiments [420]. In CASP assessments, I-
TASSER is entered as “Zhang-Server” and even in the most recent round, CASP10, it 
performed best of the template-based protein structure predictors [421]. The principle used by 
I-TASSER is to combine threading and fragment assembly to produce models. The server 
integrates a number of different techniques and external applications.  
6.1.4.3 YASARA 
This is an application named “Yet Another Scientific Artificial Reality Application” 
(YARARA). The force-field, NOVA, was developed to addressed problems identified in 
CASP4, wherein structural refinement of protein models brought them further away from the 
native state [422]. YASARA uses molecular trees, which define the environment of each 
atom in a chemical structure, including topology information and bond types. The tree is 
constructed using all atoms, usually within three bonds of the reference atom. After 
identifying the chemical environment of a given atom in the structure, a force-field is selected 
from the reference set of molecular trees. The reference trees were constructed using the top 
25 X-ray crystal structures from the PDB, based on resolution and ensuring less than 30% 
sequence identity between any two structures [422]. The YASARA algorithm was praised as 
one of the best approaches for structural refinement seen in CASP8 [423].  
6.1.4.4 RosettaCM 
RosettaCM describes a new approach to improve comparative modelling using Rosetta [196]. 
Using a threading approach, the target sequence is used to make a partial model for each of a 
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number of different templates. Full models are created using conformational sampling, using 
Rosetta, with structural restraints creating using information from the templates. Entered in 
CASP10 as “BAKER-ROSETTASERVER”, this program performed best structural 
refinement [196] and produced the best model for the most challenging targets [421]. 
6.1.5 Proposed work 
While automated modelling servers have advanced a great deal in recent years, there are still 
a number of inherent problems with using these. The most prominent of which is that the user 
does not know what is happening in the modelling process, nor do they have the ability to 
adjust parameters to achieve a better model. The aim of this chapter is to develop a set of 
scripts that automate the homology modelling process, when using MODELLER. The 
resulting automated modelling tool will need to be able to help users identify and evaluate 
templates, perform alignments, modelling and model evaluation. The use of the scripts will 
also be assessed using a simple benchmarking test. The eventual goal of this work is to 
provide an easy-to-use interface for users to reliably model protein targets. The tool aims to 
be transparent, allowing users to know what is happening in the background and enables 
them to exercise a degree of control over this process. The tool will also aim to allow 
modelling results to be reproducible. 
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6.2 Methodology 
The automated homology modelling script has been written as a Python class, named 
Auto_model. This uses five other classes, which were written for this purpose and include 1) 
a PDB parser; 2) an HHPred ‘runner’; 3) An alignment class; 4) a Pir file class; and 5) a 
MODELLER template class. The Auto_model script, as well as scripts used by Auto_model 
are given in Appendix H. 
6.2.1 PDB parser class 
This parsers files in PDB format and extracts information relevant to modelling, including 
SEQRES sequence; missing residues and the amino acid sequence, based on the coordinates 
section of the file. Also contains functionality to produce a PDB file containing the 
coordinates of a single chain from the original PDB file, as well as a method to check the 
alignment of a PIR file, by comparing the template sequence to the structure.  
6.2.2 HHPred class 
The HHPred class runs HHBlitz and HHSearch, which were installed as part of the HH-suite, 
version 2.0.16. This class also parses the results from HHSearch and stores information 
regarding the various templates found, including identifiers, query coverage, sequence 
identity matches, scores and E-values. This can also be used to extract alignment information 
between the target and template sequences and save them as in Fasta file format. 
6.2.3 Sequence alignment class 
This is used to run different alignment programs. Currently, these include MAFFT version 
7.127b, MUSCLE version 3.8.31, Clustal Omega version 1.0.3 and T-Coffee version 
10.00.r1613.  
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6.2.4 PIR file class 
This is used to read and produce both Fasta files and PIR files. This class is used in 
combination with the PDB parser class to prepare PIR files for modelling. 
6.2.5 MODELLER template class 
This contains a shell with code common to modelling jobs run using MODELLER and is 
used to create and run modelling scripts for MODELLER. Additionally, this is used to 
specify different modelling parameters.  
6.2.6 Automodel script 
It consists of a number of functions that use the classes above to perform homology 
modelling using MODELLER. The only required input is a Fasta file containing the target 
sequence to be modelled. Optional input includes the names of template PDB files to be used 
for modelling and the name of an alignment file. The location of a PDB files directory, as 
well as an uploads and results directory can be specified. The purposes of these will be 
explained with respect to the algorithm (Figure 6.1).  
6.2.6.1 Get templates step 
If a template is not specified, this will use the HHPred class to find potential template 
structures. The program can be paused at this point in order to review the potential templates 
found, but by default the single top-scoring template returned by HHSearch is selected. Once 
the templates are selected, the script checks the PDB files directory for these. Those not 
found in the directory are downloaded from the PDBe, using a wget request – URL: 
http://www.ebi.ac.uk/pdbe-srv/view/files/[PDB ID]. The PDB parser is then used to make a 
PDB object for each template.  
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Figure 6.1: Algorithm used by automatic modelling script. The algorithm is explained in text. 
Stages are coloured as follows. Green: computational process; Blue: decision; white: outcome; Grey: 
manual process. 
6.2.6.2 Alignment step 
This step is skipped if an alignment is already provided. Otherwise, it simply calls the 
sequence alignment class to align the target sequence to the sequence(s) of the template(s). 
By default MAFFT-homologs is used to perform the alignment.  
6.2.6.3 PIR file preparation step 
This uses the alignment and the template PDB objects created using the PDB parser. 
Information for the PDB objects is used to provide start and end chains and residues in the 
PIR file and ensure that only residues present in the coordinate file are included in the 
alignment. The PIR file sequences are also trimmed at the N- and C-terminals so that these 
sections do not extend beyond the boundaries of the template sequence(s).  
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6.2.6.4 Modelling step 
The MODELLER template class is used to create a modelling file so that MODELLER can 
be used to model the target protein of interest. The version of MODELLER available on the 
machine running the script can be specified as well the number of models to be produced and 
the level of refinement performed during modelling.  
6.2.6.5 Evaluation step 
This step calls MODELLER to assess the structures produced, as well as the templates used 
for modelling, using the normalized DOPE score (DOPE Z-score). The models are ranked 
according to this score and printed to a text file. 
6.2.7 Preliminary benchmarking studies 
6.2.7.1 Modelling known PDB structures using different alignment programs 
The protocol for the benchmarking test is illustrated in Figure 6.2. David Brown from RUBi 
downloaded the entire PDB as part of his own project and kindly agreed to let me use these 
PDB files to perform benchmark studies. From this collection 100 different structures were 
selected at random and their sequences were sent to run through HHBlitz and HHSearch in 
order to find templates to attempt to model these targets. The top five suggested templates 
were recorded and binned according to their sequence identity, compared to their targets. 
From each bin, the suggested templates for 15 unique targets (i.e. one target structure was 
only binned in a single identity range). For each target-template grouping in each bin, the 
automated homology modelling protocol was run (Section 6.2.6, without manual 
intervention), using each of the four different sequence alignment options; MAFFT, 
MUSCLE, Clustal and Expresso. The DOPE Z-score was calculated for each template, target 
and model. The RMSD between the 1) template and target and 2) the top model and target 
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was calculated using BioPython. An RMSD difference value was calculated by subtracting 
the value of (1) from that of (2). 
6.2.7.2 Remodelling of PDB files 
Each target PDB file from 6.2.7.1 was also remodelled using its own structure as a template. 
The sequence used for modelling only considered the residues that had been experimentally 
solved (i.e. missing residues from the template file were left as gaps). 
6.2.8 Web interface to the homology modelling tool 
An online interface was designed by David Brown from RUBi, which uses the scripts 
described above to allow users to access and use the homology modelling tool via the 
internet.  
 
Figure 6.2: Benchmark test protocol. The algorithm followed to benchmark the automated 
modelling scripts is shown and discussed in more detail text.  
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6.3 Results and Discussion 
6.3.1 Benchmarking tests 
Apart from assessing the performance of the modelling scripts as a whole, the benchmarking 
tests were used to find and resolve problems found in each component of the tool. These are 
discussed in Sections 6.3.2 and 6.3.3. Due to the large-scale nature of the benchmark test, 
only the DOPE Z-score was used as an model quality score, since other MQAP servers such 
as MetaMQAPII [329] and ProSA [332] need to be accessed manually via their web 
interfaces. Benchmark studies performed by Shen & Sali [417] indicated that the DOPE score 
function was better at finding the top model in a model set compared to other scoring functions. 
The DOPE Z-scores of the different modelling sets are displayed in Figure 6.3. Both the 
template and target PDB files were included in this assessment in order to establish the 
DOPE Z-scores returned for crystal structures.  
 
Figure 6.3: DOPE Z-scores calculated for templates and models from benchmarking test. 
Models are grouped based on the alignment program used to align the template to the target sequence. 
The template PDBs, target PDBs and remodelled targets are also shown. Groupings are further 
subdivided by the sequence identity between the templates and targets, coloured as indicated in the 
key. The DOPE Z-score axis is values are shown in reverse order, with negative values at the upper 
end of the axis, as these indicate better models. 
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In addition to this, the target PDB files were remodelled using their own crystal structures as 
templates, to represent modelling under ideal conditions (i.e. with an ideal template and a 
perfect sequence alignment). The MODELLER manual [383] states that a lower DOPE Z-
score is favourable, with a score of less than -1.0 indicating a model is close to the native 
state of the protein. These values are reflected in the analysis performed on the PDB 
structures and remodelled targets. The models calculated for templates with greater than 50% 
sequence identity also fall within this range, regardless of sequence alignment program used. 
The differences in results produced by modelling using the various alignment programs were 
seen in the 10-30% and 30-50% sequence identity bins. Expresso alignments produced the 
best models when the sequence identity fell below 30%. This is probably because it is the 
only alignment program tested that uses structural information from the template when 
aligning sequences [405]. At sequence identity range of 30-50%, all alignment programs 
resulted in models with DOPE Z-scores below -0.5, which is promising.  
Although DOPE Z-score is a good measure when predicting the quality models, it is still 
useful to measure the accuracy of modelling runs performed. Since target proteins with 
known structure were modelled, this can be achieved by measuring the RMSD between these 
targets and the models produced. To account for conformational differences between the 
template used for modelling and the target PDB files, an RMSD difference value was 
calculated. This indicates how much the model produced was closer to the target PDB, than 
the template used to model it was. The results of this, shown in Figure 6.4, were interesting. 
In the lower sequence identity ranges, where the template PDBs should be the most different 
to the targets, the models produced using Expresso were much closer to the target structure 
than the template. This was most evident in the 10-30% sequence identity range, which was 
also the range at which Expresso produced models with better measured DOPE Z-scores than 
the other alignment programs. These results, taken together, highlight the value of a good 
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sequence alignment when modelling. For the purposes of the automated homology modelling 
tool, this benchmark study indicates that at different sequence identity ranges, it may be 
better to align sequences using specific programs. Further studies will be required to firstly 
confirm this, but also to characterise the range so that a default program can be assigned.  
 
Figure 6.4: RMSD difference values calculated for templates and models from benchmarking 
test. Values are shown for models calculated and grouped according to the sequence identity between 
template and target, as well as the alignment program used, as shown in the figure key.  
6.3.2 Alignment programs 
The previous section showed the importance of the alignments when performing homology 
modelling; however, the alignment programs were the most common limitation when the 
benchmark was performed. Both MAFFT-homologues and Expresso require a connection to 
an external web server to find homologous sequences and structures. When running a 
relatively large number of alignments, this became problematic. The web servers that receive 
the request slowed down in response time with subsequent requests performed. After as few 
as five consecutive requests, the response time was long enough that the request was 
abandoned by the alignment program, resulting in the modelling run crashing. This problem 
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was fixed by enforcing a wait of five minutes between alignment runs that use these external 
web servers. If the automated modelling tool is to be incorporated into an online web service, 
then the exact wait required will need to be further characterised to ensure it is minimised and 
modelling runs proceed as smoothly as possible. Another problem was seen with Clustal. 
Sometimes, if the sequence identity was too low between template and target, the program 
crashed. As a result the models produced using other alignment programs could not be 
included in the analysis. The exact reason for this crash is not yet clear and will require 
further investigation.  
6.3.3 Gaps in templates 
Another problem identified through the benchmark studies was caused by gaps in template 
structures, which resulted from missing residues when the structure was solved. The resulting 
problem is specific to MODELLER, as the program attempts to bridge the gaps in the 
template structure. Sometimes it is impractical for MODELLER to do this, however, and it is 
better to simply model using the portions of the template that have been solved (i.e. leave the 
gap as is). The severity of this problem is dependant on the size of the gap. Using the missing 
residues information in the template PDB file, it is possible to determine this and alert the 
user to the potential problem.  
6.3.4 Automated modelling web interface 
The scripts used to create the homology modelling tool were used to create a web interface to 
perform homology modelling. This interface was designed by David Brown from RUBi and 
is presented in this thesis to show the application of the scripts described in this chapter. The 
web interface has been assigned the name “AutoModel”, and in this chapter will be referred 
to as such. The name is a contraction of the phrase “automated modelling”. However, due to 
this being the name of the MODELLER class which performs modelling, this name will 
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change in future, once the interface is ready for public use. The web front end to this tool 
(Figure 6.5) was built to reflect the functionality provided by the scripts.  
 
Figure 6.5: Current front end to the homology modelling tool. The interface to the AutoModel 
website is shown along with the required input. The optional input section is minimised.  
At its core, the only required input is a sequence of the target protein in Fasta format. The site 
also requests a license key, which is required to ensure that MODELLER is used only used 
for academic purposes [383], and a job name, which allows users to keep track of their 
modelling runs and access the results at a later date. To allow users the freedom to take 
control of their homology modelling jobs, the optional input section is provided (Figure 6.6). 
This lists the various modelling options contained within the modelling scripts, as well as a 
job description section, which simply allows users to provide more information about their 
modelling job, for their own personal reference. The optional parameters are divided into 
three sections, including template identification, alignment options and parameters for 
MODELLER. 
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Figure 6.6: Optional input section of the AutoModel web interface. The optional input section, 
minimised in Figure 6.5, is displayed.   
The layout of the optional input section largely follows the logic of the diagram represented 
in Figure 6.1 and is designed to accept user input where possible. For example, there is a 
check box provided for users to indicate whether or not they want to inspect and edit the 
alignment performed by the software provided. The page was also build using responsive 
design, meaning that the options provided will change, based on what is selected. An 
example of this is shown for the template identification section in Figure 6.7. If templates are 
selected to be identified by HHPred (Figure 6.7A), a check is box provided to allow users to 
review the templates returned by HHPred and choose the best one(s) rather than 
automatically using the template that was ranked best be HHPred. This tells the modelling 
scripts to halt and wait for user input. Alternatively, if users select the option allowing them 
to specify templates (Figure 6.7B), a text box appears for users to enter the PDB ID and chain 
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of the templates they wish to use for modelling. In this case, the scripts check if these PDB 
entries are in the PDB files directory, and, if not, send a wget request to retrieve these 
templates from the PDB, as in Section 6.2.6.1. Finally, users may wish to upload their own 
templates and select this option (Figure 6.7C), which simply adds the template file to the 
PDB files directory and continues with the modelling process as normal. 
 
Figure 6.7: Responsive design of the option input section. The page is designed to display different 
content, depending on which options are selected and relevant to the input required. Panels A, B and 
C show the input types requested for each of the possible options in the templates section, which 
include a check box, a text box and a file upload widget, respectively.  
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Once the modelling parameters are set and modelling successfully completed, the web 
interface presents a summary of the job that was run (Figure 6.8A), as well as the results of 
each stage involved in the modelling process (Figure 6.8B-D).  
 
Figure 6.8: Results of a modelling job completed using the AutoModel web interface. 
The modelling results section also includes a model evaluation segment, which can be used to 
visualise each model and assess their DOPE Z-scores (Figure 6.9). Users can download 
models with promising DOPE Z-scores and perform further model evaluation using external 
applications. The options selected in Figure 6.6 are the default parameters chosen for 
modelling - i.e. leaving this section as it is would be the same as just filling in the required 
input section and selecting “start”. The benefit of this is that it still allows the user to see what 
is happening behind the scenes in terms of what parameters were selected at each stage of 
modelling. For example, they know that HHPred was used to select the best template for 
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modelling and can refer to the specific input, which is saved in the job results ‘summary’ 
section (Figure 6.8). 
 
Figure 6.9: Model validation scores section of the AutoModel web interface. Within the results of 
for modelling stage (Figure 6.8D) is an option to view the validation scores, presented here. Models 
produced during the modelling process are tabulated and sorted by their DOPE Z-scores. 
Additionally, each model can be visualised using GLMol, as shown.  
6.4 Conclusion 
The automated modelling scripts were designed to provide a means to quickly assemble a 
modelling job and provide options to alter and improve modelling runs. The scripts can be 
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used to identify templates for modelling, perform alignments, modelling and preliminary 
model evaluation. The Z-dope scores also quickly identify the top models from these runs for 
further evaluation using external applications. MODELLER provides a range of functionality 
to perform homology modelling under different circumstances. One of the immediate future 
goals is to incorporate this functionality into the automated modelling scripts. Specifically, 
this includes complex modelling, modelling with ligands and modelling proteins with 
sulphide bridges. These will be provided to help users with less experience with these aspects 
of MODELLER. The scripts presented will also be incorporated into an online web 
application so that they may be used by anyone. 
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Chapter 7 Conclusions and future work 
This thesis was divided into two sections and hence covered two broad aims. The first part 
aimed to establish an online database of South African NPs. This was divided into database 
construction, data collection and curation, followed by the creation of an online interface. The 
database was designed to be fully referenced, containing a broad range of information about 
each compound with potential to be expanded upon. A web interface was created to allow 
users to access this information. This was named SANCDB and can be accessed at 
https://sancdb.rubi.ru.ac.za/. Searches are provided to allow users to find compounds based 
on their names, structures, properties, source organisms, classifications, uses, as well as 
information pertaining to the referenced works used to retrieve this data. This information is 
also displayed in the compound summary page, provided for each compound entry in 
SANCDB. A RESTful API has been constructed and added to SANCDB, which allows 
information to be searched and downloaded from the database without having to access the 
web interface. This also enables information from SANCDB to be easily incorporated into 
external applications. 
Various checks have been implemented to ensure the information is accurate and complete, 
including a multi-step process to allow depositors to make sure the compound SMILES 
uploaded matched the compound reported in literature. The compounds themselves have also 
been through error checking processes and 3D structures have been calculated using 
CORINA [113, 114], in combination with Open Babel [115] to convert these into different 
file formats for users to download and use in their own research. Compounds were further 
minimised using GAMESS [116], to provide 3D structures which are suitable for 
computational ligand docking experiments. 
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SANCDB currently contains information pertaining to 600 compounds housed within the 
database and linked to 170 different references. In terms of size, SANCDB is most similar to 
the Brazilian NP database, NuBBE [91], which houses 640 compounds. Additionally, there is 
the Central African library of natural compounds, ConMedNP [93], which contains 3200 
compounds, but has no web interface, making these difficult to access. One of the immediate 
goals of SANCDB, moving forward, will be to increase the number of compounds contained 
within the database, while minimising overlap with other databases. ConMedNP covers 
compounds from around the Congo basin and does not extend to regions in Southern Africa. 
As such, the first step in extending the content of SANCDB will involve including 
compounds from Southern African countries. Secondly, SANCDB provides a web-based 
compound submission pipeline, developed by David Brown from RUBi. This will allow 
researchers with both published and unpublished compound data, not yet included in 
SANCDB, to deposit this information into the database. This will aim to provide a 
community-driven development of SANCDB content. Finally, the compound criteria for 
inclusion in SANCDB will be made broader to allow the database to grow. As mentioned 
with the submission pipeline, unpublished data can be included in the database, provided it 
recorded as such. These compounds can then be linked to the account of the user who 
supplied this information, rather than a reference. The second adjustment to the set of criteria 
used would be to include compound derivatives, rather than purely unmodified natural 
products. The inclusion of these will require additional information to be captured, 
specifically the process by which they were derived. The SANCDB interface will need to be 
modified to allow users to alter their search criteria include or exclude compounds 
derivatives, as well as the unpublished compounds. This would still link users to a greater 
quantity of NP chemical data, which suits their specific needs.  
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The second part of this thesis focused on protein structural studies. This initially involved the 
analysis of malarial proteins, specifically PfHsp70-x, PfHsp70-1, PfHsp90, PfHop and 
various PfJ proteins. The work and results presented formed part of two publications. One of 
these described the is silico characterisation of PfHsp70-x, including structural work to 
predict the interactions between PfHsp70-x and potential J protein cochaperones [207]. My 
contribution to the second paper [208] involved performing structural characterisation of the 
Hsp90:Hop convex interaction interface in both P. falciparum and human proteins. This was 
also compared to the concave interaction interface, which has been the target of many drug 
discovery efforts against Hop. Both sets of analysis involved similar techniques including the 
submission of modelled protein monomers to HADDOCK, protein-protein complex 
modelling, as well as analysis of these complexes using PIC and the Robetta Alanine 
Scanning web-server.  
Results from the study involving the interaction of PfHsp70-x with potential J protein 
cochaperones yielded a number of interaction interfaces which agreed more closely with 
biochemical data from literature than the PDB structure of bovine Hsc70 cross-linked to 
auxillin used in complex modelling. Unfortunately, most of these poses appeared to be 
potentially valid. The Hsp90:Hop analyses indicated that the convex interaction sites were far 
less conserved between human and P. falciparum proteins compared to the concave sites. A 
number of hot spot residues were also identified specifically in the malarial complexes and 
not in their human counterparts. These residues may be potential site for drug development, 
aimed at specifically inhibiting the Hop:Hsp90 interaction of P. falciparum. 
The final focus of this thesis was on the development of an automated homology modelling 
tool. The ideas incorporated into this tool were inspired by the work performed in the 
previous section, which involved a great deal of homology modelling. Also presented was the 
current interface for this tool, AutoModel, which demonstrates how the tool will be made 
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available to researchers. The preliminary benchmark tests performed for the homology 
modelling scripts were promising, but the tool does still require further development. The 
benchmarking tests help to identify bugs in the code or situations that have not yet been 
considered. The immediate plan for these is to upscale the number of targets to be modelled 
until the tool can reliably model proteins without any major errors. Once this has been 
achieved, the interface will be made ready for publication and made available at 
https://automodel.ru.ac.za/. The next step will be to expand on the functionality of the tool to 
perform the different types of modelling provided by MODELLER. The goals fro this work 
include making developments to the tool, such that it can be used for protein-protein complex 
modelling, protein-ligand modelled, as well as the modelling of proteins that have disulphide 
bridges. 
The idea of tool development can be linked back to the SANCDB web interface. Apart from 
increasing the number of compounds in the database, the future of the website will lie in its 
tool development. Currently, the SMILES parser tool is under development. The most 
immediate goals for this software involve the generation of compound images from their 
SMILES, use in substructure searching and creation of compound fragments from a larger 
structure. The SMILES parser will be developed to enhance the functionality of the 
SANCDB website. The other aspect of tool development is the incorporation of the 
homology modelling tool into the SANCDB web interface. Since online compound databases 
are often used for computational screening of compounds, introducing the users of SANCDB 
to the homology modelling tool will become important, especially if they are unfamiliar with 
in silico modelling techniques. Figure 7.1 illustrates how the output from both SANCDB and 
the homology modelling tool form input for docking studies, indicating that although these 
separate sections of the thesis have their own merits and stand-alone applications, they can 
contribute to a common goal of in silico drug discovery.  
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Figure 7.1: Simple schematic diagram, illustrating how the homology modelling tool can be used 
alongside SANCDB.  
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